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ABSTRACT 
Colon carcinoma and inflammatory bowel disease (IBD) are common 
and important intestinal diseases where primary abnormalities of the 
local mucosal immune system may be of pathogenic significance. 
Nonspecific cytotoxic cells such as natural killer (NK) and 
lymphokine-activated killer (LAK) cells may have an antineoplastic role in 
colon carcinoma and may contribute to mucosa! injury in IBD. The 
production of cytokines locally in the intestinal mucosa may be important 
for the maintenance of cytotoxic mechanisms and may have 
proinflammatory effects in IBD. The aim of this thesis therefore, was to 
investigate the role of mucosa! nonspecific cytotoxicity and cytokine 
production in the pathogenesis of colon carcinoma and IBD. This question 
was approached by measuring and comparing levels of cytotoxicity in 
specimens of histologically normal intestine resected for colon carcinoma 
or nonmalignant disorders and actively inflamed mucosa resected for IBD. 
A possible relation between interleukin 2 (IL-2) and colony stimulating 
factor (CSF) activity and colon carcinoma was explored by assaying the 
levels of these cytokines produced by histologically normal specimens of 
mucosa resected for carcinoma or nonmalignant conditions. 
The frequency and distribution of intestinal NK cells was first 
studied by immunohistochemical examination of mucosa! lymphoid tissue 
for cells bearing the NK cell-associated Leu-7 surface antigen. 
Functional studies were performed on local mucosal populations of 
(vii) 
lamina propria mononuclear cells (LPMC) and peripheral blood mononuclear 
cells (PBMC), which were assayed for spontaneous and interferon 
(IFN)-inducible NK cell activity, LAK cell activity and antibody-dependent 
cellular cytotoxicity (ADCC). Lymphokine-activated killer cells were 
generated from LPMC precursor cells in vitro, by culture in the presence of 
interleukin 2 (IL-2). In order to optimize the levels of cytotoxicity 
obtained, mononuclear cells were enriched for NK cells and LAK precursor 
cells by density gradient centrifugation over Percell. In addition to the 
standard cell lines used to test for NK activity and ADCC, freshly isolated 
colon carcinoma cells and intestinal fibroblasts served as more 
biologically relevant targets for intestinal NK and LAK cells. Mononuclear 
cell populations were also examined for their ability to produce IL-2 and 
CSF activity, either spontaneously in culture, or after stimulation with 
phytohaemagglutinin (PHA). 
Lamina propria mononuclear cell populations displayed very low or 
undetectable levels of spontaneous and IFN-inducible NK activity against 
K562 targets and minimal ADCC was also registered against 
antibody-labelled P815 cells. There was also no appreciable spontaneous 
mucosa! cytotoxicity directed towards freshly isolated colon carcinoma 
cells or intestinal fibroblasts. This paucity of NK activity was consistent 
with the very small numbers of Leu-7+ cells revealed in mucosa! sections 
by immunohistochemistry. The numbers of mucosa! NK cells and their 
minimal or absent levels of cytotoxicity against any of the targets tested, 
were comparable in all specimens, irrespective of the underlying pathology. 
In contrast to mucosa! NK activity, LPMC displayed potent LAK 
(viii) 
activity after in vitro culture in the presence of IL-2. There was no 
difference between the levels of LAK activity against K562 cells generated 
from colon carcinoma, nonmalignant or IBD specimens, implying that there 
was no deficiency of LAK precursor cells associated with malignancy. 
Intestinal LAK cells had a wide spectrum of cytotoxic activity, lysing 
tumour cell lines, freshly isolated colon carcinoma cells and intestinal 
fibroblasts, all of which were resistant to peripheral blood NK cells. 
Intestinal LAK cells were also capable of ADCC, although they apparently 
lacked a CD16+ Fe receptor. The presence of LAK cells active against colon 
carcinoma was not restricted to specimens affected by carcinoma but could 
also be induced in LPMC populations from IBD and in PBMC from normal 
controls. 
Phenotypic analysis of intestinal LAK cells cytotoxic for K562 and 
colon carcinoma targets showed that both the precursor and effector cells 
were co2+3-4-a-16- Leu-7-. Intestinal LAK cells mediating ADCC were 
predominantly of the same phenotype, although a small proportion of the 
effector cells were CD1 s+. The generation of intestinal LAK cells in vitro 
was totally dependent upon the presence of IL-2 and also required cellular 
proliferation. The process was sensitive to inhibition by low 
concentrations of hydrocortisone but was unaffected by cyclosporin. 
Lamina propria mononuclear cells released biologically significant 
amounts of both IL-2 and CSF activity after stimulation with PHA, but only 
CSF was released spontaneously in detectable quantities. The amounts of 
IL-2 released from specimens resected for carcinoma were significantly 
reduced when compared to nonmalignant specimens, but the CSF activity of 
(ix) 
PHA-stimulated LPMC was unaffected by the presence of carcinoma. 
From the studies of mucosa! cytotoxicity it can be concluded that NK 
cell-mediated cytotoxicity is unlikely to have a significant antineoplastic 
influence in colon carcinoma or an important role in mucosa! injury in 180. 
The presence of significant NK activity in some LPMC populations however, 
argues in favour of the existence of a very small population of NK cells, but 
the function of these cells is unlikely to be mediated through cytotoxicity. 
On the other hand, the presence of LAK precursor cells within almost all 
LPMC populations indicates that high levels of LAK activity are potentially 
available to the intestinal mucosa. The capacity of intestinal LAK cells to 
lyse NK cell-resistant colon carcinoma cells in vitro suggests that LAK 
cells may be effective antineoplastic cells in vivo. The lysis of epithelial 
tumour cells and fibroblasts of intestinal origin also raises the possibility 
that LAK cells may damage nonmalignant cells in the mucosa affected by 
IBD. 
The ability of LPMC to secrete IL~2 and CSF in vitro suggests that the 
production of these lymphokines in the mucosa! microenviroment may be 
important under both normal and pathological circumstances. The potential 
availability of IL-2 within the mucosa suggests that LAK cells may be 
generated from precursor cells in vivo under appropriate conditions such as 
chronic immune stimulation. The reduced level of PHA-induced IL-2 
secretion associated with colon carcinoma may result in impaired local 
cytotoxic mechanisms that could otherwise be operative against the 
tumour. Abnormalities of IL-2 or CSF secretion may have other important 
consequences, particularly with respect to the initiation or prolongation of 
(x) 
mucosa! inflammation in IBD. 
The most important implication arising from the data presented in 
this thesis is that the intestinal mucosa contains both the appropriate 
precursor cells and secretory capacity to generate highly cytotoxic LAK 
cells, which may either protect or damage the intestine, depending on the 
nature and strength of the stimulus. 
CHAPTER 1 
General Introduction 
Although it is now 14 years since the initial descriptions of natural 
killer (NK) cells, widespread interest in the origin and function of this cell 
lineage continues (1 ). Natural killer cells and other nonspecific cytotoxic 
cells such as the lymphokine-activated killer (LAK) cell are still under 
evaluation as potentially important antineoplastic, antimicrobial and 
immunoregulatory cells. This literature review presents an account of the 
nature and functions of human peripheral blood and intestinal NK and LAK 
cells. The potential involvement of NK or LAK cells in human disease is 
emphasized. 
1.1 Characteristics of natural killer and killer cells. 
Before the advent of surface marker analysis, NK cells were first 
recognized and then defined by their ability to lyse both autologous and 
allogeneic tumour cells (2,3,4). Although this operational definition is 
still widely used, it is now recognised that NK cells are a heterogeneous 
group with diverse functional and phenotypic properties (5). The cytotoxic 
activity of NK cells operates on first exposure to target cells and is 
independent of both extrinsic antigenic stimulation and the major 
histocompatibility complex. Cell lines susceptible to NK cells are derived 
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from leukaemias, Band T cell lymphomas and solid tumours including 
malignant melanoma and carcinomas of the bronchus, breast and bladder 
(4, 6-10). Malignant cells freshly isolated from resected tumours were 
regarded by many authors to be resistant to NK cell activity (11 ). However 
by using highly purified NK cell populations it has been shown that resting 
NK cells may display low to moderate levels of cytotoxicity against 
freshly isolated tumour cells from tymphomas and some carcinomas 
(12,13). 
Natural killer (NK) cells constitute a unique lineage of large 
granular lymphocytes (LGL) which are postulated to arise from precursors 
in the bone marrow (14). Approximately 10-15°/o of peripheral blood 
I 
lymphocytes (PBL) are LGL and of these 70-80°/o have the potential to act 
as NK cells (15, 16). The remainder of the LGL pool lack NK cell capability 
and consist predominantly of T cells which mediate ADCC (17). All LGL 
have an indented, eccentric nucleus containing dispersed chromatin and an 
occasional nucleolus. The cytoplasm is plentiful and contains a prominent 
perinuclear Golgi apparatus. Azurophilic granules with the enzymatic 
profile of lysosomes (positive staining with acid phosphatase, 
~-glucuronidase and a-napthyl acetate esterase) are scattered throughout 
the cytoplasm (18, 19,20). In ultrastructural studies, mature granules 
contain a uniform electron-dense matrix bounded by a unit membrane. 
Despite superficial similiarities to the monocyte, NK cells are 
myeloperoxidase-negative and nonphagocytic. Although generally regarded 
as lacking adherent properties, NK cells may adhere transiently to plastic 
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after initiation of culture (21 ). There is also evidence to suggest that LGL 
may be motile cells capable of chemotaxin-induced migration (22). Little 
is known about the traffic and possible recirculation of NK cells. LGL may 
possess specific homing receptors since adoptive transfer experiments 
have shown that infused T cells and LGL display different patterns of 
organ distribution in mice (23,24). The thoracic duct lymph is devoid of 
NK cell activity and therefore does not appear to be a major site for NK 
cells from the periphery to re-enter into the circulation. 
LGL can be efficiently isolated from lymphoid cell populations by a 
method exploiting their relatively low density compared with mature 
resting T cells. Centrifugation over discontinuous gradients of Percell 
separates a population of low buoyant density lymphocytes which are 
enriched for LGL (25). In the human, small numbers of NK cells are 
detectable in the bone marrow, spleen and lung but are suprisingly rare in 
the extensive mucosa! surface of the intestine (20,26,27). 
When only B and T cells could be identified by surface markers NK 
I 
cells were considered to constitute the major "null" or "third population" 
cell in the peripheral blood. Recent phenotypic studies now reveal that NK 
cells express an array of surface antigens (28-39). Studies of this kind 
show that NK cells consist of multiple subgroups of cells which carry 
complex and often overlapping profiles of surface antigens. The finding of 
phenotypic heterogeneity is supported by cold target inhibition and 
absorption experiments which also demonstrate multiple NK cell 
subpopulations with exclusive or shared target specificities (31 ,32). The 
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diverse but overlapping target cell repetoires of cloned NK cells further 
illustrate this point (33). 
The heterogeneity of NK cells has complicated their complete 
characterization by phenotypic or functional means. No single method of 
characterization can fully define the relative cytotoxic activity, frequency 
and target specificity of each NK cell type and furthermore, results depend 
upon the purity of the cell population studied. Depletion procedures using 
monoclonal antibody and complement-mediated lysis indicate only the 
proportion of NK activity mediated by cells carrying a particular surface 
antigen. On the other hand, multiparameter analysis of cells sorted by 
flow cytometry or immunoabsorption allows complete characterization of 
particular NK cell subpopulations and also represents a more sensitive 
method for detecting minority populations. As a group, NK cells active 
against K562 targets are predominantly co3-2+, 6+ OKM1 + Leu-7+ Leu-19+ 
la+ (28,34-36). Most of these markers are not specific for NK cells and 
I 
are shared with T cells (CO2, CD3, Leu-7), monocytes (OKM1) or 
neutrophils (OKM1, CD16). OKM1 and CO2 are present on 70-80°/o of 
K562-reactive NK cells and depletion of either surface marker decreases 
NK activity by approximately 80°/o. The CDS antigen is present on 40°/o of 
NK cells but the relative contribution of these cells to total NK activity is 
controversial (35,36). The CD16 and Leu-19 antigens are found on the 
great majority of cells with NK activity while optimum treatment of 
peripheral blood lymphocytes with Leu-7 and complement deletes 
approximately 80-85°/o of total NK activity (28,29,37). The remaining 
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15-20°/o of NK activity is mediated by a potent minority population of 
CD3-16+ Leu-19+ but Leu-7- NK cells (27). A small component of 
peripheral blood NK activity is mediated by a completely separate lineage 
of co3+15- Leu-19+ cells which also have the appearance of LGL. Variable 
proportions of these cells also express the CDS and Leu-7 antigens. Some 
co3+ NK cells appear to utilize the T cell receptor (Ti)/CD3 complex to 
mediate their cytotoxic activity in a non-MHC-restricted manner 
(30,39,40). When considered as part of the entire NK cell population, these 
co3+ NK cells contribute 5°/o or less to the numbers of NK cells and their 
overall activity. The NK cell subsets which can be delineated using 
surface markers are shown in Table 1.1. CD16 is present on all CD3- NK 
cells except for a very small CD3-16- Leu-19+ subset (29). This small 
group of cells consists of both large granular and agranular lymphocytes 
which are proposed as possible precursors of mature NK cells. All NK 
cells, including the co3+ subgroup, express the Leu-19 antigen. Leu-19 is 
also carried by the majority of lymphokine-activated killer (LAK) cells, 
but has not been found on any other cell type so far studied (37,38). 
Southern blot analysis of DNA from CD3- NK cells reveals germ-line 
configuration of the a,p and y chain T cell receptor (Ti) genes whereas co3+ 
cells with NK activity possess the a and prearrangements characteristic 
of mature T cells (39,41 ). Small numbers of co3+4-3-15+ cells with an 
early form of the Ti coded for by y genes also occur in the peripheral blood. 
As a group, these cells mediate ADCC but do not possess appreciable NK 
activity (17,42,43). On the basis of these findings, some investigators 
Table 1.1 The surface phenotypes of peripheral blood natural killer cells. 
• 
Surface phenotype NK activity@ 
• 
+++ 
++ 
+ 
+ 
Presence of surface antigen indicated by+; absence by-;+/- indicates the surface antigen 
may be either present or absent. 
@ Comparative NK activity against the K562 cell line is graded from + to +++. 
6 
recommend that co3+ cells with NK activity should be classified as 
cytotoxic T cells (CTL) rather than NK cells. 
1.2 Killer (K) cells and antibody-dependent cellular cytotoxicity. 
Interaction between cell surface antigens and specific antibody may 
result in destruction of the cell by complement-mediated lysis, 
antibody-dependent cellular cytotoxicity (ADCC) or phagocytosis. At 
concentrations of cell-bound antibody too low to initiate complement 
activation or opsonization, ADCC remains an effective mechanism for 
causing cell lysis (44,45). In ADCC, antibody directed specifically 
towards the cell surface acts as a bridge between the target and the Fe 
receptor of the cytotoxic effector cell and by cross-linking Fe receptors 
the cytotoxic cell becomes activated and lyses the target (44). Cells 
capable of ADCC express Fe receptors for lgG and therefore include K cells, 
Ty lymphocytes, monocytes/macrophages, eosinophils, neutrophils and LAK 
cells. The ability to mediate ADCC is an important facet of host defence 
against microbes and also possibly malignant transformation. Bacteria, 
fungi, protozoan and helminth parasites and viruses including the human 
immunodeficiency virus type 1 (HIV-1) appear to be susceptible to 
lymphocytes mediating ADCC (46-49). A special feature of murine 
intestinal lymphocytes is the expression of Fe receptors for lgA which 
facilitate ADCC of enteric pathogens recognized by specific secretory lgA 
(47). 
7 
The term Killer (K) cell refers to large granular lymphocytes which 
express the Fe receptor for lgG (the CD16 antigen) and are therefore 
capable of ADCC. The majority of the K cell population is phenotypically 
identical to CD3- NK cells and is regarded by many investigators as a 
subset of NK cells which have the additional capacity to mediate ADCC 
(15,50). Visualization of NK cells mixed with both NK-susceptible and 
antibody-labelled target cells confirms that a single NK cell can bind to 
and lyse both targets simultaneously (50). Furthermore, many cloned NK 
cell lines are capable of both forms of cytotoxic activity (51 ). 
Suggestions that separate cells mediated NK activity and ADCC were 
originally proposed on the basis of the differential effects of trypsin, 
interferon and prostaglandin E1 on these forms of cytotoxicity (52,53). 
However these findings can also be explained by the differential effects of 
chemical agents on two separate classes of receptors on the same cell. 
The discordance between impaired NK activity and normal ADCC in the 
acquired immunodeficiency syndrome is also due to a selective defect of 
NK receptors which spares Fe receptors on the same cell (54). 
A small proportion of K cells is comprised of co3+15+ T cells which 
were previously designated as Ty cells (17). These lymphocytes lack the 
CD4, CD8 and Leu-19 antigens and are incapable of NK activity. The 
existence of co3+ cells mediating ADCC has been questioned because 
depletion of co3+ lymphocytes from the peripheral blood does not alter 
ADCC (55). However direct phenotypic analysis of cytotoxic cells in ADCC 
plaque assays reveals co3+ lymphocytes in up to 40°/o of lytic conjugates. 
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The discrepancy between these findings may be explained by (i) the marked 
interindividual variation in Ty cell numbers and (ii) a slower recycling 
time for Ty cells compared to NK cells (17,55). The data suggest 
therefore, that that the more efficient and functionally important 
lymphocyte mediating peripheral blood ADCC is the NK cell. 
1.3 The origin and differentiation of natural killer cells. 
Sufficient evidence now exists to assign NK cells to a unique 
lineage of lymphocytes which arises directly from a multipotential stem 
cell. NK cells were originally thought to be derived from T lymphocytes or 
myelomonocytic cells because of their apparent expression of CO2, CD3 
and OKM1 antigens during differentiation (56). However the existence of 
NK cells in invertebrates and in the human foetus well before T cells are 
i 
detected argues in favour of a distinct NK lineage (57). The lack of Ti gene 
rearrangements in the majority of mature NK cells is further convincing 
evidence that they are not T cells (39). Apart from the common expression 
of OKM1, there are few fundamental similiarities between NK cells and the 
myeloid/monocytic lineages. The OKM 1 antigen and other leucocyte 
function associated (LFA) molecules function as adhesion molecules for 
many cell types and are not lineage-specific (58). Analysis of human Band 
T cell immunodeficiencies supports the view that NK cells are derived 
from a common stem cell which also gives rise to granulocytes, Band T 
cells. The complete dissociation of NK activity and B cell function 
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in immunodeficiencies further suggests that the NK lineage is more 
closely related to the granulocyte and T cell precursors (59). 
Abo et al have proposed a scheme for NK cell differentiation which 
is based on morphological, functional and phenotypic studies of NK cell 
populations in the lymphoid organs of foetal, neonatal and adult humans 
(20,40,56). The authors propose that NK cells at all stages of development 
are Leu-7+. Immature cells in the bone marrow or peripheral blood showed 
increasing expression of the CD3 antigen, whereas mature cells lose CD3 
and gain the CD16 and OKM1 antigens. Consistent with this scheme, the 
cytotoxic activity and granule content of the NK cells appeared to increase 
in parallel with the evolving surface antigen changes. 
This scheme for the development of NK cells is under challenge, 
however, because of recent data. Detection of a functional Ti on a minor 
subset of co3+ cells with NK activity indicates that these cells belong to 
the T cell lineage and are therefore probably not an integral step in the 
differention of most NK cells as suggested (39). Furthermore, studies 
using more specific NK markers (CD16) indicate that the original scheme 
of differentiation proposed by Abo and Balch requires substantial 
modification. Although the majority of peripheral blood NK cells are 
CD16+ Leu-7+, a subgroup with the most potent NK activity lack the Leu-7 
antigen (28). It is uncertain which subgroup is the more differentiated as 
both cell types have proliferative potential in short term cocultures with 
K562 tumour cells (60). In this system Leu-7+ cells were not able to 
serve as precursors for Leu-7- cells. As CD1 s+ Leu-7- cells can give rise 
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to either Leu-7 positive or negative cells they may occupy a more 
intermediate step in the differentiation pathway of NK cells (60). There 
is also disagreement in the literature concerning the expression of CD16 
on immature NK cells in the foetus and neonate. Abo et al attributed 
significant CD16 reactivity in cord blood to immature granulocytes but 
independent observations by others suggest that CD16+ LGL are plentiful in 
neonatal blood (61,62). The degree of expression of CD16 on NK cell 
precursors in the adult is uncertain but significant populations of CD15+ 
lymphocytes have been detected in both the bone marrow and spleen (61). 
Although it remains to be proven, it is likely therefore that the CD16 
antigen is present on all stages of developing NK cells. The Leu-19 marker 
is known to be expressed on both the CD15+ and co3+ groups of NK cells in 
the peripheral blood, but similiar studies of other lymphoid compartments 
have not been reported (29). In addition, a small proportion of circulating 
NK cells are CD3-16-Leu-·, g+ (28). The expression of the Leu-7 antigen 
on these cells has not been studied but it is postulated that this small 
population may be precursors of mature NK cells. 
In the light of recent studies using new surface markers the original 
scheme of NK cell differentiation proposed by Abo et al should be 
abandoned. As yet the available data do not fit into a plausible scheme of 
NK cell differentiation but future proposals should acknowledge that co3+ 
NK cells belong to a lineage distinct from that of the bulk of CD3- NK 
cells. Further phenotypic and functional studies of human bone marrow 
and peripheral blood are required in order to identify early NK cell 
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precursors. 
Human and murine studies provide circumstantial evidence that the 
NK progenitor cell is located in the bone marrow. Marrow transfer 
experiments in the murine system support this concept and also indicate 
that the microenviroment of the bone marrow is critical for NK cell 
development (63,64). Restoration of NK activity in severe human 
immunodeficiencies by bone marrow transplantation strongly suggests 
that NK precursors capable of repopulating the peripheral blood are located 
in the bone marrow (59). After bone marrow transplantation for human 
leukaemias, NK activity returns within 3-4 weeks, but it has not been 
convincingly shown that these cells are of donor origin (65). The 
generation of cells with NK activity from human or murine bone marrow in 
vitro presumably reflects the presence of NK precursors, but 
"contaminating" mature .NK cells or LAK cells may also contribute (12,63). 
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Little is known about the kinetics of NK cell differentiation. A clinical 
study of the effects of azathioprine suggests that the generation of 
significant numbers of functionally active NK cells may take up to 2-3 
months, as this period of time elapsed after cessation of the drug before 
NK activity recovered completely (66). 
1.4 Modulation of natural killer cell activity. 
The importance of NK cells as antineoplastic cells has stimulated 
great interest in cytokines and pharmacological agents which can 
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potentiate or inhibit NK activity. Although the bulk of experiments on NK 
cell modulation have been performed in vitro, the effects of 
administration of recombinant interferons (IFN) and interleukin-2 (IL 2) 
in vivo are currently under investigation in clinical trials. This section 
deals primarily with the effects of IFN and IL-2 on NK cells in vitro, but 
other cytokines and mediators which influence NK cells are discussed. An 
account of attempts to modulate NK activity in vivo concludes this 
section. 
Interleukin 2 is critical for the differentiation, cytotoxic activity 
and proliferation of human and murine NK cells. Functionally inactive 
foetal and neonatal NK cells can be stimulated to full cytotoxic potential 
by exposure to IL-2 (67). Short-term incubation with IL-2 for periods 
from 4 to18 h significantly boosts NK activity (68-70). This stimulation 
requires protein synthesis but is noted well before IL-2-induced 
proliferation is detected (71,72). Interleukin 2 also appears to maintain 
NK cells in their resting "physiological" state, because in the absence of 
IL-2, NK activity disappears within 20 h (72). This rapid boosting effect 
is unaffected by the anti-Tac monclonal antibody which blocks the 
proliferation of both T cells and LAK cells induced by exogenous IL-2 
(28,69,71,74,75). The anti-Tac antibody reacts with a glycoprotein chain 
common to the high and low-affinity IL-2 receptors. The low affinity IL-2 
receptor consists only of this chain but when it combies with another 
molecule to form a dimer, the high affinity IL-2 receptor is formed . These 
observations suggest that IL-2 may rapidly augment NK activity by 
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interacting with a receptor not recognized by anti-Tac. Alternatively, the 
recombinant IL-2 added to the cultures may successfully compete with 
anti-Tac for receptor binding sites. 
Exposure of pure populations of mature NK cells to IL-2 in culture 
for periods longer than 24 h induces proliferation (68-79). The 
proliferation of NK cells requires only the presence of IL-2, but the 
response can be augmented by mitogenic lectins, interleukin 1 (IL-1) and 
IFN-y (69,75,80). The optimal concentration of IL-2 for NK cell 
proliferation is tenfold higher than that required by cytotoxic T cells and 
kinetic studies detect NK cell proliferation occurring by 4 days in culture 
with peak activity at 6 days. The precursor frequency of proliferating NK 
cells in peripheral blood mononuclear cell (PBMC) populations was 1.4°/o, 
with a marginally lower NK cell cytotoxic precursor frequency (75). When 
cultured in the presence of IL-2, NK cells develop augmented cytotoxic 
activity and express increased densities of surface activation antigens 
(T10, la, IL-2 and transferrin receptors) (78). Unlike the rapid 
augmentation of NK activity, the IL-2-induced proliferation of NK cells is 
blocked by the anti-Tac antibody, indicating the participation of IL-2 
receptors (68,70). It is uncertain how IL-2 can initiate NK cell 
proliferation in view of the very low numbers of IL-2 receptors on these 
cells (70,80). It is probable that sufficient numbers of high affinity 
receptors exist to trigger the division of NK cells. Under the stimulus of 
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IL-2, NK cells may release lymphokines such as IL-1, IFN-y and tumour 
necrosis factor (TNF), which singly or synergistically may upregulate IL-2 
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receptor expression, thus perpetuating NK cell division (80-83). Whether 
activated by IL-2 in a proliferation-dependent or independent manner, NK 
cells lyse a wide range of tumour cell lines and freshly isolated tumour 
cells which are normally resistant to resting NK cells (68,72,79). 
Although IL-2 appears to boost both NK cell proliferation and 
cytotoxicity directly, it has been postulated that IFN- 'Y released by IL-2 
stimulated NK cells may also be involved (69,84). Most authors discount a 
role for IFN in the rapid boost in NK activity induced by IL-2 because 
IFN-neutralizing antibodies have no effect on this process (68,72). 
However in some exper,iments, anti-lFN antibodies were inhibitory and so 
it cannot be excluded that small amounts of IFN in microenviroments 
protected from antibodies stimulate NK cells directly (69,70) . It is 
generally accepted that IFN plays no direct role in NK cell proliferation, 
but it may be possible to 'prime' NK cells for the stimulatory effect of 
IL-2 by preincubation with IFN (69). Thus NK cell proliferation can be 
enhanced by the presence of IFN-y, possibly due to an upregulation of IL-2 
receptors (83). 
The cytotoxic activity of resting NK cells and their precursors is 
rapidly potentiated by short exposure to IFN-a, '3 or 'Y (85). Studies using 
the single cell cytotoxicity assay have shown that virtually every stage in 
the interaction between .NK cells and susceptible targets can be enhanced 
by IFN (16,86). When K562 or MOLT-4 cells are used as targets, IFN has the 
following potentiating effects: (i) the proportion of target-binding cells 
which are cytotoxic is increased; (ii) the time required for an NK cell to 
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lyse a bound target is reduced; (iii) increased amounts of natural killer 
cell cytotoxic factor (NKCF) are secreted and (iv) NK cell recycling time is 
reduced. Against anchorage-dependent target cells, IFN will also recruit 
and activate NK cell precursors from the cells which do not bind target 
cells. Maximum stimulation of NK activity by IFN-a is achieved within 
4 -6 h, whereas the effect of IFN-r takes 12-18 h to complete (85). Few 
studies have defined a dose-response curve for the action of I FN on NK 
cells. For IFN-a it appears that doses greater than 500 U/ml produce no 
further stimulation and doses greater than 1000 U/ml may be inhibitory 
(87). The action of IFN on NK cells also results in increased lysis of 
freshly isolated leukaemic blasts and lymphoma cell lines which are 
relatively resistant to resting NK cells (8,88). 
Activation of NK cells by IFN may be counterbalanced by protective 
effects on some target cells. Preincubation of target cells with IFN 
permits binding by NK cells but lysis is reduced because NKCF release is 
not triggered (89). Little is known about the mechanisms underlying the 
immunomodulatory properties of the IFNs, including their activation of NK 
cells (83). Inhibitors of mRNA and protein synthesis block the effect of 
IFN on NK cells (90). Increased levels of 2'-5' Oligo A synthetase measured 
in NK cells after I FN treatment also suggest that common biochemical 
pathways underly many of the actions of IFN (85). However there was no 
correlation between the antiviral and NK-stimulatory profiles of different 
species and subspecies of IFN (85). 
The most important pharmacological inhibitors of spontaneous or 
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IFN-activated NK cell activity are the prostaglandins (PGs). The addition 
of physiological concentrations of PGA1, PGA2, PGE1 or PGE2 to NK assays 
results in a rapid, but reversible loss of 50-75°/o of cytotoxic activity 
(90-94). The suppression of NK activity by activated monocytes and 
macrophages can be explained by their secretion of PGs (95,96). In a 
comparative study of human macrophages obtained from normal organs, 
those from the lung were the most potent inhibitors of NK cells (96). 
Macrophages associated with human malignancies have similiar 
suppressive properties and may account for the low levels of NK activity 
found in tumours and tumour-draining lymph nodes (97,98). Additional 
amounts of PG in tumours may also be derived directly from the neoplastic 
cells (92). In this context, IFN may mediate an antineoplastic effect by 
protecting NK cells from PG-induced suppression (99). Other cells not 
related to macrophages are capable of inhibiting NK activity, either via 
direct cell contact or by the release of soluble suppressor factor(s) (SSF). 
A mixed lymphocyte culture-generated Leu-7+ FcµR+ lymphocyte inhibits 
NK activity by blocking binding between the NK cell and its target, 
possibly by direct competition for the recognition receptor (100). 
Unstimulated peripheral blood lymphocytes depleted of monocytes and 
cultured under serum-free conditions release a SSF which is capable of 
inhibiting more than 50°/o of NK cell activity (101 ). The identity of the SSF 
is unknown, but its activity is unlikely to be accounted for by 
prostaglandins or any known cytokine. 
Reports in the literature suggest that NK cells are influenced by a 
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diverse range of cytokines, inflammatory mediators and hormones in 
addition to IL-2, IFN and PG's. Interleukin 1 (IL-1) is not an effective NK 
stimulant by itself, but its presence potentiates the increase in NK 
activity induced by IFN and /or IL-2 (102,103). Tumour necrosis factor 
(TNF) is capable of stimulating NK activity alone but its effect is also 
synergistic with that of IL-2 (82). Both IL-1 and TNF may be able to 
enhance the effect of IL-2 by the upregulation of NK cell IL-2 receptors 
(81,82). The neutrophil myeloperoxidase enzyme system has important 
bactericidal, inflammatory and immunoregulatory properties mediated by 
hypohalite ions generated from hydrogen peroxide and halides (104). 
Without affecting cell viability, products of the myeloperoxidase system 
cause a marked, but reversible suppression of NK activity (105). In animal 
models of tumour metastasis, oestrogens selectively inhibit NK activity 
and lead to an enhanced susceptibility to metastasis (106). In pregnant 
women and neonates, the significant depression of NK cell lytic function 
may be related to elevated levels of oestrogen hormones (107). 
Large numbers of patients with advanced malignancy have been 
treated with purified or recombinant preparations of IFN because of its 
antiproliferative effects on tumour cells and stimulation of NK cells in 
vitro (108,109). In general, the results have been disappointing with little 
effect noted on carcinomas and a response rate of only 20°/o ach ieved for 
tumours such as multiple myeloma or non-Hodgkin's lymphoma. However, 
hairy cell leukaemia appears uniquely sensitive to IFN-a with complete 
remissions achieved in 90°/o of cases (110). It is postulated that NK 
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activity may be important in controlling this leukaemia as low NK activity 
noted in most pretreatment cases is restored to normal levels after I FN 
therapy. Continuous intermittent therapy with IFN produces a peak in 
peripheral blood NK activity one to three weeks after commencement of 
therapy, followed by a gradual decline to normal levels (109). The NK cells 
from patients treated with IFN are not active against NK-resistant 
targets, as is the case with cells treated in vitro. The reason for the 
consistent decline in NK activity with continued administration of I FN is 
unknown, but the induction of increased numbers of circulating T 
supressor cells by I FN is one hypothesis. 
Interleukin 2 given intravenously to patients with disseminated 
malignancy produces a partial remission of the tumour in 13°/o of cases 
(111 ). Despite the intermittent injection of megaunit doses of IL-2, a 
consistent increase in peripheral blood NK activity has not been noted 
(112). However, the circulating precursors of lymphokine-activated killer 
(LAK) cells were depleted, suggesting that LAK or NK cells may migrate to 
peripheral organs during therapy with IL-2. Direct evidence showing that 
murine NK cells can be recruited from the circulation into the liver and 
lung after treatment with NK-stimulating agents has been reported (113). 
The bioavailability of recombinant IL-2 is limited by its extremely short 
half life which has been attributed to a lack of glycosylation (113). 
Preliminary studies confirm the efficacy of IL-2 given by continuous 
infusion but the in vivo immunological effects of this treatment 
modification remain to be reported (114). 
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1.5 Mechanisms of natural killer cell cytotoxicity. 
Accumulating evidence from a vast literature on the mechanisms of 
NK cell cytotoxicity indicates that the process is a complex sequence of 
programmed events culminating in target cell lysis. Analytical methods 
allowing protein purification and characterization, lymphocyte cloning, 
membrane receptor isolation, monoclonal antibody synthesis and 
pharmacological inhibition of cellular function have all contributed to a 
coherent, but as yet incomplete concept of NK cell-mediated cytotoxicity 
(115). Target cell lysis by NK cells best fits a "stimulus-secretion model" 
which can be dissected experimentally into the following stages: (i) target 
cell binding; (ii) triggering of activation; (iii) NK cell activation and 
release of cytotoxic molecules; (iv) target cell death; (v) recycling and 
further lysis. Elucidation of the cytotoxic mechanism has largely been due 
to the studies of Targan et al (115,116) which exploit the different ionic 
requirements of the various stages. Binding occurs in the presence of 
magnesium ion (Mg+2) and will not proceed to activation until calcium ion 
(Ca+2) is added as a pulse. Neither the triggering nor lysis phases require 
ca+2, so the cytotoxicity assay can be arrested at each step and studied 
using the methods described above. 
The initial binding of NK and target cells to form a conjugate 
involves interaction between an NK cell recognition receptor (RR) and a 
target structure (TS). Cold target inhibition studies of freshly isolated 
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and cloned NK cells illustrate that there are different RR, some of which 
are specific for only a single target while others can mediate the binding 
and lysis of several different cell types (6). The reactivity of an NK cell 
population against a range of susceptible targets is not based upon a 
clonal distribution of single RR's among NK cells. Instead, individual NK 
cells express a variable profile of different RR 's which may overlap 
partially with the receptor complement of other NK cells (5). 
Characterization of the NK RR has not progressed beyond preliminary 
experiments which suggest that the RR is a glycoprotein or glycolipid 
(53,117). Treatment of NK cells with proteolytic enzymes or metabolic 
inhibitors of glycosylation markedly inhibited the degree of binding to 
NK-susceptible targets. Murine data suggest that expression of the RR 
may be genetically determined by loci linked to the major 
histocompatibility genes (118). In contrast to NK cells, the RR on K cells 
mediating ADCC has been well characterized by phenotypic and functional 
studies as an Fe receptor for lgG (119). Once specific recognition is 
mediated by this receptor, lysis of the antibody-coated target proceeds by 
mechanisms identical to those of NK activity. 
Target cell structures (TS) isolated from K562 cell membranes have 
been characterized as glycoproteins of molecular weight 200, 120 and 80 
kD which are capable of selectively inhibiting the binding of NK cells to 
K562 cells (120,121). The two smaller molecules were also isolated from 
additional NK cell-susceptible but not resistant cell lines and 
demonstrated similar inhibitory binding to NK cells. Inhibition of the NK 
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cell binding function by pretreatment with nonphosphorylated sugars 
suggests that the TS may be glycosylated (122). The heterogeneity of TS 
was demonstrated in studies where the target specificities of NK cell 
populations were examined after adsorption of NK cell subsets on target 
cell monolayers (32). These data suggest that some TS may be common to 
all target cell lines whereas others are restricted in their distribution. 
Candidate molecules postulated for the TS on human cells include 
the transferrin receptor, virus-induced glycoproteins and differentiation 
antigens. Data concerning the transferrin receptor are contradictory and 
apply only to some target cell types in the human NK cell system 
(123-128). The observed correlation between NK-susceptibility and 
transferrin receptor expression on nonmalignant or tumour targets and the 
sensitivity of NK activity to antitransferrin antibodies favour a role for 
this structure. The ability of malignant cell lines to compete with K562 
cells for NK cell lysis also loosely correlates with their level of 
transferrin receptor expression, but complete inhibition of K562 lysis was 
not achieved with any of the lines tested (124). These studies imply that 
the transferrin receptor does not function as a complete TS, although it 
may act as an accessory NK-binding molecule for some, but not all target 
cells. Viral infection of target cells results in the expression of 
glycoproteins that are recognized by NK cells. In the case of Herpes 
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simplex virus type 1 (HSV-1 ), the NK receptor is of viral origin and the 
degree of target lysis is .directly related to the number of glycoprotein 
subunits expressed in the receptor (129). Surveys of nonmalignant cell 
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populations and tumour cell lines have highlighted the direct correlation 
between level of differentiation and susceptibility to NK cell activity 
(130,131). This relationship suggested that the TS may be a primitive 
developmental antigen. Supporting evidence came from a study where 
monoclonal antibodies to stage-specific embryonal antigen protected cell 
lines against NK-mediated lysis (131 ). Alternatively, the resistance of 
differentiated cells to NK activity may be explained by increased amounts 
of membrane sialic acid which shields the TS by steric hindrance (132). 
The ability of NK cells to lyse cells devoid of detectable HLA 
antigens suggests that these structures are not prime targets for NK cells, 
but it does not preclude the possibility that HLA antigens associate with 
and influence the expression of TS on some cells (133). Evidence for this 
proposal comes from studies where the NK susceptibility of cell lines 
varied inversely with the levels of HLA class I antigen and p2 
microglobulin expression. Only one description of a single cloned NK cell 
line suggests that HLA antigens may also associate with the RR on 
effector cells (134). Antibodies against both class I and II antigens either 
enhanced or inhibited NK activity of this clone but the lack of effect on 
bulk NK cell populations suggests that the participation of HLA antigens in 
target cell recognition is a rare event. 
Conjugate formation between NK and target cells occurs within 
minutes at temperatures between 4°C and 37°C and requires the presence 
of Mg+2, but not ca+2 ions (115,116) . Inhibition of binding in a 
dose-dependent and reversible fashion by pretreatment with dimethyl 
23 
sulfoxide (OMSO) and 2-mercaptoethanol (2-ME) suggests that membrane 
protein-lipid structures and disulphide bonding participate in conjugate 
formation. The resistance of pre-formed conjugates to OMSO and 2-ME 
suggests however, that multiple binding mechanisms may maintain 
effective NK cell-target interaction. 
Analysis of the cells binding NK-susceptible targets in a single cell 
cytotoxicity assay shows that a significant proportion may not be NK cells 
but are mainly T cells (16,135). These binding non-NK cells do not, 
however, make a significant contribution to the overall lysis of target 
cells. In similar assays, NK cells are also observed binding to 
NK-resistant targets. The membrane structures accounting for this 
nonspecific binding are unknown, although the family of leucocyte function 
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antigens (LFA) are likely candidates (58). Blockade of the LFA-1 and 
LFA-2 (CO2) molecules on NK cells results in almost total inhibition of NK 
activity due to inhibition of conjugate formation (58). Furthermore, 
congenital deficiencies of LFA-1 are also characterized by deficient NK 
activity (136). The relative contributions of specific receptor interaction 
and nonspecific adhesion to effective NK-target cell binding are unknown. 
It is likely that both specific receptor interactions and indiscriminate 
binding mechanisms are required to produce maximum target lysis by NK 
cells. 
Recent experiments using a panel of monoclonal antibodies directed 
against different epitopes on the CO2 and C016 antigens on NK cells 
suggest that parts of both of these structures may be involved in NK cell 
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activation (137). Whereas the majority of antibodies studied inhibited NK 
cell activity, one directed against CO2 and another specific for CD16 
stimulated cytotoxicity after binding. Thus the CO2 and CD16 structures 
may serve the dual functions of target cell binding and NK cell activation. 
The precise role of the CO2 and CD16 activation structures in the process 
of NK cell-mediated lysis remains to be defined. 
Studies using the monoclonal antibody 13.1 have revealed a short 
triggering phase linking NK cell binding and activation. The 13.1 antibody 
is directed against an epitope carried by the polymorphic T200 
glycoprotein which is found on the membranes of all PBMC including NK 
cells and cytotoxic T cells (138,139). After treatment with 13.1, 
cytotoxicity mediated by NK but not T cells was abrogated. Inhibition of 
NK activity towards K562 cells occurred only if the antibody was added 
before commencement of activation by ca+2 pulsing . As no inhibition of 
NK binding was noted, 13.1 appears to be a potentially useful marker 
specific for the ca+2-independent triggering event. Experiments using 
inhibitors of transmethylation have confirmed the existence of a trigger 
stage. Transmethylation of phosphatidylethanoleamine in the cell 
membrane is important in cell activation and in increasing membrane 
fluidity (140). Inhibitors of transmethylation inhibit NK activity and 
appear to selectively block the triggering event, preventing progression to 
activation despite ca+2-pulsing (141,142). 
Conjugate formation and triggering of the NK cell leads on to the 
"activation" or "programming for lysis" phase. During this period the NK 
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cell must remain bound to its target in order to deliver what is popularly 
known as the "lethal hit" (115,116). Morphologically this phase is 
characterised by the polarization of NK cell granules and secretion of 
granule contents in the vicinity of the bound target. Target cell lysis is 
able to proceed without NK cell contact once the "killer cell independant 
lysis" step (KCIL) begins. In order to determine the kinetics of the 
activation and KCIL steps, NK-target cell conjugates formed in the 
presence of Mg+2 alone are then pulsed with ca+2 which is necessary for 
activation to proceed (115). At intervals after activation, the effect of 
conjugate disruption on target cell lysis is determined. These 
experiments have delineated an activation phase which may last up to 2 h 
for some effectors before maximum lysis of K562 or Molt-4 targets can be 
achieved. Addition of ethylenediaminetetraacetic acid (EDTA) at intervals 
after the calcium pulse has shown that the activation phase requires ca+2 
for only the first 90 min and thereafter the reaction can proceed 
independently. It must be appreciated that the duration of activation 
determined by calcium pulse experiments is the time taken for the entire 
population of NK cells to complete this phase. Kinetic studies of cytotoxic 
reactions show that detectable lysis of targets by some NK cells begins 
within minutes of conjugate formation. Unlike the binding stage, 
activation occurs optimally in a narrow temperature range around 37°C 
(115). 
Heterologous and monoclonal antisera which are known to inhibit NK 
cell activity have been used to probe for membrane structures crucial to 
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target cell lysis (143). The heterologous antiserum RH2 and monoclonal 
antibodies RH 7.2 and RH 17.2 were raised against sodium 
periodate-modified mixed lymphocyte culture-activated cytotoxic 
lymphocytes but the epitope(s) detected by these antibodies have not been 
identified. All three antibodies blocked NK cytotoxic activity at both the 
activation and KCIL stages and before the assay were shown not to react 
with the target cells. Therefore, blocking of activation was at the level of 
the NK cell whereas inhibition of KCIL was an effect on the target cell, 
implying that transfer of membrane components from NK to target cell 
was important for cytolysis. 
Although the stages of NK cell-induced lysis can also be defined and 
subdivided using pharmacological agents, little is known about the site of 
action of these agents or how they produce their effect. The early, 
ca+2-dependent period of activation is blocked by inhibitors of ca+2 flux 
into cells such as Verapamil and Lignocaine (116). The ca+2 ion may be 
involved with the calcium-binding enzyme Calmodulin in regulating 
numerous enzymatic activities and indeed, the presence of ca+2 in the 
cytosol is a known cofactor for granule secretion (116,144). Elevation of 
the intracellular cAMP/cGMP ratio by Prostaglandin E (PGE), theophylline 
or cAMP also inhibit NK activation (116,145,146). Both PGE and 2-ME 
block the late, ca+2-independant phase of activation as well as KCIL (116). 
In the activation stage, PGE inhibits NK cells by increasing intracellular 
cAM P but interruption of KCIL is attributed to a cytoprotective effect of 
PGE (116). 
--
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The participation of free oxygen radicals in NK cytotoxicity is 
suspected because chemically unrelated scavengers of the hydroxyl radical 
' (OH ) are known to abolish NK activity without affecting the frequency or 
viability of effector-target conjugates (147,148,149). It has been 
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suggested that peroxidation of NK cell lysosomal membranes by OH 
facilitates secretion of cytotoxins in a fashion similar to that proven for 
mast cell granules (150). There is mounting evidence however, against 
free radical production by NK cells (151 ). Although free radical production 
is detected by chemiluminescence seconds after contact between NK cells 
and susceptible targets, it is likely that the actual producers are a 
minority population of monocytes contaminating enriched LGL 
' preparations. Further evidence against NK cell OH production is the intact 
NK activity found in chronic granulomatous disease which is characterized 
by the absence of free oxygen radical generation due to genetic defects in 
the NADPH oxidase system (152). However NK cells may produce small 
' amounts of OH as byproducts of the lipoxygenase pathway (153). This 
hypothesis is supported by the inhibitory effects of lipoxygenase 
' inhibitors on NK activity (148) while potent inhibitors of OH production 
by the NADPH oxidase pathway are without effect (148,149). The issue of 
' OH function in NK activity remains to be resolved. It is possible that NK 
' cells may generate small amounts of OH in cellular microenviroments 
which are undetectable by present methods. 
The activation of NK cells is signalled by morphological changes 
affecting the LGL secretory apparatus. Within minutes of binding to a 
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sensitive target, the Golgi apparatus and microtubule organizing centre of 
the NK cell polarizes towards the area of mutual cytoplasmic contact. 
Granules derived from the Golgi are then guided by microtubules to the 
vicinity of membrane contact (154). Whether granule contents are 
transferred onto the target surface directly from the effector's membrane 
or via secretion into the extracellular space is unresolved. Natural killer 
cells bind to targets by finger-like protrusions which intrude into 
reciprocal pockets in the target cell as well as by broad areas of intimate 
contact (154). Interference with the secretory process of LGL shows that 
release of the granules is vital to delivery of the lethal hit. Disruption of 
vesicular traffic from the Golgi to the cell surface by microtubule 
inhibitors inhibits NK activity and chemicals which degranulate lysosomes 
or pervert their function have the same effect (155,156). Genetic defects 
of lysosomes reported in the beige mouse or in man (Chediak-Higashi 
syndrome) are also characterized by absent NK activity (157,158). 
After delivery of the lethal hit, target cell destruction occurs 
whether or not the NK cell remains attached. The progression to lysis is 
not inevitable as evidenced by the protective effect of PGE and of 
modulators which increase the rigidity of lipid membranes (116). There is 
some controversy surrounding the processes involved in NK cell-mediated 
target cell lysis. The formation of membrane pores has been observed in 
target cells after attack by CTL, the membrane attack sequence of 
complement and NK cells (159,160). However, careful ultrastructural 
studies question the role of pore formation and suggest that target cells 
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may die by apoptosis. In this distinctive process, the target cell 
cytoplasm and nucleus are actively segregated into multiple 
membrane-bound vesicles which are endocytosed by adjoining parenchymal 
and scavenger cells (161 ). The nature of the lytic molecules mediating 
apoptosis is unknown and the overall relative importance of the multiple 
lytic molecules secreted by NK cells remains to be determined. 
Cytolysins so far associated with NK cells include perforin, NK 
cell-associated cytotoxic factor (NKCF) and a collection of proteases and 
esterases (162,163). All are granule-associated and are released during 
the activation stage of NK cytolysis. Perforin is probably the most 
significant cytotoxin secreted by NK cells (162). Most is known about this 
molecule because of its role in killing by cytotoxic T lymphocytes (CTL) 
and its similiarity to the ninth component of complement (C9). 
Polymerization of the 60-75kD perforin molecule in the presence of ca+2 
results in the formation of a cylindrical hollow channel which is able to 
insert into the lipid bilayer of the target cell membrane (160). The 
resulting pore is postulated to allow free inflow of electrolytes and other 
solutes into the cell, leading· to osmotic lysis. Large pores comprised of 
polyperforin (internal diameter 16 nm) and smaller structures (6 nm) 
thought to be single perforin molecules, have been visualized by 
electronmicroscopy in the membranes of cells after lysis by complement, 
NK cells or CTL. Perforin is antigenically simil iar to C9 and considerable 
homology exists between their genes, making it likely that the perforin 
gene arose from the C9 gene by a primitive reduplication event. The 
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granular location of this molecule is suggested by the formation of 
identical membrane pores by isolated and purified NK cell granules. 
Purified perforin or isolated NK granules possess potent nonspecific 
cytotoxic properties extending well beyond NK-sensitive cells to include 
most nucleated cell lines (159,162). It is postulated therefore, that the 
specifity of lysis by NK cells is conferred by prior binding and activation 
steps. Bystander damage to cells near NK reactions may be avoided by the 
intimate nature of the contact between target and effector which prevents 
leakage of perforin into the extracellular space. Damage to the NK cell 
itself may be limited by granule derived sulphated proteoglycans which 
can bind to and neutralize excess liberated perforin (164). 
The existence of NK cell-derived cytotoxic factor (NKCF) was first 
suspected when the supernatants from cocultures of NK cells and their 
susceptible targets were found to have cytotoxic activity (165,166). 
Unlike perforin, NKCF retains the target specificity profile of the secreter 
NK cell population. This property implies the existence of specific 
receptors on target cells which are recognized by NKCF molecules. The 
nature of the NKCF-receptor system remains elusive. Inhibition 
experiments with phosphorylated sugars show that this receptor system is 
independent of membrane structures which mediate initial target 
recognition and binding (167). It is also evident that the release of NKCF 
is relatively nonspecific as NK-resistant tumour cell lines can bind to and 
stimulate NK cells to release NKCF. The specificity of NKCF is therefore 
at the level of the target cell which will only be lysed if receptors 
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specific for NKCF are expressed. The target cell receptors for NKCF are 
poorly understood but appear to contain protein because of their 
sensitivity to papain (168). Natural killer cytotoxic factor is a 20-30,000 
kD MW glycoprotein which appears to be located in NK cell granules 
because of its inhibition by antigranule antibodies (168,169). Both 
increased cytosol ca+2 and protein kinase C are involved in the release of 
NKCF. In patients with AIDS, defective release of NKCF underlies the 
defective NK activity seen in this infection (170). A paradox evident in 
NKCF studies was that the NKCF produced by NK cell-target cocultures was 
only weakly cytotoxic unless incubated in concentrated form with targets 
for periods of up to 40 h (168). However NKCF may function as a 
significant cytolysin when released into the microenviroment of the 
NK-target cell contact area. The mechanism or site of action of NKCF is 
unknown but recent studies have convincingly demonstrated that NKCF 
activity was not attributable to, or enhanced by, tumor necrosis factor 
(TNF), Lymphotoxin (LT) or IFN (169). 
Some NK cell secretory products have an antineoplastic action by 
inhibiting tumour cell proliferation rather than directly causing lysis. The 
IFNs secreted by NK cells are prime candidates for this cytostatic role 
(83). A 44kD protein synthesized by NK cells has been called Leukoregulin 
because it also has antimitotic effects against NK cell-susceptible tumour 
cell lines (171 ). In addition to its cytotoxic properties on some tumour 
cells, TNF is also cytostatic (172,173). This cytokine is released by 
either resting or IFN-y activated NK cells but does not appear to contribute 
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significantly to the cytostatic or cytotoxic effect on NK cell-susceptible 
targets in vitro (168,172). However under special conditions in vivo, NK 
cell derived TNF may have a significant effect. 
The third group of toxic molecules involved in the cytotoxicity of NK 
cells are serine proteases, serine esterases, arylsulphatase, phospholipase 
and possibly endonuclease enzymes located in the NK cell granules 
(162, 17 4-176). Current evidence suggests that the serine proteases are 
instrumental in enzymatically activating NKCF or perforin in an enzymatic 
cascade similiar to that of the complement system. There may be a 
limited role for phospholipase and arylsulphatase in mediating direct 
injury to cell membranes and the degradation of nuclear DNA early in cell 
lysis may be mediated by passage of enzymes through membrane pores to 
the nucleus. 
Mathematical analysis of the data from single cell and 51 Cr-release 
cytotoxicity assays run simultaneously suggests that a single NK effector 
is capable of lysing several target cells in succession (177). During a four 
h cytotoxicity assay, the average number of K562 or MOL T-4 targets killed 
by a single LGL is estimated to be 3.2 and 4.5 respectively. This recycling 
capacity of NK cells implies that l.ysis involves a tightly controlled 
secretory process which allows sufficient reserves for further target cell 
encounters in a brief period of time. The relatively slow regeneration of 
granule contents after degranulation suggests that only a fraction of the 
NK cell's cytolysins are used during each lytic encounter (168). 
In summary, the complicated sequence of steps necessary for target 
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lysis by NK cells is best ·explained by three receptor-mediated events 
which all contribute to the overall specificity of the effector-target 
interaction. The first set of receptors mediates effector-target binding 
and is followed by NK cell activation which is mediated by a second set. 
Finally, NKCF must interact with a third specific receptor on the target 
cell surface before lysis is effected. There is evidence to suggest partial 
sharing of antigens or membrane structures between the receptors 
mediating this complex sequence. The participation of the same membrane 
glycoprotein from the K562 cell line in both effector cell binding and lysis 
by NKCF suggests that the receptors for these events may share membrane 
structures (178). Antigenic similiarities between receptors are further 
suggested by the inhibition of both binding and activation stages by a 
single antibody specific for this glycoprotein. 
The enigmatic receptor system responsible for the cytotoxic 
activity of classical CD3- NK cells is different from that used by a small 
population of co3+ peripheral blood lymphocytes which also mediate 
spontaneous NK activity (39). It has been shown that the T cell receptor 
and adjacent CD3 activation complex may mediate the nonspecific 
cytotoxic activity of these T cells. The target cell structure specifically 
recognized by this receptor is a 140 kD glycoprotein heterodimer which is 
an activation marker on a wide range of cells (179). Despite its wide 
distribution, this molecule is not recognized by NK cells. Like 
antigen-specific reactions, the nonspecific cytotoxicity of co3+ NK cells 
can be blocked by monoclonal antibodies against either the T cell receptor 
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or the CD3 antigen (39). This receptor system is not available to CD3- NK 
cells which do not rearrange the genes encoding for the T cell receptor. 
1.6 The antineoplastic role of natural killer cells. 
Abundant evidence exists to support an important role for NK cells 
among the defence mechanisms which prevent the development and spread 
of malignancy. The most convincing data come from experimental models 
of malignancy in rodents where the background NK activity, timing, site of 
tumour induction and NK-susceptibility of the tumour can be manipulated 
independently. These investigations form a basis for the discussion of 
clinical studies of patients with malignancy where the evidence for an 
antineoplastic function for NK cells is, by its nature, largely 
circumstantial. 
In rodent models of malignancy, NK cells are effective against a 
wide range of leukaemias, lymphomas, carcinomas and sarcomas 
(180-187). These tumours were induced in vivo by inoculation of 
established tumour cell lines or by chemical carcinogens or irradiation. In 
these studies, there was a clearcut inverse correlation between the level 
of pre-existing splenic and peripheral blood NK activity and the subsequent 
development of malignancy (181,182). Natural killer cell activity was 
diminished in vivo by the use of immature animals, genetic variants with 
low NK activity (the beige mouse) or by the chemical suppression of NK 
activity using agents such as p-oestradiol (185). The supplementation of 
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NK activity by adoptive transfer of functional cells or treatment with IFN 
was then followed by restoration of resistance to the development of 
malignancy (181,182). This effect however, was noted only with small 
starting doses of tumour and furthermore, once the malignancy was 
well-established, the level of NK activity of the host was found to be 
irrelevant to further progression (184). The selective effect of NK cells 
on tumours in vivo was studied against NK cell-susceptible or resistant 
mutants of the same tumour cell line which had identical susceptibility to 
lysis by activated macrophages and cytotoxic T lymphocytes (186). These 
experiments showed a direct correlation between the tumourigenicity of 
the cell line mutants and their resistance to NK activity. Natural killer 
cells were also effective in reducing the incidence of lung metastases 
complicating primary footpad tumours or implanted following intravenous 
innoculation of tumour cells (185-187). Reconstitution experiments 
I 
suggest that NK cells exert maximal suppression on metastasis formation 
within 24 h of tumour cell entry into the circulation. After this time, 
numbers of malignant cells sufficient to produce metastases may have 
entered tissues where they were inaccessible to NK activity (187). 
Conclusions drawn from animal models where tumours are experimentally 
induced may not apply to tumours arising spontaneously in humans. 
Because of the constraints of time, experimental animals are rarely 
observed for long enough periods to relate the incidence of spontaneous 
malignancy to the level ,of NK cell activity. Nevertheless, one such study 
I 
of beige mice has documented a twofold increase in spontaneous tumours 
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in homozygous as compared to heterozygous littermates (188). 
Due to the nonspecific suppressive effects of large tumour burdens 
and cancer therapy, a definitive role for NK cells in human malignancy has 
been more difficult to prove (189,190). Peripheral blood NK activity 
against K562 targets is preserved in the early stages of most 
malignancies but NK activity declines as the disease progresses (189). 
Lymphomas and leukaemias are exceptions to this observation as NK 
activity is significantly impaired even at the earliest stages of these 
tumours prior to therapy (191,192). The reduced NK activity in advanced 
malignancy has been attributed to hyporesponsiveness to IFN, decreased 
recycling capacity and to reduced numbers of circulating Leu-7+ NK cells 
(193-195). In acute and chronic leukaemias, defects in NK cell binding, 
lytic activity and recycling time all contribute to low levels of NK 
activity (192). A similiar early suppression of NK activity may exist in 
malignant melanoma where NK activity against a melanoma cell line target 
was enhanced after surgical excision of early lesions (196). Thus with the 
possible exception of select tumours, pre-existing defects in peripheral 
blood NK activity do not appear to predispose to human malignancy. 
A more fundamental analysis of the role of NK cells in human 
maligancy can be made by using freshly isolated tumour cells as targets to 
assess the cytotoxic potential of lymphoid cells isolated not only from the 
peripheral blood, but also from organs affected by malignancy and the 
tumour itself. Such organs frequently affected by malignancy have 
variable levels of endogenous NK activity. The intestinal lamina propria 
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displays minimal levels of NK activity against either K562 cells or freshly 
isolated colon carcinoma cells (197). On the other hand, cells from the 
lung interstitium and alveolar spaces mediate significant NK activity 
against K562 cells (26,198). Testing peripheral blood lymphocytes (PBL) 
and tumour-infiltrating lymphocytes (TIL) for cytotoxic activity against 
freshly isolated tumour cells yields conflicting results. While a number of 
investigators report no spontaneous PBL cytotoxicity against fresh targets 
(11,199), there are other reports of significant levels of tumour-directed 
PBL cytotoxic activity in up to 50°/o of normal donors and patients with 
malignancy (12, 13,199,200,201). lmmunohistochemical studies suggest 
that NK cells are infrequent in malignant tumours (202), but functional 
studies of isolated TIL show low grade but significant activity against 
K562 cells and fresh tumour cells in 10-50°/o of cases (203-205). Tumour 
cells isolated from breast, colon and lung carcinomas demonstrated 
susceptibility to lysis by both PBL and TIL. Positive identification of the 
anti-tumour effector cell(s) in PBL and TIL populations has not been 
achieved. However in some studies an IFN-inducible large granular 
lymphocyte was isolated with cytotoxic activities against both autologous 
and allogeneic targets (23,200,203,205). Although the evidence therefore 
favours an NK cell, some studies indicate that cytotoxic T cells may also 
be involved in antitumour cytotoxic activity (206). 
Epidemiological studies of apparently normal individuals at 
increased risk for malignancy support a role for NK cells in tumour 
immunesurveillance. There is a tendency for the relatives of patients 
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with solid tumours to have significantly reduced peripheral blood NK 
activity (9,207). In the case of malignant melanoma, significant 
depression of NK activity was detected only against melanoma cell line 
targets. Furthermore, the level of NK activity in normal subjects exposed 
to carcinogens such as ultraviolet light or tobacco smoke is significantly 
lower than unexposed controls (208,209). The increased rate of maligancy 
in immunodeficiencies such as Chediak-Higashi disease, severe combined 
immunodeficiency and the acquired immunodeficiency syndrome has been 
attributed to reduced or absent NK activity (42,210,211), but in these 
disorders, defective NK activity is usually accompanied by numerous other 
immune abnormalities which could equally well predispose to neoplasia. 
The general conclusions from animal models of malignancy is that 
NK cells are primarily effective in preventing the emergence of malignant 
cell clones. A secondary role for NK cells may lie in their ability to 
rapidly neutralize haematogenous metastases. It is difficult to define 
such a clear role for NK cells in human malignancy. Against selected 
tumours such as lymphoma, NK cells may be an important primary defence 
and in unusual cases of familial malignancy, a defect in NK activity may 
lower resistance to malignant transformation. The presence of small 
numbers of tumour-reactive NK cells in the peripheral blood and tumours 
of some individuals further suggests an active role for NK cells in human 
malignancy. On balance, NK cells are likely to be important as a 
surveillance mechanism early in tumour development in humans rather 
than a significant influence after the tumour has presented clinically. 
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1.7 The antimicrobial properties of natural killer cells. 
There is abundant evidence available to suggest that NK cells form 
an intergral component of host defence against certain viruses, bacteria, 
fungi and parasites. The bulk of these data is circumstantial and depends 
upon demonstration of a correlation between resistance to infection and 
level of NK activity or upon the ability of NK cells to lyse microbial 
pathogens in vitro. In addition, most studies utilize murine NK cells which 
are known to differ biologically from human NK cells, particularly in 
organs such as the intestine (212). Based on evidence of this nature, NK 
and K cells have been implicated in resistance against a wide range of 
bacterial, fungal and protozoan pathogens including Salmonella (213), 
i 
Shigella (47,214), Legionella (215), Cryptococcus (49,216), Giardia (48) 
and Trypanosoma (217). 
Much more is known about the interaction between NK cells and 
viruses. After viruses penetrate the host's physical defences, readily 
inducible (eg IFN activated) NK activity may limit viral dissemination 
until specific responses by T and 8 cells evolve. This role for NK cells 
was first suggested by the prominent proliferation and activation of NK 
cells noted early in some viral infections (218) and was later confirmed in 
models of murine cytomegalovirus (CMV) infection (219). Identification of 
NK cells as the mediators of early resistance to viral infection depended 
on the following clinical and experimental observations: (i) cytotoxic 
activity against virus-infected cells was comparable in subjects with or 
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without serological evidence of prior infection; (ii) resistance to infection 
in vivo correlated closely with the level of NK activity against 
virus-infected cells in vitro; (iii) addition of NK cells to infected cell 
monolayers limited viral replication; (iv) murine adoptive transfer and in 
vivo depletion experiments identified the anti-virus effector cells as NK 
cells; (v) effector cells in human studies were CD15+ OKM1 + Leu-7+ la-
LGL and (vi) cytotoxicity against virus infected targets was not 
HLA-restricted and was rapidly boosted by IFN-a or~ and IL-2 (220-226). 
In some viral infections such as murine lymphocytic choriomeningitis, 
elevated NK activity may be an epiphenomenon that has no bearing on the 
progression of infection (227,228). 
The rapid increases in NK activity and IFN levels in early viral 
infections act synergistically to limit viral replication. In murine CMV 
infections, high levels of circulating IFN-a have little protective effect 
without an intact NK system (219). The main function of IFN-a in CMV 
infection appears therefore, to be the augmentation of endogenous 
antiviral NK activity rather than a direct antiviral effect. Investigation of 
human CMV infections with IFN-neutralizing antibodies in vitro indicates 
that production of IFN-a was mandatory for anti-CMV activity (221,226). 
Characterization of the IFN-secreting cell showed that an la+ CD16-
0KM1-Leu-7- mononuclear cell without NK activity was the source (221 ). 
The lack of correlation between the levels of HSV-1 induced IFN-a 
production and NK activity in patients with the acquired immunodeficiency 
syndrome also suggests that NK cells are not an important source of IFN-a 
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(228). As well as increasing the cytotoxicity and target-binding capacity 
of antiviral NK cells, IFN may also modify the susceptibility of target 
cells to lysis. Uninfected target cells such as fibroblasts may have 
reduced, equivalent or increased sensitivity to NK activity when compared 
with infected targets (230). In the case of human and murine CMV, 
treatment with IFN reduces the sensitivity of uninfected targets to lysis 
but leaves the sensitivity of infected cells unchanged (231,232). This 
effect may selectively protect uninfected host cells from NK 
cell-mediated cytotoxicity. Similar experiments using viruses resistant 
to NK activity show that IFN markedly reduces the lysis of both infected 
and uninfected target cells (231 ). 
The nature of the membrane structure on virus-infected target cells 
mediating recognition and lysis by NK cells is obscure and evidence 
' 
suggests that the target structure may be either a host cell or a viral 
product. On the one hand, competition between CMV or HSV-1 infected and 
uninfected fibroblasts in cytotoxicity assays suggests that the NK cell 
receptor is also found on uninfected cells and may therefore be a modified 
or enhanced component of the normal cell surface (231,232). However 
under different experimental conditions, NK cells appear to lyse HSV-1 
infected cells only if a membrane glycoprotein of viral origin is expressed 
(130). The NK cell receptor on CMV-infected fibroblasts is expressed 
early in the course of infection, coinciding with the virus induced 
synthesis of "early proteins" which precedes assembly and release of 
intact virions by up to 40 h (130,232,233). This property of NK cells may 
42 
limit CMV infection at an early stage before large numbers of complete 
virions are released from infected cells. The target cell structure 
recognized by NK cells may be expressed independently of major antigenic 
variations in viral products which are also expressed on the infected cell's 
surface. Whereas specific T cell responses to different strains of the 
influenza virus must evolve to match antigenic shifts in haemagglutinin 
and neuraminidase determinants, NK cells from the same donor are active 
against different strains of virus irrespective of their antigenic 
variability (234). 
Subsets of NK cells mediating cytotoxicity exclusively against 
viruses or tumour targets can be identified. Cold target inhibition studies 
show that NK cells with activity against HSV-1 overlap minimally with 
those mediating cytotoxicity against K562 cells (31,230). While both 
subsets of cells were CD16+ Leu-7+ OKM 1 +, anti-K562 effectors were 
co2+ la- whereas thos~ active against HSV-1 were co2- la+. Further 
evidence supporting the independence of NK cells active against K562 and 
HSV-1 infected fibroblasts is the dissociation found between the levels of 
these activities in some normal human subjects (31 ). The apparent 
differences between antiviral and antitumour NK cells may however 
depend more upon the type of target cell used to carry the virus rather 
than the nature of the infecting virus itself. When, for example, 
HSV-infected lymphoblastoid cell lines are used as targets there is no 
detectable difference between the antiviral NK cells and those which lyse 
K562 cells (235). 
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Spontaneous and IFN-augmented human NK cell activity has been 
detected against other important viral pathogens including the 
Epstein-Barr virus, Measles, Mumps, Vaccinia, Influenza, Varicella, Human 
T Cell Lymphotrophic Virus type 1 and the HIV-1 (230,234,236-238). The 
demonstration that NK cells can lyse targets infected with these viruses 
in vitro offers only circumstantial evidence that NK cells are important in 
influencing the course of these infectious diseases. Studies probing for an 
immunoregulatory role of NK cells in resistance to infection are 
infrequent, but they illustrate that the anti-viral effect of NK cells may 
act through mechanisms other than direct cytotoxicity. In the case of 
influenza, NK cells provide accessory cell function for the generation of 
specific cytotoxic T cells in addition to mediating nonspecific 
cytotoxicity (239). 
1.8 Regulatory functions of natural killer cells. 
In addition to their nonspecific cytotoxicity against tumours, cells 
belonging to the NK lineage contribute to the regulation of nonmalignant 
cellular growth and differentiation. Following an early report that 
immature thymocytes were susceptible to lysis by NK cells, other 
populations of rapidly proliferating precursor cells in the bone marrow and 
peripheral lymphoid tissue were examined for the presence of NK 
cell-mediated control mechanisms (240-242). Lymphoid and haemopoietic 
cells from the thymus, spleen and bone marrow were susceptible to NK 
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activity with those cells in earlier stages of differentiation or from 
foetal tissue showing the greatest sensitivity to lysis. Consistent with 
NK cell-mediated cytotoxicity were the comparable sensitivies of 
autologous or allogeneic targets to lysis and their ability to compete 
effectively with NK cell-susceptible tumour cell targets in cytotoxicity 
assays. An expanding body of evidence now indicates an important 
regulatory role for NK cells mediated through both their cytotoxic capacity 
and their secretion of cytokines and proinflammatory mediators. 
Stem cell growth and differentiation in the bone marrow 
microenviroment is regulated by the colony stimulating factors (CSF's) and 
bone marrow stromal cells (243,244). Additional control of stem cell 
proliferation may be mediated by NK cells either by direct lysis or by the 
secretion of colony inhibiting or stimulating factors. Numerous studies 
show that preincubation of bone marrow stem cells with NK cells retards 
the subsequent development of differentiated erythroid, 
granulocytic/monocytic and mixed (erythroid/granulocytic/monocytic/ 
megakaryocytic) colonies in semisolid agar culture or in vivo (245-250). 
An identical inhibitory effect was achieved by pretreatment of bone 
marrow cultures with the soluble products of NK cells which had been 
activated by brief contact with either nonadherent la+ bone marrow cells 
or NK cell-susceptible tumour cells (249). Although the profile of bone 
marrow colony types affected varied according to the purity of isolated NK 
cell preparations, colonies arising from more primitive precursor cells 
were more consistently inhibited. The nature of the interaction between 
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NK cells and haemopoietic stem cells is unclear, but there is convincing 
evidence to suggest that bone marrow cells may be lysed directly by NK 
cells after an initial contact phase (251 ). Mediators secreted by NK cells 
may also exert a significant cytostatic effect on bone marrow cells by 
inhibiting their proliferation in response to the CSF's, but the colony 
inhibiting activity secreted by NK cells following contact with bone 
marrow cells (NKCIA) has not been characterized extensively (249). There 
is some physiochemical evidence indicating that NKCIA is identical to 
NKCF which mediates the cytotoxic effect of NK cells against tumours 
(252). Additional studies suggest that NKCIA is a heterogeneous 
collection of marrow inhibitory factors which may also contain IFN-y and 
TNF (246,252,253). Inhibitory activity against bone marrow cells is 
restricted to a population of large granular lymphocytes with the CO2, 
CD16 and Leu-7 antigens typical of NK cells (250). Despite the sparsity of 
NK cells in human bone marrow, regulatory cellular interactions are 
nevertheless feasible with small numbers of cells (40). However not all 
interactions between NK cells and haempoietic stem cells may be 
inhibitory. The reported promotion of peripheral blood stem cell 
erythropoiesis by LGL may be attributable to their secretion of colony 
stimulating factors (254,255). The physiological significance of this 
observation is uncertain however, as the effect of NK cells on 
haemopoiesis i.o. vitro is almost alw·ays inhibitory. 
The recognition that NK cells regulated haemopoiesis stimulated 
interest in the role of NK activity in bone marrow transplantation. As a 
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result, NK cells have been implicated in the pathogenesis of graft 
rejection and graft versus host disease (GVHD). In the murine model of 
bone marrow transfer from identical inbred parents to irradiated F1 
hybrids, graft rejection occurs by an unknown mechanism independent of 
major HLA antigens and T cell mediated immune responses (256). Adoptive 
transfer and cell depletion experiments in vivo suggest that NK cells 
mediate this hybrid resistance (183,257), but at present there is no direct 
evidence for a similar mechanism of graft rejection in humans. 
Circumstantial evidence linking NK cells to GVHD in humans arose from 
striking correlations discovered between the incidence of GVHD and high 
levels of pre or post transplant NK activity (258,259). More direct support 
came from a model of murine GVHD where in vivo depletion of recipient NK 
cells alleviated the disease (260). These observations suggest that NK 
cells in the recipient may act as stimulators of GVHD. Alternatively the 
abnormalities of NK activity in GVHD may be secondary to the elevated 
levels of interferon documented after bone marrow transplantation (261 ). 
The ability of NK cells to serve as stimulator or accessory cells in mixed 
lymphocyte reactions provides a possible mechanism of action for these 
cells in graft rejection and GVHD (262,263). 
Natural killer cells may intervene at several stages in the 
differentiation of the antigen-stimulated B cell to either inhibit or 
support the development of a specific antibody response. In the bulk of 
studies which demonstrate NK cell-mediated suppression of spontaneous 
or pokeweed mitogen-induced antibody production, the mechanism of the 
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inhibition is unclear (264-270). Nevertheless, it is known that 
antigen-presenting cells, particularly after encounter with antigen, are 
susceptible to inhibition by NK cells (268,271). There is also suggestive 
evidence that NK cells are able to lyse B cells by contact initiated release 
of NKCF. In these experiments, NK cell-mediated suppression of antibody 
production by B cells was negated by competition with NK-sensitive K562 
cells and by treatment of NK cells with a monoclonal antibody against the 
K562 target recognition structure (272). Natural killer cell derived IFN 
may also directly suppress antibody production and the presence of IFN 
also enhances the suppressive effects of NK cells on antibody production 
(269,273,274). Comparative studies with T suppressor cells suggest that 
NK cells are the more potent inhibitors of antibody production and in some 
assay systems, NK cells maintain effectiveness even when comprising less 
than 1 °/o of the total cell population (263,264). Paradoxically, antibody 
production may also be supported by NK cells by virtue of their secretion 
of a B cell growth factor (BCGF) and IL-2, both of which stimulate the 
proliferation of B lymphoblasts (255,275,276). These functional 
observations are consistent with the presence of Leu-7+ LGL in the 
germinal centres of lymphoid follicles (277,278) where NK or related cells 
would be strategically placed to influence B cell development. Less is 
known about the effect of NK cells on T cell growth and differentiation. 
The maturation of primitive T cells in the human thymus may be limited 
through NK-mediated lysis (242) and as producers of IL-2 and IFN , NK 
cells provide direct support for the proliferation and activation of 
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post-thymic T cells. Natural killer cells expressing the OKM1 and la 
antigens provide antigen-presenting or accessory cell function for T 
cell-mediated reactions to alloantigens or polyclonal stimulants 
(262,263). There are reports that NK cells inhibit mixed lymphocyte 
reactions but this effect was only noted after activation of the NK cells by 
immune complexes containing erythrocytes or by IFN (266,267). 
Many of the regulatory functions of NK cells are based upon their 
capacity to secrete immunomodulatory cytokines. The release of IFN- a 
and IFN-y, IL-1, IL-2 and CSF's from NK cells after mitogenic or microbial 
stimuli is well documented (254,273,275,279). Interleukin 2 is also a 
potent stimulus for IFN- y secretion by NK cells (84). Other mediators 
released from NK cells relevant to the control and amplification of the 
inflammatory response include an uncharacterized chemotactic factor, TNF 
and plasminogen activator (173,280,281). On a per cell basis, the 
secretion of IL-1 and IL-2 exceeds that of the macrophage and T cell, 
implying that LGL are physiologically important producer cells 
(254,279,282). Phenotypic and functional studies suggest that the NK cell 
population responsible for cytokine secretion is heterogeneous and that 
partially overlapping subsets of cells may produce different cytokines. The 
phenotypic and functional characteristics of freshly isolated LGL 
producing cytokines is summarized in Table 1.2. 
Studies of cloned NK cells confirm that they have potent secretory 
potential (5). Using these homogeneous populations, it was demonstrated 
that a single NK cell can produce more than one cytokine and that a 
Table 1.2 The surface phenotypes of large granular lymphocytes capable of producing cytokines. 
* 
Cytokine secreted 
IL-1 
IL-2 
IFN-y 
BCGF 
* Phenotype@ 
co2+/-16+ OKM1 + 1a+ 
co2+3- OKM1 +/- la+ Leu-7-
IL-1 (Interleukin 1 ); IL-2 (Interleukin 2); IFN-y (gamma Interferon) and 
BCGF (B cell Growth Factor). 
Reference 
279 
254,282 
282,283 
275 
@ Presence of surface antigen indicated by +; absence by -; +/- indicates the surface antigen 
may be either present or absent. 
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secretory cell can be either cytotoxic or noncytotoxic. 
1 .9 Characteristics of lymphokine-activated killer (LAK) cells. 
Lymphokine-activated killer (LAK) cells are a heterogeneous 
collection of activated lymphocytes distinguished by their ability to lyse 
tumour cells which are resistant to NK cell activity (11,27, 197,284). 
Numerous tumour cell lines which are either resistant or sensitive to NK 
cells are lysed by LAK cells and furthermore, freshly isolated tumour cells 
are also highly susceptible to the cytotoxic activity of LAK cells. 
Malignant cells obtained from several types of carcinoma, melanoma, 
hepatoma, sarcoma, lymphoma and leukaemia are reportedly destroyed by 
LAK cells prepared from PBL (11, 192,285-287). There is disagreement 
concerning the capacity of LAK cells to damage nonmalignant cells. 
Autologous and allogeneic PBL were reported to be either resistant or 
susceptible to highly active LAK cells (288-290). Nonlymphoid targets 
including endothelial and epithelial cells and fibroblasts were also found 
to be lysed by LAK cells in one study (291 ). Like the nonspecific 
cytotoxicity of NK cells, LAK cell activity is operative on first exposure to 
the target and is not MHC-restricted. Peripheral blood LAK cells from 
cancer patients or normal controls are equally effective against either 
allogeneic or autologous tumour cell preparations (11,27,285). Although 
resting NK cells may display low grade activity against fresh tumour 
cells, LAK cells generally have a much greater cytotoxic effect (11-13). 
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In contrast to the two-signal mechanism of T cell activation, only 
/ 
exposure to IL-2 is required for the generation of LAK cells (11,27,294). 
' 
The inhibition of LAK cell generation by the presence of antibodies to the 
IL-2 receptor suggests that interaction of IL-2 with its receptor is the 
triggering event (27). Cellular proliferation is essential for the activation 
of LAK precursor cells, as inhibitors of cell division prevent the induction 
of LAK cell activity (11,197,295). The LAK activity of PBL exposed to 
optimal concentrations of IL-2 reaches maximum levels after 6-7 days in 
culture. Lymphocyte populations with LAK activity contain a high 
proportion of proliferating lymphoblasts with plentiful cytoplasm 
containing a variable number of small azurophilic granules (11,27,292). 
Although IFN-a or 'Y and IL-1 do not appear to participate in LAK cell 
generation, the involvement of other cytokines or cell types in 
intermediate steps has not been excluded (296). A recent report shows 
that murine splenic but not peripheral blood LAK cells can be generated by 
IL-4, either alone or in combination with IL-2 (297). It remains to be 
shown whether human LAK precursor cells can be activated by IL-4. The 
induction of LAK cells is subject to inhibition by exposure early in culture 
to PHA-induced suppressor cells or activated macrophages (298,299). 
Paradoxically, the addition of peripheral blood monocytes to LAK precursor 
cells enhanced culture-generated LAK activity by an unknown mechanism 
(299). The process of LAK cell generation is unaffected by the presence 
of Cyclosporin, whereas hydrocortisone is inhibitory (197,295). As one of 
the prime actions of Cyclosporin is to inhibit antigen-induced IL-2 
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production by lymphocytes, this result shows that induced IL-2 production 
by cells in culture is not necessary for LAK cell generation. The 
mechanism accounting for the suppressive effect of hydrocortisone on LAK 
cell generation is unknown and further investigation of this 
pharmacological effect may reveal more about the LAK cell phenonemon 
(197,295). 
Although Grimm et al first described the generation of LAK cells 
by exposing PBL to highly purified or recombinant IL-2, cytotoxic cells 
with similar properties are also detected after exposure of PBL to T cell 
mitogens (300), viruses (301) or alloantigens (302-308) in a mixed 
lymphocyte culture (MLC). Mixed cultures containing lymphocytes and 
autologous or allogeneic tumour cells (ML TC) lead to the formation of both 
tumour-specific cytotoxic T lymphocytes and LAK cells (308). It is 
probable therefore, that LAK cells will be generated during any 
immunological event which generates enough IL-2 to activate LAK 
precursor cells. Cells with LAK activity which are generated by methods 
other than direct exposure to IL-2 have been called NK-like cells 
(302,303), activated lymphocyte killer (ALK) cells (285), anomalous killer 
cells (298) and promiscuous killer cells (290). In future, all these 
effector cells should be collectively classified as LAK cells, because 
possible differences in induction requirements and phenotype do not 
justify separate designations. 
Analysis of LAK cell surface markers reveals a heterogeneous 
array of effector cell phenotypes (Table 1.3) which vary according to the 
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method of generation and precursor cell population used. In MLC, ML TC or 
after mitogen exposure, LAK cells are predominantly T cell-derived and 
express T cell phenotypes (299,302-304,307,308). When PBL are exposed 
to IL-2 in culture, LAK cells with the phenotype of NK cells predominate. 
These co2+3-16+ Leu-7 +/- Leu-19+ LAK cells are the most frequent, 
because of lower IL-2 requirements and shorter generation times 
compared to the other types of LAK cells (38,60,309). Experiments using 
sorting procedures to prepare pure populations of precursor cells show 
that LAK cells with NK cell phenotypes are derived from resting NK cells. 
A minority population of LAK cells generated in an MLC are derived from 
peripheral blood NK cells and are CD3-16+Leu-7- (305,306). These LAK 
cells derived from NK cells were previously described by some authors as 
NK-like cells. 
Culture and analysis of minor PBL subpopulations isolated by flow 
cytometry or immunoadsorption show that a number of other LAK effector 
cell phenotypes exist (Table 1.3). These variants differ from NK 
cell-derived LAK cells in their target specificity and generation 
requirements. Lymphokine-activated killer cells with cytotoxic T cell 
(CTL) markers (Co2+3+8+Leu-7+/-Leu-19+) are reported in some studies 
to be relatively ineffective against freshly isolated tumour cells and the 
K562 target (38,304,309,310). T cell-derived co3+ LAK cells also require 
higher concentrations of IL-2 and longer culture times to achieve 
maximum cytotoxic potential against tumour cell lines. There is 
convincing evidence to suggest that some CD3+8+ LAK cells were 
Table 1.3 The surface phenotypes of peripheral blood lymphokine-activated killer (LAK) cells. 
* Surface phenotype LAK activity@ 
* 
+++ 
+++ 
++ 
++ 
Presence of surface antigen indicated by+; absence by-;+/- indicates the surface antigen 
may be either present or absent. 
@ Comparative LAK activity against the K562 cell line is graded from + to +++. 
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originally antigen specific CTL which acquired LAK activity due to further 
activation by exposure to high concentrations of IL-2 (290,304,311). 
Indeed, studies of human MLC-derived T cell clones show that alloantigen 
specific cytotoxicity and LAK activity can coexist in the same T cell 
(307). Murine experiments support this view and also show that the 
acquisition of LAK activity by CTL may be reversible (311 ). 
Antigen-specific, resting CTL may be capable therefore, of mediating both 
antigen-specific cytotoxicity and LAK activity after exposure to IL-2 
without any further antigen contact (304). 
A proportion of T cell-derived LAK cells express the Leu-7 antigen 
and may therefore originate from CD3+Leu-7+ NK cells (284,311). Ty cells 
can give rise to LAK cells which bear an identical co3+4-a-16+ Leu-7-
surface antigen profile and which are therefore capable of mediating 
ADCC. Cloned cells of this phenotype express an unusual Ti receptor 
consisting of one or two y chains, whereas LAK cells bearing the CD3 and 
CD4 or CDS antigens have Ti composed of functional a and p chains 
(312,313). Leu-19+ LAK cells which lack both the CD3 and CD16 antigens 
have not been subjected to further surface marker or genomic analysis to 
determine their cell lineage (307). 
Clonal studies confirm that LAK cells are heterogeneous in terms 
of their phenotype and cytotoxic activity (292,304,307,308,314). Clones 
bearing the CD16 antigen generally possessed higher levels of cytotoxicity 
against tumour cell lines and fresh tumour cells when compared to 
co3+16- clones. Limiting dilution studies show that approximately 10°/o of 
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CD16+ PBL but fewer than 1 °/o of co3+ precursors gave rise to LAK cells 
(314). The distribution of the Leu-19 antigen on clones with LAK activity 
has not been reported, but all such clones, irrespective of phenotype, 
appear to express the 40 kD CD? (T40) antigen. lntrathymic and 
post-thymic T cells and NK cells bear the T 40 antigen and the significance 
of its detection on LAK cells of all types may reflect its expression on 
most of the know~ LAK precursor cell types (315). A recently described 
120 kD surface epitope designated as LAK-1 has a very similar 
distribution to CD7. However unlike CD7, LAK-1 appears to participate in 
the cytolytic process of LAK cells (316). 
Precursor cells with a wide variety of phenotypes are capable of 
giving rise to LAK cells when cultured in the presence of IL-2. The 
variation in reported phenotypes largely reflects the heterogeneity of LAK 
precursor cells, but the differing methods used to purify and culture 
precursor cell populations has also contributed. In the first description of 
LAK cells, Grimm et al (318) reported that the LAK precursor cells in 
unsorted PBL were null cells (CD3_4_8-Leu-7-). However these precursor 
cells were purified before culture by a series of steps involving antibody 
and complement-mediated lysis and furthermore, at the time of this study, 
anti-Leu-11(CD16) antibodies were unavailable. Recent studies have used 
the more efficient methods of immunoadsorption or flow cytometry to 
reexamine this issue. There is consensus that the most numerous and 
efficient LAK precursor cell in the peripheral blood is the CD16+ NK cell 
(38,60,79,302,309,310,318). The ability to prepare pure samples of 
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minority subpopulations for LAK cell generation shows that T cells and 
"null" cells can also act as precursor cells (38,298,309,317,320). It is 
well documented that cos+ CTL are LAK precursors, but noncytotoxic cos+ 
and co4+ T cells may also acquire LAK activity in culture with IL-2 (318). 
Null cells acting as LAK precursors lacked detectable T cell (CO2, CD3), NK 
cell ( C016, Leu-7) or B cell (C020) associated antigens (318). The 
suggestion that even cp20+ B cells develop LAK activity after exposure to 
IL-2 (317) is supported by another report showing that B lymphoblasts 
mediate nonspecific cytotoxic activity (319). 
The generation of LAK cells from lymphocytes isolated from sites 
other than the peripheral blood is well documented (14,27, 197,317,320). 
Thymocytes or splenocytes exposed to IL-2 acquire the cytotoxic activity 
of LAK cells and analysis of the effector cell shows a T cell phenotype 
(317,320). By contrast, LAK cells derived from human bone marrow 
lymphocytes are C 03-1 s+Leu-19+ ( 14). M ucosal lamina propria 
lymphocytes from the human intestine also contain LAK precursor cells 
(27,197,321). The phenotypes of LAK precursor and effector cells as 
determined by antibody and complement-mediated lysis were similar 
(Co2+3-4-s-1 s- Leu-7-) and the cells were active against both cell lines 
and freshly isolated colon carcinoma cells (27,197). More recent studies 
using panning techniques report that intestinal LAK precursor cells are 
co2+3-4-s+1 s-Leu-19+(321). A minority peripheral blood LAK cell 
population is co2+3-1 s- Leu-19+ and so it is possible that intestinal LAK 
precursor cells are related to this cell type (309). There is also evidence 
56 
from murine tumour models and from clinical studies of malignant 
melanoma and other solid tumours to show that tumour-infiltrating 
lymphocyte (TIL) populations contain LAK precursor cells (285,322,323). 
Lymphocytes infiltrating melanoma tisssue gave rise to LAK cells which 
expressed a T cell phenotype (285). There is also a suggestion, as yet 
unconfirmed in human studies, that LAK cells originating from TIL are 
more potent than their counterparts derived from the peripheral blood 
(322). It can be concluded therefore, that the LAK cell phenomenon is not 
restricted to peripheral blood lymphocytes and that LAK cells prepared 
from extravascular lymphocyte populations may express uncommon or 
unique phenotypes and cytotoxic properties. 
Little is known about the receptors needed to trigger the cytotoxic 
activity of LAK effector cells. The majority of T cell clones mediating 
both antigen specific cytotoxicity and nonspecific LAK activity do not 
utilize their antigen receptor (Ti) or associated CD3 antigen to lyse 
LAK-susceptible targets (304,307,311,324,325). However, antibodies 
directed towards the Ti or CD3 antigens significantly inhibit the LAK 
activity of a few reported T cell clones (293,326-329). In one system, the 
Ti on co3+ LAK cells was necessary for recognition of a 120 kD 
heterodimeric activation antigen on target cells (329). In other studies of 
co3+ LAK cell clones however, glycolipid structures on melanoma target 
cells were bound by receptors unassociated with the Ti (325). Natural 
killer cell-derived LAK cells appear to possess receptors identical to 
those of the precursor cell, but in addition, develop novel receptor 
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populations which are capable of recognizing both NK-sensitive and 
resistant target cells (304,327). Like NK cell populations, LAK cells 
derived from heterogeneous precursor populations express a variable, but 
partially overlapping profile of target receptors (307,327,328). Although 
some LAK receptors are able to interact with several different targets, 
there are others which are apparently exclusive for one tumour type 
(325,327). In the case of T cell clones with dual CTL and LAK activity, the 
nonspecific adhesion molecule LFA-1 participates in alloreactive 
cytotoxicity but is not necessary for binding to and lysis of 
LAK-susceptible targets (308). On the other hand, a recently described 
LAK cell clone lacking T cell antigens required both surface LFA-1 and 
LAK-1 antigens for effective cytotox ic activity (316). 
Receptor-med iated target recognition by a LAK cell may activate 
a functionally separate, nonspecific lytic process in the same way as has 
been demonstrated for virus-specific CTL (330). The nature of the LAK 
cell cytotoxic apparatus triggered by target ce ll binding is undefined but 
it may comprise the same ce llular organe lles and mediators as utilized by 
their NK cell and T cell precursors. Stimulation of LAK cells is mediated 
not only through the ir target ce ll receptors but also by cross linking of 
surface CO2 or CD16 antigens (331 ). The functional significance of this 
observation is uncertain, but one poss ibili ty is that these structures may 
funct ion in the ir own right as both target cell receptors and activat ion 
structures. 
On a theoretical basis, LAK ce lls are potentially important 
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antineoplastic cells, but their presence (as indicated by their 
characteristic cytotoxic activity) has never been detected in the 
tumour-infiltrating, mucosa! or peripheral blood lymphocyte populations 
of patients with malignancy (202,27,11 ). Furthermore, the levels of LAK 
activity generated in vitro from peripheral blood or intestinal precursor 
cells are comparable in both normal controls and patients with malignancy 
(11,27, 197,285). This observation suggests that a deficiency of LAK 
precursor cells does not predispose to the development of neoplasia. 
Nevertheless, experimental and clinical data dealing with the treatment of 
advanced malignancy by the adoptive transfer of LAK cells suggest that 
these cells can be effective against tumours in vivo (111,114,332). It 
remains to be determined however, whether LAK cells exist spontaneously 
in vivo in numbers sufficient to influence the initial development or 
subsequent spread of malignancy. 
The LAK cell phenomenon has revived interest in adoptive 
immunotherapy as a treatment for human cancer. Using leucophoresis and 
tissue culture methodology, adoptive immunotherapy is being investigated 
by infusing large numbers of culture-generated autologous LAK cells and 
IL-2 into patients with disseminated cancer. In both clinical and animal 
studies, the combinatio~ of LAK cells and IL-2 was significantly more 
effective against established tumours than either therapy administered 
alone (111,114,332). The human malignancies most susceptible to this 
protocol were renal cell carcinoma and melanoma. The results of these 
trials have provoked controversy because the modest rate of complete (8°/o) 
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and partial (14°/o) responses must be balanced against the great expense 
involved and the serious complication rate. lmmunotherapy with LAK cells 
is an attractive treatment modality with a sound theoretical basis, but 
many problems have to be addressed before it gains widespread 
acceptance. Most serious complications are related to the intermittent 
injection of megaunit doses of IL-2 which can result in acute renal failure 
and fluid overload with consequent cardiopulmonary failure. Reduction of 
this adverse effect by continuous infusion of IL-2 has recently been 
achieved (114). Responses to therapy in many patients are transient, 
possibly because of the short life span and uncertain tissue distribution of 
LAK cells after infusion. Although proliferating LAK cells are known to 
seed to the lungs and liver after infusion in animals, similar data is not 
available for human studies (333). In the future it is likely that LAK cell 
immunotherapy will prove most useful in combination with other forms of 
treatment for malignancies which are resistant to present day 
conventional therapy. 
1.10 Evidence for the participation of natural killer and 
lymphokine-activated killer cells in nonmalignant human diseases. 
Previous descriptions of the antimicrobial and immunoregulatory 
functions of NK cells would strongly suggest that these cells may play 
some part in the pathogenesis of diseases where disturbances of immunity 
are suspected. However, it has proved difficult to convincingly implicate 
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NK cells in the causation of autoimmune disease (334). Impairment of 
spontaneous and IFN-inducible NK activity in peripheral blood is a 
consistent feature of systemic lupus erythematosus (SLE) and similar 
findings have also been reported in other autoimmune diseases such as 
inflammatory bowel disease (IBD) and primary biliary cirrhosis (335-337). 
It has been suggested that an increased frequency of viral infections 
secondary to reduced NK activity may predispose to the development of 
SLE and other autoimmune diseases (334). However, apart from this 
unsubstantiated theory, there is no other plausible role for NK cells in the 
immunopathogenesis of a~toimmune diseases. Indeed the reduction in NK 
cell function in SLE is generally considered to be secondary to the effects 
of the disease and its treatment or to recruitment of cells from blood to 
disease-affected tissue. Even when mononuclear cells have been isolated 
from diseased tissue (eg intestinal mucosa in inflammatory bowel 
disease), very little NK activity has been observed (336). Thus, on the 
basis of the existing evidence, NK cells are unlikely to play an important 
primary role in autoimmunity. 
Antibody-dependent cellular cytotoxicity mediated by 
lymphocytes may be an important mechanism of organ injury in 
autoimmune diseases. In studies of autoimmune haemolytic anaemia, K 
cells mediate ADCC against human erythrocyte targets sensitized with 
antibodies specific for the blood group antigens (45,338). In autoimmune 
haemolysis, the density and class of antibody binding to erythrocytes 
dictates whether their elimination occurs by complement-mediated lysis 
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and/or clearance by the hepatic and splenic mononuclear phagocytic 
system. The main mechanism of erythrocyte disposal is probably by 
opsonization, but ADCC mediated by macrophages and K cells may also be 
important (45). The human antibody isotypes lgG1 and lgG3 are most 
efficient in mediating ADCC of erythrocytes by both K cells and 
monocytes. According to recent observations, ADCC may be the main 
mechanism responsible for clearing sensitized Rh+ foetal erythrocytes in 
Rh- mothers who are given anti-Rh (D) antibody perinatally (45). 
Moreover, ADCC may contribute to tumour cell eradication in the treatment 
of malignancy with tumour specific monoclonal antibodies which may not 
be able to fix human complement (339). 
Cells of the NK lineage are also implicated in the spectrum of 
disorders designated Ty-lymphoproliferative disease (Ty-LPD). The 
hallmark of Ty-LPD is the finding of excess numbers of large granular 
lymphocytes (LGL) in the peripheral blood, liver, spleen and bone marrow. 
It is a rare, indolent lymphoproliferative disorder characterized by 
hepatosplenomegaly, lymphocytosis, anaemia, neutropaenia and recurrent 
bacterial infections (340-342). Early attempts to classify the disease 
using rosetting techniques identified the LGL as T cells bearing Fe 
receptors for lmmunoglobulin G ( Ty cells). More recent analysis of larger 
series has revealed the heterogeneous nature of this disorder despite the 
apparent uniformity of LGL (340). Most cases (80-90°/o) of Ty-LPD are 
clonal proliferations of co3+s+ T cells which were detected by uniform 
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rearrangements of the Ti~ gene (341 ). In the remaining cases, non-T NK 
cells expressing the Leu-7 and CD16 antigens but lacking CD3, are the 
predominant cell type (342). In a variable proportion of cases, LGL of 
either T cell or NK cell derivation mediate NK activity and/or ADCC. 
Evidence from in vitro experiments suggesting that the abnormal LGL can 
inhibit the formation of haemopoietic colonies provides a plausible 
explanation for the neutropaenia and anaemia complicating Ty-LPD (340). 
Because the LAK cell was originally a culture-generated phenomenon, 
there is doubt surrounding its relevance in the normal human or 
experimental animal. Since LAK cells have no distinctive surface markers, 
their presence in normal tissue or blood cannot be detected by 
immunohistochemical methods. Furthermore, under normal conditions, 
lymphocytes isolated from the peripheral blood, lymphoid organs or 
mucosal surfaces do not express cytotoxicity characteristic of the LAK 
cell (11,27). Even after the intermittent infusion of high doses of IL-2, 
circulating LAK cells were not detected in human subjects, although 
depletion of LAK precursor cells was reported (112). On the other hand, 
murine studies have documented the generation of splenic and peritoneal 
LAK cells during continuous infusion of human recombinant IL-2 in high 
doses (343). 
Although LAK cells cannot be detected under normal physiological 
conditions, their presence has been demonstrated during immune responses 
and in disease states characterized by chronic inflammation. During acute 
infectious mononucleosus, both LAK cells and Epstein Barr virus (EBV) 
63 
specific CTL are detectable in the peripheral blood (301 ). 
Lymphokine-activated killer cells were reactive against EBV-infected 
lymphocytes and may thus provide an important accessory function to 
virus-specific CTL in this and other viral diseases. The potential 
importance of LAK cells in viral infections is exemplified by a case of 
fatal infectious mononucleosus where LAK cells could not be generated 
from the peripheral blood (344). Other pathogens which cause 
intracellular infections such as the rickettsiae are also susceptible to 
control by LAK cells (345). During murine intestinal responses to dietary 
antigens, LAK cells are generated within the intestinal mucosa (346). The 
presence of potent nonspecific cytotoxic cells in this locality may serve 
to control the potentially harmful overproliferation of B and T 
lymphoblasts in the early stages of a specific immune response. 
Mononuclear cells with spontaneous LAK activity have also been described 
in Ty-LPD (342) and after bone marrow transplantation (65). In one 
reported case of Ty-LPD, circulating malignant cells with the co3-15+ 
phenotype mediated LAK activity (342). After bone marrow 
transplantation, the phenotype of the cells mediating LAK activity was not 
specified (65). 
There is some evidence to suggest that LAK cells can be detected 
in autoimmune diseases where tissue destruction and chronic 
inflammation are prominent. Lymphokine-activated killer cells may 
possess an important primary role in mediating parenchymal cell injury in 
autoimmune diseases, although it is still uncertain under what conditions 
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nonmalignant cells become susceptible to LAK activity in vitro (288). 
Alternatively, LAK cells may arise merely as an epiphenomenon 
accompanying autoimmune stimulation. In the case of rheumatoid 
arthritis, co2+3-16- LAK cells active against K562 cells were found in 
the synovial fluid from cases of active arthritis, but their cytotoxic 
activity was not tested against synovial membrane lining cells or 
fibroblasts (347). Some authors report that freshly isolated lymphocytes 
and fibroblasts, or endothelial cells in primary culture can be lysed by LAK 
cells (289-291 ). Others have found however, that normal peripheral blood 
lymphocytes are susceptible only after chemical modification of the cell 
membrane (288). Thus, it is possible that the altered expression of 
parenchymal cell surface antigens (particularly increased MHC class II 
antigens) in conditions such as 180 and primary biliary cirrhosis, may 
predispose to organ damage by LAK cells in vivo (348,349). 
From the above data it may be postulated that LAK cells can be 
generated in the blood or peripheral lymphoid tissues during any immune 
response which is accompanied by IL-2 secretion. Thus, LAK cells may 
function as cytotoxic effector or regulatory cells during the amplification 
stage of any specific systemic or mucosa! reaction to microbial or 
enviromental antigens. Lymphokine-activated killer cells may also arise 
as a consequence of, and possibly participate in, the abnormal 
immunological responses which underly autoimmune diseases. 
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1.11 Cytotoxic cells in the human intestinal mucosa. 
The recognition that peripheral blood lymphocytes represent a 
"transit" population of uncertain relevance to mucosa! immunological 
events stimulated interest in the study of lymphoid cell populations 
associated with the intestinal mucosa. Because of their accessibility and 
ease of isolation, lamina propria mononuclear cells (LPMC) have been 
extensively characterized. Less is known about the functional properties 
of human intestinal intraepithelial lymphocytes (IEL) as they are difficult 
to isolate as pure cell populations in sufficient numbers for study. This 
section reviews the cytotoxic properties of human intestinal lymphocytes 
and briefly highlights major differences between the cytotoxic systems of 
the human and rodent intestines. Types of cytotoxicity discussed include 
NK cell activity, antibody-dependent cellular cytotoxicity (ADCC), 
lectin-induced cellular cytotoxicity (LICC), LAK cell activity and cytotoxic 
T cell-mediated lympholysis (CML). 
There is general consensus that only very low levels of 
spontaneous NK activity occur in unfractionated human LPMC populations. 
When compared with peripheral blood mononuclear cells (PBMC), LPMC have 
low or absent spontaneous cytotoxicity against the standard NK 
cell-susceptible K562 target (27,350-354). Because a minority population 
of cytotoxic cells may be obscured within LPMC populations, techniques 
designed to specifically isolate NK cells have been applied to the 
intestinal mucosa. Enrichment of LPMC populations for NK cells by 
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density gradient centrifugation results in only a small increase in the 
cytotoxicity of LPMC (27). Amplification of LPMC cytotoxicity by 
employing very high effector to K562 target ratios in cytotoxicity assays 
has detected CD16+ Leu-7+ cytotoxic cells which are probably NK cells 
(355,356). A recent unconfirmed study using panning techniques to isolate 
cells from the intestinal mucosa has shown that a minority CD16-Leu-19+ 
LPMC population mediates moderately high levels of spontaneous 
cytotoxicity against K562 targets (321 ). The authors propose that these 
LPMC may be related to infrequent peripheral blood NK cells of similar 
phenotype (29). In studies of unfractionated LPMC populations, the levels 
of NK activity were not influenced by the disease process affecting the 
resected intestine. Hence, LPMC isolated from histologically normal 
mucosa resected for colorectal carcinoma or nonmalignant conditions and 
LPMC from actively inflamed mucosae affected by inflammatory bowel 
disease (IBD) all have comparable NK activity (350,351,353,354,356,357). 
It was also confirmed by a number of studies that corticosteroid therapy 
did not alter the levels of intestinal NK activity in IBD (354-356). The 
results of functional assays for NK cells are confirmed by 
immunohistochemical surveys of the intestinal mucosa which show very 
small numbers of cells expressing the Leu-7 or CD16 surface antigens 
(354,356). The NK activity of LPMC can be significantly increased after 
treatment with IFN-a or y, but only by a small increment 
(27,354,356,357). Although the enzymatic procedure used to isolate LPMC 
does not inhibit NK activity (27,353,354), prostaglandins liberated during 
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disaggregation or secreted by intestinal macrophages may be suppressive 
(358,359). In some authors' hands, incubation of LPMC for 24 h after 
isolation in the absence of macrophages enhances NK activity (358,359) , 
but others were unable to achieve consistent increases in LPMC NK 
activity by periods of incubation (27,353) or by the removal of intestinal 
macrophages (350). 
A possible explanation for low intestinal NK activity may be that 
the standard cell lines used as targets in NK cell assays are not lysed by 
intestinal NK cells. In view of the proposed antineoplastic and 
immunoregulatory properties of NK cells, LPMC have been assayed for NK 
activity against freshly isolated intestinal epithelial and colon carcinoma 
cells. Single cell suspensions of colonic epithelial cells were reported to 
be lysed by intestinal lymphoid cells but the uncertain nature of the 
cytotoxic effector cells and the questionable viability of the target cells 
flaw these investigations (360,361). A recent study has described the 
preparation of viable colonic epithelial cell crypts which serve as suitable 
targets, but as yet, a detailed study of the cytotoxicity of LPMC against 
these cells has not been reported (362). 
The conclusion of a large number of studies is that ADCC against 
nucleated cell targets is lacking in LPMC populations, irrespect ive of the 
underlying disease process (350-352,363-365). Detectab le ADCC against 
nucleated targets was consistently demonstrated in two stud ies of LPMC, 
but the levels of cytotoxicity were low (10°/o specific release or less) 
(357,366). Significant levels of ADCC are often detected against 
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antibody-sensitized chicken erythrocytes, but the significance of this 
observation and the nature of the effector cells is unknown. In PBMC 
populations, the majority of ADCC is mediated by killer (K) cells which are 
regarded as a subset of NK cells (50), while Ty cells also contribute a 
small proportion of peripheral blood ADCC (16). The minimal ADCC found 
in the intestine is therefore consistent with the known paucity of NK cells 
and further indicates that Ty cells are not plentiful in the intestinal 
mucosa. 
The hallmark of lymphokine-activated killer (LAK) cell activity is 
nonspecific cytotoxicity directed against cell lines and freshly-isolated 
tumour cells which are resistant to NK activity (11). Using these criteria, 
it is evident that LAK cells do not exist spontaneously in the intestinal 
mucosa in significant numbers (27,197,354). Nevertheless, LAK cells with 
the capacity to lyse tumour cell lines and colon carcinoma cells can be 
generated from LPMC by exposure to proliferative doses of IL-2 in vitro 
(27,197,354,321). These results indicate that precursor cells capable of 
giving rise to LAK cells are present within LPMC populations. There did 
not appear to be any gross differences between the frequencies of mucosa! 
LAK precursor cells in colon carcinoma, nonmalignant colonic diseases or 
180 (27,197,354). 
Lectin-induced cellular cytotoxicity (LICC) is postulated to 
indicate the presence of primed antigen-specific cytotoxic T lymphocytes 
(CTL). This type of cytotoxicity is assayed by adding agglutinating doses 
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of specific lectins to potential effector cells and labelled targets in a 
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short term cytotoxicity assay (367,368). Following the formation of 
effector and target cell conjugates by nonspecific agglutination, lectin 
binding to the Ti/CD3 complex activates the CTL and triggers cytotoxicity 
of targets which are not normally susceptible to lysis. Although NK cells 
are bound to targets by lectin they do not mediate LICC because they lack 
Ti/CD3 surface structures (368). CTL may also be stimulated to mediate 
this nonspecific cytotoxicity by treatment with antibodies directed 
against CD3 (367,368). Isolated LPMC readily mediate levels of LICC 
which are usually at least 50°/o or more of normal PBMC populations 
(321,350-353,357). As with other forms of cytotoxicity, there was no 
consistent correlation between the level of LICC and the presence of colon 
carcinoma or 180. The ability of LPMC to mediate LICC suggests that 
primed antigen-specific CTL are present in significant numbers in the 
intestinal mucosa. Surface marker analysis of LPMC using double labelling 
studies confirm that from 9 to17°/o of LPMC express surface antigens 
associated with CTL (369). 
Recent studies of intestinal cytotoxicity have also attempted to 
identify mucosa! CTL on the basis of their antigen specificities. Only one 
study has so far attempted to generate alloantigen-specific CTL from the 
lamina propria, but the levels of cytotoxicity achieved were insignificant 
(370). Convincing evidence indicates that human mucosa! CTL specific for 
intestinal epithelial cell-associated components (ECAC) may participate 
in the pathogenesis of IBD (371 ). Preliminary analysis of ECAC reveals 
four, distinct protein and carbohydrate-containing macromolecules which 
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are found only on the surface of intestinal epithelial cells. co2+3+ LPMC 
with cytotoxicity directed specifically towards ECAC-labelled targets 
were detected within inflamed IBD mucosa but not in histologically normal 
control specimens. 
Unlike the diverse mononuclear cell population of the lamina 
propria, the normal human intestinal epithelium is infiltrated by a uniform 
population of co3+s+ intraepithelial lymphocytes (IEL). Approximately 
25°/o of IEL have cytoplasmic azurophilic granules, but NK cell-associated 
surface antigens are not expressed on IEL (372,373). Populations of IEL 
are incapable of NK activity or ADCC, but are able to mediate LICC 
(351,372,373). It is unknown whether IEL can act as LAK precursor cells, 
but this possibility is unlikely as exposure to IL-2 did not induce 
proliferation in cultured IEL (373). The phenotype and cytotoxic properties 
of I EL suggest therefore that these cells may function as CTL, but as yet, 
their antigen specificities are completely unknown. 
Comparison of human and rodent intestinal mucosa! cells reveals 
striking differences in their cytotoxic properties. Rodent I EL are a 
complex, heterogeneous population whose origin and function are 
controversial. Approximately 50°/o of IEL are thymus-dependent cytotoxic 
T cells (Thy 1 + Lyt 1 + Lyt 2+) which account for the specific cytotoxicity 
directed against alloantigens (346,374). A large proportion of the 
remaining IEL lack Thy 1 and develop independently of the thymus (374). 
The latter population accounts for most of the granulated IEL but its 
function is obscure. Cells with NK activity comprise a minority 
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population within the IEL and are unusual in that they often lack surface 
antigens found on peripheral blood NK cells (375,376). The levels of NK 
activity and ADCC mediated by unfractionated rodent IEL populations are 
comparable to those of splenic or peripheral blood lymphocytes (375-380) . 
Lymphokine-activated killer cells exist in the intestinal epithelium after 
antigen challenge and specific CTL clones derived from IEL can also be 
induced to mediate LAK activity by exposure to IL-2 (346,381). Another 
form of nonspecific spontaneous cytotoxicity mediated by natural 
cytotoxic (NC) cells is also present in the rodent intestinal epithelium 
(382). The presence of these cells in lymphoid populations is identified by 
their capacity to lyse the NK cell-resistant WEHl-164 cell line and their 
! 
dependency upon interleukin 3 (383). Murine NC cells appear not to be 
macrophages and they also lack NK or T cell associated membrane 
antigens. The precise phenotype, distribution and lineage of NC cells is 
unknown but they are postulated to supplement the cytotoxic functions of 
NK cells. In a recent study of human NC cells, the evidence suggested that 
the effector cells may be related to monocytes (384). No studies of human 
IEL or LPMC have so far tested for the presence of NC cells. 
Lymphocytes from the remaining compartments of the rodent 
intestine have received less attention than the I EL. Peyer's patch 
lymphocytes represent an interesting population which lacks NK activity 
but is able to mediate NC (378,382). Lamina propria lymphocytes from the 
mouse and rat contain a population of functional NK cells which mediate 
levels of cytotoxicity comparable to IEL (375,379). Like IEL, NK cells from 
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the lamina propria are unusual in their lack of typical NK cell-associated 
surface markers (375). Some lamina propria lymphocytes are also CTL, as 
detected by their ability to specifically recognize and lyse alloantigens on 
target cells (378). 
This section has reviewed the current state of knowledge 
concerning intestinal cytotoxic lymphocytes. Studies of intestinal 
cytotoxicity in experimental animals and man reveal an array of different 
mechanisms active against a diverse range of potential targets. Further 
investigation is required to confirm the presence of and characterize the 
infrequent cells mediating spontaneous nonspecific cytotoxicity in the 
human intestinal lamina propria. In the human, more efficient methods are 
needed to isolate IEL, so that this population can be made more accessible 
for further study. The functions of different cytotoxic systems in the 
normal and diseased intestine are still largely unknown and attempts to 
implicate aberrant cytotoxicity in the pathogenesis of intestinal disease 
are in their preliminary stages. In these studies, the important species 
differences which exist between human and animal intestinal lymphocytes 
I 
must be considered. Target cells such as intestinal epithelial cells which 
are more relevant to the study of IBD or colon carcinoma should be used in 
future investigations. The role of other potentially important cytotoxic 
cells such as the intestinal macrophage or granulocyte has yet to be 
examined in any detail. Recently described methods for isolating 
intestinal macrophages should facilitate these studies (385). 
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CHAPTER 2. 
Intestinal natural killer cells in colon carcinoma and inflammatory bowel 
disease: an immunohistochemical survey. 
I. Introduction 
The existence of peripheral blood natural killer cells with 
antineoplastic (386), antimicrobial (219,220) and immunoregulatory 
(255,268) properties has prompted searches of mucosa-associated 
lymphoid tissue for the presence of similar cells (348,350-366,387). 
Locating intestinal mucosa! NK cells is of interest because such cells may 
protect the normal mucosa from microbial invasion or malignant 
transformation. Mucosal NK cells may also participate in the disturbed 
immunoregulation (388) and extensive inflammation and tissue injury 
(389) found in the intestine during inflammatory bowel disease (IBD). 
Intestinal lymphocyte populations isolated from cases of colon carcinoma 
or IBD have uniformly low levels of NK activity against conventional 
target cell lines (27,350,351). However these results have been 
questioned because the enzymatic isolation of intestinal lymphocytes may 
adversely affect their NK activity (358) and may also cause the selective 
' 
loss of some types of mononuclear cells (390). 
The detection of NK cell-associated surface antigens in sections of 
intestine using immunohistochemistry provides a complementary approach 
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to functional studies of NK activity in lamina propria mononuclear cells 
(LPMC) isolated by mucosa! disaggregation. The chief attraction of 
immunohistology is that the number and location of NK cells in both the 
lamina propria and the epithelial layer of the intestinal mucosa can be 
determined. Initial investigations of isolated LPMC or mucosa! sections 
demonstrated very few cells expressing the Leu-7 marker which detects 
approximately 80°/o of peripheral blood NK activity (28,355,387). Equally 
low numbers of NK cells have been found in the intestine using antibodies 
to the Fe receptor for lgG (CD16) which is present on the great majority of 
NK cells in the peripheral blood (28,354,356,321). 
Previous immunohistochemical studies of the intestinal mucosa have 
been disadvantaged by distortion of tissue morphology attributable to the 
freezing and fixation methods in use. In a recent study of the human 
intestine, modified methods of fixing and freezing mucosa! sections for 
immunoperoxidase staining have improved tissue morphology and 
preserved surface antigens on lymphocytes and macrophages (391 ). This 
technique was followed in the present chapter to examine the intestinal 
mucosa and associated lymphoid tissue for the presence of NK cells using 
the anti-Leu-7 antibody. The aim of this survey was to investigate 
possibile abnormalities ~n the number or distribution of human intestinal 
NK cells in colon carcinoma and 180. For this purpose, mucosa! specimens 
from intestines resected for colon carcinoma, 180 or nonmalignant 
conditions other than 180 were surveyed and compared for the presence 
and distribution of the Leu-7 cell membrane antigen. 
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11. Materials and Methods 
2.1 Mucosa! specimens and patients. 
Seven histologically normal specimens of colonic mucosa and one of 
ileum were obtained at surgery for colon carcinoma (four patients), 
diverticular disease (two patients) and sigmoid volvulus (one patient). 
Samples of intestinal mucosa showing active inflammation (seven from 
the colon and seven from the ileum) were taken from a total of eight 
patients submitted to su.rgery for Crohn's disease. Mesenteric lymph nodes 
from three of these subjects with Crohn's disease were also removed and 
examined. All the patients with Crohn's disease were receiving 
corticosteroids (10-40 mg of prednisone daily) at the time of surgery. 
2.2 Fixaton and freezing of mucosa! specimens. 
Within 1 h of resection, specimens of mucosa were cut into strips 
1-2mm wide and 5-10mm in length and were fixed for 4 h at 4 °c in 
freshly prepared periodate-lysine-paraformaldehyde fixative (392). The 
fixative was prepared by adding 2g of paraformaldehyde (dissolved in 25ml 
of distilled water with 0.05 ml of 1 OM NaOH heated to 60°C) and 0.214g of 
' 
sodium-m-periodate to 75ml lysine phosphate buffer. The final solution 
was then adjusted to pH 7.4 by adding 1 OM NaOH. Lysine phosphate buffer 
was prepared by dissolving 18.27g of L-lysine hydrochloride 
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(Sigma Chemical Co., Mo) in 500 ml of distilled water adjusted to pH 7.4 by 
the addition of from 150-250 ml of 0.1 M Na2HP04 in distilled water. The 
solution was then increased to a total volume of 1000ml by the addition of 
0.1 M sodium phospate buffer (prepared by combining four parts of 0.1 M 
Na2HP04 in distilled water and one part of 0.1 M NaH2Po4 in distilled 
water). Stock lysine phosphate buffer was stored frozen in 75ml aliquots 
at -20°c. After fixation the specimens were transferred to a solution of 
7°/o sucrose in phosphate buffer (70g sucrose, 5.68g Na2HP04 and1 .56g 
NaH2Po4 in 1000ml distiller water) and were equilibrated with 4 changes 
of this buffer at 4°C for the next 24 h. The strips of mucosa were then 
removed from the buffer, blotted to remove excess moisture, and snap 
frozen at -120°c in the liquified refrigerant Genetron 22R 
(Monochloro-difluoromethane) (Allied chemicals, Morristown, NJ). The 
refrigerant gas was liquified by passage through a coil of plastic tubing 
immersed in liquid nitrogen. The specimens were embedded in 0.C.T. 
compound (Miles Scientific, Naperville, Illinois) and were frozen in stages 
over dry ice, in liquid nitrogen and then stored at -20°c until sectioned 
and stained. 
2.3 lmmunoperoxidase staining. 
lmmunoperoxidase staining utilized the avidin-biotin-peroxidase 
(ABC) method (388) with reagents supplied by Vector Laboratories 
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(Burlingame, California). Tissue sections cut 6-8µm in thickness on a 
cryostat were placed on ethanol washed glass slides which had been 
coated in a 0.1 °/o solution of 40,000 MW poly-L-lysine in distilled water 
(Sigma Chemical Co, Mo) for 10 min and air dried. The sections were air 
dried briefly on the glass slides before transfer to phosphate buffered 
saline (PBS). 
Staining took place at room temperature in a humidifeid perspex 
chamber. Sections were initially incubated for 30 min in PBS containing 
1.8°/o normal horse serum and 1 °/o human gamma globulin (Commonwealth 
Serum Laboratories, Melbourne, Australia) and were then incubated with 
the primary monoclonal antibody for 2 h. After two 10 min washes in PBS, 
the endogenous peroxidase activity of granulocytes was neutralized by 
dehydrating the sections in a brief 60 sec passage through a graded series 
of solutions of ethanol in water up to 100°/o ethanol and then treating with 
0.1 °/o H2o2 in methanol for 10 min: Dehydration was necessary because the 
presence of water in solution (more than 1 °/o) prevented the inactivation of 
eosinophil peroxidase activity. Sections were rehydrated, washed and 
incubated with biotinylated goat anti-mouse antibody (diluted 1 in 200 in 
PBS with 1.8°/o normal horse serum) for 1 hand then 
avidin-biotin-peroxidase complex for 1 h. Specific peroxidase activity 
was visualized by incubation of the sections in PBS containing 0.5°/o 
diaminobenzidine, 1 OmM imidazole and 0.3°/o H2o2. The sections were 
washed, lightly counterstained with Mayer's haematoxylin and then 
mounted under D.P.X. nonaqueous mountant. Control sections were treated 
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with PBS instead of the primary antibody to detect residual nonspecific 
peroxidase and nonspecific binding of the biotinylated second antibody or 
avidin-biotin-peroxidase complex. Photomicrographs were taken with a 
blue filter to enhance the contrast between the brown peroxidase reaction 
product and the blue counterstain. 
In order to confirm that this method produced positive staining with 
the Leu-7 monoclonal antibody, normal peripheral blood mononuclear cells 
(PBMC) were processed in the same way as the tissue sections. Cytospin 
preparations of PBMC on poly-L-lysine coated slides were fixed by a 
modified two step procedure at 4 °c consisting of incubations in 2°/o 
paraformaldehyde with 1 OmM sodium-m-periodate for 10 min, PBS for 5 
min and then lysine phosphate buffer for 10 min. After a 10 min wash in 
PBS, the PBMC slides were processed in parallel with the tissue sections. 
2.4 Monoclonal antibodies. 
The anti-Leu-7 monoclonal antibody (Becton-Dickinson, Mountain 
View, California) was used at the predetermined optimal dil ution of 1 /20 
in PBS with 0.1°/o human serum albumin (C.S.L., Austral ia) and 0.1°/o sod ium 
azide. Optimum detection of CD4+ cells was achieved by using a 
combination of 1/100 OKT4 (Ortho Diagnostic Systems Inc., Raritan , N.J.) 
and 1/100 anti-Leu-3a (Becton-Dickinson) in the same diluent. Other 
monclonal antibodies used were 1/20 OKT3, 1/100 OKT8, 1/20 OKT11 , 
anti-Leu-11 b in dilutions between 1/10 and 1/1000 and 1/100 25F9 wh ich 
,..... 
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was a generous gift from Ors Zwaldo and Sorg of the Universitats 
Hautklinik, Munster, West Germany (393). 
2.5 Quantitation of Leu-7+ cells in the intestinal lamina propria. 
Five to six hundred mononuclear cells in inter-crypt areas of the 
lamina propria were counted under oil immersion. The percentage of 
peroxidase-positive cells in control sections was subtracted from the 
value for the anti-Leu-7-treated sections to calculate the actual 
percentage of Leu-7+ cells. 
Ill. Results 
2.1 Normal histology of the ileum and colon. 
To assist in interpretation of the mucosa! morphology, sections of 
histologically normal colon and ileum prepared by conventional 
histological staining methods are shown in Figure 2.1. 
2.2 The number and distribution of Leu-7+ cells in the intestinal 
mucosa. 
A mean of 0.5°/o of LPMC in all fifteen specimens were Leu-7+ (Table 
2.1 ). The positively-staining cells were small to medium-sized 
Figure 2.1 (A) and (B). Sections of histologically normal colon (A) and 
.. 
ileum (B) from an intestine resected for colon carcinoma. The crypts (C) 
of the colon and crypts (C) and villi (V) of the ileum are indicated. The 
lamina propria of the intestine (LP) is bounded on the luminal aspect by 
the epithelium (E) and on the serosal aspect by the muscularis mucosae 
(M). Lamina propria (small arrow) and intraepithelial (large arrow) 
lymphocytes are indicated. (Formalin fixative and paraffin embedding. 
Haematoxylin and eosin stain, magnification x 175). 
Table 2.1 The frequency of Leu-7+ cells in the intestinal lamina propria. 
* Intestinal disorder Frequency of Leu-7+ cells (0/o) 
colon carcinoma (colon)@ 0.0°/o 
colon carcinoma (colon) 0.0°/o 
colon carcinoma (ileum) 0.5°/o 
colon carcinoma (colon) 0.7°/o 
diverticular disease (colon) 0.0°/o 
diverticular disease (colon) 1.0°/o 
sigmoid volvulus (colon) 0.6°/o 
Crohn's disease (colon) 0.7°/o 
Crohn's disease (colon) 0.0°/o 
(ileum) 1.5°/o 
Crohn's disease (ileum) 0.0°/o 
Crohn's disease (colon) 0.0°/o 
(ileum) 1.0°/o 
Crohn's disease (colon) 1.0°/o 
(ileum) 0.40/0 
Crohn's disease (colon) 0.5°/o 
(ileum) 0.2°/o 
Crohn's disease (colon) 0.5°/o 
(ileum) 0.0°/o 
Crohn's disease (colon) 1.0°/o 
(ileum) 1.3°/o 
* All samples of mucosa resected for colon carcinoma or nonmalignant conditions other than 
Crohn's disease were histologically normal. Mucosa! specimens from colon carcinoma were 
sampled from an area at least 5 cm away from the tumour. All specimens from patients 
with Crohn's disease showed histological evidence of active inflammation. 
@The source of the mucosa examined is indicated in brackets. In most cases of Crohn's disease 
both ileal and colonic mucosa from the same resection specimen were examined. 
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lymphocytes but the density of the membrane staining did not permit 
identification of cytoplasmic granules. There was no apparent difference 
between the mean percentages of Leu-7+ LPMC in histologically normal 
mucosa resected for colon carcinoma (0.3°/o) or nonmalignant conditions 
other than IBD (O.So/o). Although the specimens affected by Crohn's disease 
were infiltrated by increased numbers of inflammatory cells, the mean 
proportion of Leu-7+ cells remained very low (0.6°/o). The paucity of 
Leu-7+ cells in representative sections of histologically normal colon and 
inflamed ileum affected by Crohn's disease is illustrated in Figures 2.2 
and 2.3. 
Within the lamina propria, Leu-7+ cells were uniformly distributed, 
with no visible concentrations near the epithelium or the submucosa. None 
of the intraepithelial lymphocytes in either histologically normal or 
Crohn's disease mucosa were Leu-7+. Peripheral blood mononuclear cells 
stained with the same immunoperoxidase method used for intestinal 
mucosa showed approximately 10°/o Leu-7+ cells (Fig 2.4). This result 
agrees with previous phenotypic studies of PBMC and confirms that the 
method used in this study has adequate sensitivity for the detection of 
Leu-7+ cells (394). 
2.3 The distribution of Leu-7+ cells in mesenteric lymph nodes and 
mucosa! lymphoid tissue. 
Mesenteric lymph nodes from three patients with Crohn's disease all 
A B 
• 
Figure 2.2 Leu-7+ cells in the lamina propria of histologically normal 
colon resected for colon carcinoma. (A) Control section treated with PBS. 
(B) Anti-Leu-7 treated section. A single positive cell (large arrow) is 
present in the lamina propria. The intraepithelial lymphocytes (small 
arrow) are Leu-7-. (lmmunoperoxidase stain, magnification x 650). 
A B 
Figure 2.3 Leu-7+ cells in inflamed ileal mucosa resected for Crohn's 
disease. (A) Control section treated with PBS. (B) Anti-Leu-7 treated 
section. The mononuclear cell infiltrate in the lamina propria of the villus 
contains a single Leu-7+ cell (arrow). 
(lmmunoperoxidase stain, magnification x 650). 
A B 
Figure 2.4 Leu-7+ peripheral blood mononuclear cells from a normal donor. 
(A) Control section treated with PBS. (B) Anti-Leu-7 treated section. 
The leu-7+ cells (arrows) show the indented nucleus and cytoplasmic 
granules of large granular lymphocytes. 
(lmmunoperoxidase stain, magnification x 750). 
81 
showed a single prominent cluster of Leu-7+ cells within germinal centres 
(Fig 2.5). These cells had large nuclei and plentiful cytoplasm but 
intracytoplasmic granules were not visible. A similar staining pattern of 
germinal centres was obtained using the 25F9 monoclonal antibody which 
binds to a membrane antigen present on human lung, liver and intestinal 
macrophages but absent from blood monocytes (391,393) (Fig 2.5). 
Germinal centre cells positive with 25F9 were approximately the same 
size as the Leu-7+ cells in the same locality, but the limitations of the 
staining method precluded further morphological comparison. Outside the 
germinal centres, small Leu-7+ lymphocytes were scattered sparsely 
throughout the 8 and T cell cortical areas and medulla of the lymph nodes. 
A submucosal lymphoid follicle in the colon and a Peyer's patch in the 
ileum from two different specimens resected for colon carcinoma also 
showed clusters of Leu-7+ cells in germinal centres. 
Sections of mucosa and mesenteric lymph nodes stained with 
anti-Leu-11 b were uninterpretable due to dense nonspecific staining at 
dilutions from 1/10 to 1 /250 and a lack of specific staining at higher 
dilutions of the antibody. 
2.4 The distribution of T cells and macrophages in the intestinal mucosa 
and mesenteric lymph nodes. 
For the purposes of comparison with the distribution of Leu-7+ cells, 
the numbers and distribution of T cells and macrophages in the intestine 
B 
GC 
Figure 2.5 Leu-7+ and 25F9+ cells in the mesenteric lymph node from a 
patient with Crohn's disease. (A) Control section treated with PBS. 
(B) Anti-Leu-7 treated section. (C) Anti-25F9 treated section. 
Staining with either antibody shows positively-staining cells (arrows) 
clustered within germinal centres (GC). 
(lmmunoperoxidase stain, magnification x 250). 
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and mesenteric lymph nodes are shown in representative tissue sections. 
In agreement with previous studies, co4+ and cos+ lymphocytes were 
located in the lamina propria in a ratio of approximately 2:1 and all 
intraepithelial lymphocytes were co3+s+ (Fig 2.6) (395). Staining the 
mucosa with the 25F9 antibody identified a population of intestinal 
macrophages located predominantly in the subepithelial zone of the lamina 
propria (Fig 2.7). A mesenteric lymph node from a patient with Crohn's 
disease was stained with the anti-T cell monoclonal antibody OKT3 to 
delineate the T cell and B cell areas of the node (Fig 2.8). 
IV. Discussion 
The finding of small numbers of Leu-7+ cells in LPMC is consistent 
with all previous studies of the human intestinal mucosa (354,355,387). 
The Leu-7+ LPMC population is far outnumbered by intestinal T cells and 
macrophages and contrasts with the much larger proportion (10-25°/o) of 
peripheral blood lymphocytes which bear the Leu-7 surface antigen (394). 
The Leu-7 marker may not provide a precise reflection of mucosa! NK cell 
numbers as it is absent from a small population of CD16+ peripheral blood 
NK cells which might also exist in the intestine (28). Moreover, the Leu-7 
antigen is also present on subsets of T cells which lack NK activity 
(396-398). The CD16 antigen is therefore, a more suitable marker for NK 
cell detection, because .it is found only on neutrophils and TY cells in 
addition to NK cells (42,61, 119). Technical problems precluded the use of 
A B 
Figure 2.6 T lymphocyte subsets in histologically normal colonic mucosa 
resected for diverticular disease. (A) Control section treated with PBS. 
(B) Section treated with OKT3. (see over for figure 2.6, parts C and D). 
C D 
Figure 2.6 (continued). T lymphocyte subsets in histologically normal 
colonic mucosa resected for diverticular disease. (C) Section treated 
with OKT4/Leu-3b. (D) Section treated with OKT8. All intraepithelial 
lymphocytes (arrow) were co3+a+. Lamina propria lymphocytes were 
mainly co3+ and stained for CD4 or COB in a ratio of 2:1. 
(lmmunoperoxidase stain, magnification x 650). 
A B 
Figure 2.7 Intestinal macrophages in histologically normal intestine 
resected for colon carcinoma. (A) Control section treated with PBS. 
(8) 25F9 treated section. Large irregular cells with intracytoplasmic 
granules are located in the subepithelial zone of the lamina propria 
(arrow). (lmmunoperoxidase stain, magnification x 650). 
Figure 2.8 The T and 8 cell areas in the cortex of a mesenteric lymph node 
from a patient with Crohn's disease. (A) Control section treated with 
PBS. (B) Section treated with OKT3. The unstained germinal centre (GC) 
and surrounding mantle (M) of lymphocytes (B cell area) contrast with the 
surrounding T cells which are CD3+. 
(lmmunoperoxidase stain, magnification x 250). 
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this marker in the present study, but fluorescent analysis of LPMC 
suspensions for the C016 antigen confirm that NK cells bearing this 
marker are very infrequent (321,356). The paucity of intestinal NK cells 
demonstrated by immunohistochemistry is thus consistent with low 
intestinal NK activity which reaches levels comparable to those in the 
peripheral blood only when tested at very high effector to target ratios 
(356). 
It is difficult to postulate a significant role for NK cells in the 
normal or diseased intestine using immunohistochemistry because their 
sparse distribution would make it difficult to detect any subtle change in 
NK cell number due to disease. A comparison of intestines resected for 
colon carcinoma or nonmalignant conditions other than 180 showed that 
there was no discernible alteration in mucosa! NK cell numbers in colon 
carcinoma. These data indicate that there is no gross abnormality of 
mucosa! NK cell numbers associated with established colon carcinoma. 
Because of their small numbers and absence from the intraepithelial 
lymphocyte population, the scattered NK cells observed in 180 mucosae are 
unlikely to be a significant cause of either epithelial cell or connective 
tissue injury. However, NK cells can exert immunoregulatory effects even 
when present as a small minority (263,266). Thus it is possible that the 
immunoregulatory properties of NK cells may be important in certain 
I 
microenviroments of the normal or inflamed intestinal mucosa despite 
their small numbers. 
The clusters of Leu-7+ cells noted in germinal centers of mesenteric 
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lymph nodes and mucosa! lymphoid follicles have been described 
previously in the normal human spleen, tonsil and peripheral lymph nodes 
(277,278,399). Double staining analysis shows that these cells are 
co3+4+Leu-7+ granular lymphocytes (278,396). Although rarely found in 
the normal peripheral blood, these cells are expanded in association with 
lymphoproliferative disorders such as B cell chronic lymphocytic 
leukaemia (396-398). Recent studies of cloned CD4 +Leu-7+ tonsillar cells 
show that they lack NK activity and do not secrete of IL-2 or B cell growth 
factor (BCGF) (398). On this basis, germinal centre CD4+Leu-7+ 
lymphocytes differ from Leu-7+ peripheral blood LGL which modulate B 
cell activity through the secretion of BCGF (275). Although the function of 
the CD4+Leu-7+ lymphocyte is unknown, their location in germinal centres 
suggests that they mediate an important immunoregulatory function such 
as control of isotype switching or isotype-specific T cell help. Both T 
switch cells and isotype specific T helper cells are CD4+, but their 
expression of the Leu-7 antigen has not been investigated (400) . 
The identity of the 25F9+ cells in lymph node germinal centres is also 
uncertain. Without double-labelling studies it cannot be decided whether 
the Leu-7 and 25F9 markers are carried on the same or different cells. It 
is likely however, that the 25F9+ cells are the prominent 'tingible body' 
macrophages of the germinal centre (401 ). The follicular dendritic cell 
(FDC) also expresses some macrophage-related surface antigens and so is 
also a candidate for the cell type bearing the 25F9 marker (401 ). 
In conclusion, this study has demonstrated by immunohistochemistry 
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that cells bearing the NK cell-associated Leu-7 surface antigen comprise a 
very low proportion of all intestinal mononuclear cells. The possible 
consequences of these low NK cell numbers with regard to the defence 
mechanisms of the intestinal mucosa is uncertain. These data cast doubt 
on the role of NK cell-mediated cytotoxicity in intestinal diseases because 
of the paucity of identifiable NK cells and also because the number and 
distribution of Leu-7+ cells was no different in cases of colon carcinoma, 
Crohn's disease and other nonmalignant conditions. An unusual Leu-7+ cell 
population located in the germinal centres of mucosa-asociated lymphoid 
tissue may have immunoregulatory functions of relevance to the intestinal 
mucosa. 
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CHAPTER 3. 
Lymphokine-activated and natural killer cell activity in the human 
intestinal mucosa. 
I. Introduction 
Natural killer (NK) and lymphokine-activated killer (LAK) cells may be 
important components of host defence against neoplasia. Natural killer 
cells lyse a range of murine and human tumour cell lines in vitro 
(181,188,189) and selective defects in NK activity in vivo are associated 
with an increased incidence of spontaneous (188) and experimentally 
induced tumours in animals (181 ). Interleukin 2 (IL-2) is essential for 
both the cytotoxic activity (71) and proliferation (77) of NK cells, whereas 
interferon (IFN) augments NK activity mainly by increasing the lytic 
efficiency of functionally immature "pre NK" cells (16). 
Lymphokine-activated killer (LAK) cells are a recently described group of 
cells which also display nonspecific cytotoxicity against tumours, but 
they can be distinguished from NK cells on the basis of target specificity, 
kinetics of activation and surface phenotype 
(11,34,296,300,317,402-404). LAK cells are induced in culture by the 
proliferation of precursor cells in response to exogenous IL-2 (296) and 
can also be detected in mitogen or alloantigen-stimulated cultures where 
IL-2 is plentiful (34,300,403,404). 
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The functions of NK cells of relevance to the intestinal mucosa are 
not restricted to nonspecific cytotoxicity as there is considerable 
evidence to support a regulatory role for NK cells. As well as being IL-2 
and IFN-responsive, NK cells release these lymphokines after exposure to 
viruses, bacteria and mitogens (255,273). Rapidly proliferating lymphoid 
and haemopoietic cells may be susceptible to control through NK 
cell-mediated lysis (245,266) and antibody production may also be 
modulated by NK cells (269). Although peripheral blood LAK cells have 
been well characterized (11,38,284,309,317) their role in human disease 
is controversial. The capacity of peripheral blood LAK cells to lyse tumour 
cell lines and freshly isolated tumour cells suggests an important 
antineoplastic function (11,403). While the cytotoxicity of peripheral 
blood NK and LAK cells has been studied in patients with cancer (11,189), 
the relevance of these activities to local organ involvement by malignancy 
is uncertain. 
Attention has therefore focused on the investigation of local NK 
activity in intestines resected for colon carcinoma or for nonmalignant 
disorders (350-353,355,360,361 ). In all such studies of colon cancer so 
far reported, spontaneous mucosa! NK activity was weak or absent, 
whereas peripheral blood NK activity in patients with colon carcinoma was 
readily detectable (353,355). The question now arises therefore, as to 
whether the LAK cell is the predominant nonspecific cytotoxic cell in the 
intestinal mucosa. 
In the present study, the activities of spontaneous and IFN-inducible 
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NK cells and of LAK cells were assayed in the lamina propria of 
histologically normal intestines resected for colon carcinoma or for 
nonmaligant conditions. In contrast with the low level or absent 
spontaneous and I FN-inducible NK activity observed, LAK activity against 
K562 target cells was readily induced by IL-2. These findings indicate 
that LAK cells may be an important potential source of nonspecific 
cytotoxicity in the intestinal lamina propria. 
II. Materials and Methods 
3.1 Patients and specimens. 
Sixty-one surgical specimens of intestine obtained from 57 patients 
were included in this study. Data recorded for patients included: 
pathological diagnosis, extent of tumour spread according to Duke's 
classification, histopathological description of intestinal mucosa and 
relevant drug therapy administered at the time of surgery. There were 40 
specimens of colon and five of terminal ileum taken from patients with 
colorectal carcinoma. Uninvolved mucosa, taken at least five cm away 
from the carcinoma, was confirmed to be histologically normal in all 
patients. Fifteen histologically normal specimens of colon and one of 
ileum were taken from intestine resected for diverticular disease (11 
cases), tubulovillous adenoma (one case), sigmoid volvulus (one case) , 
appendiceal abscess (one case), redundant colon (one case) and adhesive 
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small bowel obstruction (one case). 
3.2 Disaggregation of intestinal mucosa. 
Full thickness samples of intestine were selected from opened 
surgical specimens immediately after resection and transported to the 
laboratory in ice cold RPMI 1640 medium (Gibco, Grand Island Biological 
Co., N.Y.) supplemented with penicillin (100 IU/ml), streptomycin (100 
µg/ml) and neomycin (100 µg/ml). Tissue was then disaggregated as 
previously described by Golder and Doe (385). Mucosa! specimens 
dissected from muscularis were incubated sequentially in 1 mM 
dithiothreitol (Sigma Chemical Co., St. Louis, MO.) and then 0.75mM EDTA 
until all epithelial cells were removed. After overnight incubation in 
medium containing 2U/ml collagenase (CLSPA Worthington, New Jersey, 
USA); SU/ml deoxyribonuclease (Calbiochem. Type II, Behring Diagnostics, 
La Jolla, CA) and 5°/o human AB serum, lamina propria mononuclear cells 
(LPMC) were separated from particulate debris by filtration through eight 
layers of sterile surgical gauze. LPMC were then washed and resuspended 
in RPMI 1640 medium supplemented with 10°/o heat-inactivated foetal 
bovine serum (FBS) (Sterile Systems, Inc.) for density gradient 
centrifugation. 
The average yield of LPMC (mean± SD) for all specimens was 
17.8 ± 10 x 106 cells/g mucosa with viability always greater than 95°/o. 
Yields from carcinoma and benign conditions were not significantly 
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different. 
3.3 Isolation of peripheral blood mononuclear cells. 
Twenty ml of venous blood was obtained by venipuncture from three 
normal controls and three patients whose colons were later resected for 
carcinoma. Peripheral blood mononuclear cells (PBMC) were separated by 
centrifugation over Ficoll-Hypaque gradients ( Pharmacia Fine Chemicals, 
Uppsala, Sweden) and interface cells were harvested, washed twice and 
resuspended in RPMI 1640 medium with 10°/o FBS. 
3.4 Enrichment of LPMC and PBMC for natural killer cells. 
Suspensions of LPMC and PBMC were enriched for NK cells by 
discontinuous gradient centrifugation using four step gradients of Percoll 
(Pharmacia Fine Chemicals, Uppsala, Sweden ) which was a modification of 
the method of Timonen et al (25). Cell suspensions ( 75-100 x 106 cells in 
5 ml medium) were layered over four Percoll fractions consisting of 1 ml 
of 1.125 g/ml Percoll, 3ml of 1.073 g/ml Percoll, 3ml of 1.063 g/ml and 3 
ml of 1.053 g/ml in 15ml plastic centrifuge tubes. Percoll fractions were 
adjusted to the physiological osmolality of 285 mOsmoles/Kg H20. 
Gradients were centrifuged at 500g for 30 min at room temperature and 
then cells were harvested from all interfaces, washed twice and 
resuspended in medium containing 5°/o FBS for cytotoxicity testing and 
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morphological studies. 
Measurement of the NK activity of mononuclear cell populations both 
before and after density gradient centrifugation confirmed that 
cytotoxicity was significantly enriched for both LPMC and PBMC 
populations (see results). Maximum NK activity was found in the cell 
fraction immediately above Percell density 1 .063 g/ml. Therefore all 
studies described in this section for both LPMC and PBMC utilized cells 
from this interface. 
3.5 Short term culture of LPMC. 
Ten LPMC populations (four colon carcinoma, six nonmalignant) were 
assayed for NK activity both before and after a 24 h period of incubation. 
LPMC were incubated in 30 ml tissue culture flasks (Lux) at a 
concentration of 1 x 106 cells/ml in 5-1 O ml of medium supplemented 
with 3°/o AB serum at 37°C in an atmosphere of 5°/o CO2 in air. After 
culture the LPMC were washed and resuspended in medium with 5°/o FBS for 
cytotoxicity testing. 
3.6 Removal of adherent cells from LPMC. 
Seven LPMC specimens resected for carcinoma were assayed for NK 
activity both before and after removal of plastic-adherent cells. Five ml 
of the LPMC suspensiohs (1 x 106 cells/ml medium) were incubated in 
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90mm plastic petri dishes for 60 min at 37°C in an atmosphere of 5°/o CO2 
in air. Nonadherent cells were removed in four washes with medium and 
tested for NK activity simultaneously with paired unprocessed LPMC 
specimens. Nonspecific esterase staining of the nonadherent LPMC showed 
less than 2°/o macrophages in all cases. 
3.7 Culture of LPMC in MLA144 conditioned medium. 
Conditioned medium from the primate lymphoma MLA144 cell line 
(MLA 144 CM) was used as a proven source of IL-2 (408). Filtered MLA 144 
CM was added at a predetermined optimal dilution to RPMI 1640 and 
supplemented with 2mM L-glutamine, penicillin (100 IU/ml), streptomycin 
(100 µg/ml), neomycin (100 µg/ml) and 3°/o heat-inactivated AB serum and 
stored at 4°C. LPMC (25 specimens from carcinoma and eight from 
nonmalignant disorders) were first assayed for NK activity and then 
incubated at 1 x 106 cells/ml MLA 144 CM in 30 ml tissue culture flasks 
(Lux) at 37°C in an atmosphere of 5°/o CO2 in air. LPMC from the 1.063 
g/ml interface were found to generate maximum cytotoxicity compared 
with cells from other fractions or unfractionated cells (see results). 
Thus, the cell populations used to generate LAK cells in this study were 
from this interface. As a control experiment, nine of these specimens 
(seven from carcinoma, two nonmalignant) were also cultured under the 
same conditions in RPMI 1640 medium supplemented only with 3°/o AB 
serum and antibiotics. Cytotoxicity against K562 cells was tested at 
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intervals of up to ten days in culture for all specimens and their paired 
medium controls. Cytotoxicities recorded as results were the maximum 
levels of activity assayed during the culture period. 
3.8 Treatment of LPMC with anti-Tac antibody. 
Four specimens of LPMC from colon carcinoma patients and one 
sample of PBMC from a normal control were cultured at 1 x 106 cells/ml 
with anti-Tac monoclonal antibody (409) diluted 1/200 with MLA144 CM. 
Controls included LPMC specimens grown in medium alone or in OKT4 
monoclonal antibody diluted 1 /200 with MLA 144 CM. Cytotoxicity was 
measured after four days in culture. 
3.9 Culture of LPMC in medium supplemented with recombinant IL-2. 
Fourteen LPMC specimens (11 from carcinoma and three from 
nonmalignant disorders) were cultured at 1 x 1 o6cells/ml RPMI 1640 
medium supplemented with 250 U/ml recombinant human IL-2 (Hoffman-
La Roche Inc.,) and 3°/o AB serum for up to ten days. This concentration of 
IL-2 was found to be optimal for the generation of LAK activity (see 
results). Cytotoxicity against K562 cells was then assayed at intervals 
during culture. 
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3.1 O Culture of intestinal LAK cells in the absence of IL-2. 
Eight LPMC populations (five carcinoma, three nonmalignant) cultured 
in medium containing IL-2 were split at day five into two separate 
subpopulations. One aliquot of cells remained in the same culture medium 
with IL-2 whereas the other fraction was washed three times and 
resuspended at 1 x 106 cells/ml in medium supplemented with 3°/o AB 
serum but no IL-2. After 24 h, the cultures were terminated and tested 
for cytotoxicity against K562 cells. 
3.11 Incubation of LPMC with interferon. 
Triplicate samples of freshly isolated LPMC from six patients (four 
carcinoma and two nonmalignant disorders) were incubated with 100 U/ml 
and 250 U/ml of human leucocyte interferon (MRC Research Standard 
869/19) in microculture wells (Titertek) at a concentration of 1 x 106 
cells/ml in 0.1 ml RPMI 1640 and 5°/o FBS. After incubation for 1 hat 37°c 
in an atmosphere of 5o/o CO2 in air, cytotoxicity was measured leaving IFN 
in the microculture wells for the duration of the assay. 
3.12 Cytotoxicity Assay. 
Samples of LPMC and PBMC were tested for NK activity using K562 
cells in log phase of growth (407). One million K562 cells were incubated 
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with 50 µCi sodium 51chromate for 1 h in 0.2 ml RPMI with 5°/o FBS at 
37°c in an atmosphere of 5°/o CO2 in air. After four washes, K562 cells 
were resuspended at 1 x1 o5 cells/ml medium supplemented with 5°/o FBS. 
Effector cells were assayed in triplicate in 96 well round bottom 
microculture plates by adding 1 x1 o4 target cells to LPMC or PBMC to 
produce effector to target cell (E:T) ratios ranging from 100 : 1 to 12.5 : 1 
in a final volume of 0.2 ml. For spontaneous release controls, aliquots of 
labelled K562 cells were suspended in medium alone. After 4h incubation, 
0.1 ml of supernatant was removed for counting in a gamma counter. 
Maximum release of 51 Cr from K562 cells was calculated by addition in 
triplicate of 1 x 1 o4 K562 cells in 0.1 ml medium to 0.4 ml 5o/o Triton X100 
(Ajax Chemicals) in 1 O ml plastic centrifuge tubes. After 2 h incubation, 
the detergent solution was centrifuged at 300g for 10 min and 0.25 ml of 
the supernatant from each tube was removed and placed in 3DT tubes 
(Disposable Plastics) for counting. 
Cytotoxicity was expressed as percent specific Cr51 release and was 
calculated as follows : 
0/o specific release = experimental release - spontaneous release x100 
maximum release - spontaneous release 
The mean spontaneous release expressed as a percentage of maximum 
release was 12.0°/o for K562 cells. A specific release value was 
considered to represent significant cytotoxic activity when it exceeded a 
cut off level equal to the mean plus three standard deviations of the 
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spontaneous release controls. This cut off level was 3.0°/o for K562 cells. 
3.13 Phenotyping of intestinal LAK cells using complement-mediated 
lysis. 
Intestinal LAK cells induced by culture in MLA 144 CM were 
phenotyped against K562 target cells by using monoclonal antibody and 
complement-mediated lysis. Cultures of LAK cells were washed and 
resuspended in RPMI 1640 with 1 °/o FBS at a concentration of 2.5 x 106 
cells/ml. The monoclonal antibodies used were Ortho Pharmaceutical 
OKT3, OKT4, OKT8, OKT11, OKia, OKM1 (all diluted 1/50 in medium) and 
Becton Dickinson Leu-M2 (1/50), Leu-7 (1/50) and Leu-11 b (1/20). These 
dilutions of antibody were shown by fluorescent antibody analysis to 
produce maximum complement-mediated lysis of the corresponding LPMC 
subpopulation. The concentrations of Leu-7 and Leu-11 b also resulted in 
maximum reduction of peripheral blood NK activity by antibody and 
complement-mediated lysis. Ten µI of antibody was added to 2.5 x 1 o4 
LPMC in an equal volume of medium in duplicate round bottom microculture 
wells and stored on ice for 60 min. LPMC were then washed in cold 
medium, pelleted by centrifugation at 200g for 5 min and after 
supernatants were removed by needle aspiration the LPMC were 
resuspended in 20 µI of medium containing a 1/10 dilution of rabbit 
complement (Cedarlane Laboratories). Following incubation with 
complement for 60 min at 37°c in an atmosphere of 5°/o CO2 in air, a 
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similar volume of diluted complement was added for a further 30 min. 
Control cells were treated with medium, antibodies or complement alone. 
Test and control cells were then washed with medium at room 
temperature and resuspended in 0.1 ml of RPMI 1640 with 5°/o FBS. 
Cytotoxicity of treated and control cells was determined by adding 1 x 1 o4 
K562 cells in 0.1 ml to each well. 
3.14 Depletion of LAK precursor cells by complement-mediated lysis. 
Subpopulations of cells were depleted from four LPMC specimens (all 
from carcinoma patients) by using complement and each of the antibodies 
OKT3, OKT4, OKT8, OKT11, OKM1, OKia, Leu-7 and Leu-11 b. The treated 
LPMC populations were then cultured in MLA 144 in order to generate LAK 
cells. The same procedure outlined above for phenotyping was followed 
except that 1 x 1 o5 LPMC were treated with 40 µI of monoclonal antibody 
and 160 µI of diluted complement in duplicate microculture wells. After 
depletion treatment, LPMC were washed and resuspended at a 
concentration of 1 x106 cells/ml in MLA 144 CM. Controls included LPMC 
treated with complement, monoclonal antibody or medium and were 
cultured in either MLA144 CM or medium alone. Test and control 
specimens were tested for cytotoxicity against K562 cells after three to 
eight days in culture. 
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3.15 Sorting of LPMC by panning. 
LPMC from four patients with carcinoma were sorted into co2+ and 
co3+ cells using the OKT11 and OKT3 antibodies respectively. Thirty-five 
mm x 10mm bacteriological grade plastic Petri dishes (Kayline) were 
coated with 1 ml of rabbit anti-mouse immunoglobulin (DAKO code 2109) 
diluted 1/1000 with phosphate buffered saline (PBS) for 40 min at 4°C. 
The antibody solution was decanted and the plates were washed four times 
with PBS, once with 1 °/o FBS in PBS and were stored at 4 °c until used. 
Samples of LPMC were treated separately with the antibodies OKT3 and 
OKT11 by incubation of 20 x 106 LPMC in 1 ml of medium containing a 
1/50 dilution of either antibody. After 40 min incubation at 4°C, the 
treated cells were centrifuged and resuspended in 3.75 ml of Hank's 
balanced salt solution and 5°/o FBS. Approximately 4 x 106 cells were 
poured gently into each of five antibody-coated Petri dishes and were 
incubated at 4°C for a total of 70 min with gentle swirling at 40 min to 
redistribute cells. Nonadherent cells were then harvested from the initial 
supernatant and in four subsequent gentle washes with PBS and 1 °/o FBS. 
Adherent cells were removed after a further two washes using a rubber 
policeman and were resuspended in PBS. Adherent and nonadherent cell 
populations were washed and resuspended in RPM I 1640 medim for 
counting. The viabiltiy of both cell populations always exceeded 95°/o. 
Cells sorted by panning were cultured in microculture wells for three to 
eight days at 1 x 106 cells/ml in 0.1 ml MLA 144 CM and were then tested 
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for cytotoxicity against K562 cells. 
To detect nonspecific binding of antibody to Fe receptors, LPMC 
incubated in medium alone were added to antibody coated plates. After 
incubation and removal of nonadherent cells, direct microscopic 
examination and counts of adherent cells showed that fewer than 1 °/o of 
LPMC were binding nonspecifically. Fluorescent analysis of LPMC sorted 
by panning showed less than 5°/o contamination with cells of the unwanted 
phenotype. 
3.16 Morphological Studies. 
Cell viability was determined by exclusion of 0.125°/o Trypan Blue. 
Differential counts were made on methanol-fixed, May Grunwald-Giemsa 
stained slides prepared in a Shandon cytocentrifuge for 5 min at 500 rpm. 
The percentage of nonspecific esterase (NSE) positive cells was assessed 
using a-naphthyl butyrate as substrate as described by Yam et al ( 405) 
and Ornstein et al (406). 
3.17 Statistical analysis. 
Differences between the cytotoxic activities of cell populations were 
analysed using the Wilcoxon Rank Sum Test. A p value of 0.05 or less was 
required for significance. 
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111. Results. 
3.1 The NK activity of freshly isolated LPMC and PBMC. 
In preliminary experiments, five populations of LPMC and two of PBMC 
were subjected to discontinuous gradient centrifugation in order to 
determine which density of mononuclear cells had the maximum NK 
activity. Analysis of unfractionated cells and the LPMC subpopulations 
harvested from the Percoll gradient interfaces showed that the cells from 
the 1.063 g/ml fraction consistently displayed the maximum NK activity 
(Table 3.1 ). 
The NK activity in this fraction of freshly isolated LPMC was assayed 
in 34 colon carcinoma specimens and 13 specimens resected for 
nonmalignant conditions (Fig 3.1 ). The overall mean activity for all LPMC 
specimens was 3.4 °/oat an E:T ratio of 50:1. By contrast, PBMC NK 
activities from three pati,ents with colon carcinoma and three normal 
subjects showed a mean activity of 53.7°/o (P< 0.01 ). No relation was found 
between LPMC NK activity and the presence or absence of malignancy 
(mean cytotoxicities were 3.8°/o and 2.2°/o respectively) or the extent of 
carcinoma spread. When the lower limit of significant cytotoxic activity 
for each assay was set at a value equal to the mean plus three standard 
deviations of the spontaneous release controls, low level but significant 
NK cell activity was detectable in 14 specimens (41 °/o) from carcinoma 
Table 3.1 The NK and LAK activity of LPMC and PBMC fractions in discontinuous Percoll 
gradients. 
. (a) 
Percoll fraction 
Unfractionated 
1.053 g/ml 
1.063 g/ml 
1.073 g/ml 
1.125 g/ml 
NK activity(b) 
LPMC PBMC 
4.3°/o(d) 40.0°/o 
1.9°/o 43.3°/o 
8.2°/o 66.5°/o 
1.9°/o 24.7°/o 
0.0°/o 15.6°/o 
LAK activity(c) 
LPMC 
26.2°/o 
15.8°/o 
44.3°/o 
9.9°/o 
5.7°/o 
The results shown are representative of five LPMC and two PBMC populations tested. 
(a) Cells tested for NK and LAK activity included an unfractionated population before 
centrifugation and also cells harvested from interfaces above each of the Percoll densities 
indicated. 
(b) LPMC and PBMC from unfractionated and interface populations were tested for spontaneous 
NK activity immediately after centrifugation. 
(c) LPMC from unfractionated and interface populations were cultured in MLA 144 CM and then 
tested for LAK activity. 
(d) Percent specific release from K562 cells at an E:T ratio of 50:1. 
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Figure 3.1 Spontaneous NK activity of LPMC from intestines resected for 
colon carcinoma or nonmalignant conditions. Peripheral blood NK activities 
in three normal control subjects and three carcinoma patients are included 
for comparison. The NK activities of the two LPMC subgroups were not 
significantly different (P< 0.20) but the cytotoxicities of both LPMC 
subgroups were significantly less than that in the peripheral blood (P<- 0.01 ). 
Cytotoxicity is expressed as percent specific release from K562 cells at an 
E:T ratio of 50:1. 
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patients and four (30o/o) from mucosa resected for benign conditions. No 
significant activity was detected in the remaining 29 specimens. The NK 
activity of LPMC assayed against K562 cells is therefore absent or 
detectable at levels which are very low compared to PBMC. 
The NK activity of LPM C was not affected by the presence of 
intestinal macrophages as their depletion by plastic adherence did not 
significantly alter the low levels of NK activity (Table 3.2). Moreover, 
incubation of LPMC in medium for 24 h after their isolation did not result 
in any consistent increase in NK activity for the ten specimens examined 
(Table 3.3). In order to determine whether the isolation procedure altered 
NK activity, PBMC from two normal subjects were assayed for cytotoxicity 
before and after exposure to the treatment used to disaggregate the 
intestinal mucosa. No substantial difference was found between pre and 
post treatment PBMC NK activities. 
3.2 The effect of IFN on LPMC NK activity. 
As the spontaneous NK activity of LPMC was shown to be either low or 
absent, an attempt was made to augment NK activity using human 
leucocyte IFN. LPMC from six specimens were tested for NK activity after 
incubation in either medium alone or in medium containing 100 U/ml of 
human leucocyte IFN. There was a minor, but significant increase (P< 0.01) 
in mean NK activity from 0.5°/o to 2.4 °/o (Table 3.4) , but only one specimen 
reached significant levels of cytotoxicity. Incubation of two 
Table 3.2 The effect of intestinal macrophage depletion on the NK activity of LPMC. 
Intestinal disorder Before depletion(a) After depletion 
colon carcinoma 1.8°/o(b) 1.2°/o 
colon carcinoma 0.0°/o 0.0°/o 
colon carcinoma 0.0°/o 0.0°/o 
colon carcinoma 1.2°/o 2.0°/o 
colon carcinoma 2.2°/o 0.9°/o 
colon carcinoma 0.6°/o 0.0°/o 
colon carcinoma 0.3°/o 0.0°/o 
(a) Freshly isolated LPMC were tested for spontaneous NK activity before and after depletion of 
intestinal macrophages by plastic adherence. 
(b) Percent specific release from K562 cells at an E:T ratio of 50:1. 
Table 3.3 The spontaneous NK activity of LPMC before and after incubation in medium. 
Intestinal disorder O h incubation(a) 24 h incubation 
colon carcinoma 3.2o;)b} 1.8°/o 
colon carcinoma 0.0°/o 0.0°/o 
colon carcinoma 0.40/0 0.3°/o 
colon carcinoma 1.2°/o 4.0°/o 
colon carcinoma 1.0°/o 0.2°/o 
colon carcinoma 1.0°/o 2.6°/o 
diverticular disease 0.0°/o 0.0°/o 
diverticular disease 1.0°/o 0.40/0 
diverticular disease 0.4°/o 3 .2°/o 
sigmoid volvulus 0.2°/o 1.8°/o 
(a) Paired LPMC specimens were tested for spontaneous NK activity immediately upon isolation 
(0 h) and after incubation in medium for 24 h. 
(b) Percent specific release from K562 cells at an E:T ratio of 50:1. 
Table 3.4 The effect of IFN on the NK activity of LPMC. 
Intestinal disorder spontaneous NK activity(a) IFN-augmented NK activity 
colon carcinoma 0.2°/o(b) 2.6°/o 
colon carcinoma 0.2°/o 3.0°/o 
colon carcinoma 1.0°/o 2.8°/o 
colon carcinoma 0.8°/o 1.8°/o 
diverticular disease 0.0°/o 1.4°/o 
appendiceal abscess 1.0°/o 2.6°/o 
(a) The NK activity of LPMC was assayed with or without the addition of 100 U/ml IFN. 
(b) Percent specific release from K562 cells at an E:T ratio of 50:1. 
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specimens with concentrations of IFN up to 500 U/ml resulted in no 
further increase in cytotoxicity. Although the spontaneous NK activity of 
LPMC was increased by IFN, the levels achieved were still much lower than 
peripheral blood NK activity (p< 0.01 ). 
3.3 The effect of MLA 144 CM on LPMC cytotoxicity. 
In view of the minimal spontaneous or IFN-inducible lamina propria 
NK activity, intestinal lymphokine-activated killer (LAK) cell activity was 
investigated by culturing LPMC in MLA 144 CM which is a known source of 
IL-2 (408). Culture of LPMC from the 1.063 g/ml Percell fraction produced 
maximum levels of LAK activity when compared with cells from the other 
fractions or unfractionated specimens (Table 3.1 ). After their isolation 
and assessment for spontaneous NK activity, 1.063 g/ml fraction LPMC 
from 25 carcinoma specimens and eight nonmalignant specimens were 
cultured in MLA 144 CM for up to ten days and the maximum cytotoxicity 
against K562 cells was determined. To ensure that increases in 
cytotoxicity were due to a constituent of the MLA 144 CM, nine of the LPMC 
specimens were also cultured simultaneously in RPMI 1640 medium and 3°/o 
AB serum in the absence of MLA 144 CM. The cytotoxicity of LPMC cultured 
in MLA 144 CM (mean activity 26.3°/o) was markedly higher than that of the 
specimens cultured in medium without MLA 144 CM (2.0°/o) (P< 0.01 ). 
As shown in Figure 3.2, the spontaneous NK activity of each LPMC 
specimen (at time 0) is ~ompared with its maximum LAK activity attained 
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Figure 3.2 The NK and LAK activities of LPMC (25 specimens from carcinoma 
and eight from nonmalignant disorders) before and after culture in MLA 144 
CM. The initial spontaneous NK activities (o) at time Oare compared with 
the maximum LAK activities (0) attained in culture ( > 72 h). The increases 
in cytotoxicity were significant for both groups (p< 0.01 and p< 0.05 
respectively). Cytotoxicity is expressed as percent specific release from 
K562 targets at an E:T ratio of 50:1. 
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after culture in MLA144 CM (time> 72 h). Results from specimens with 
carcinoma or nonmalignant conditions were considered separately. There 
was a highly significant increase in cytotoxicity for specimens from both 
carcinoma (4.3o/o to 83.6°/o) and nonmalignant disorders (3.1 °/o to 37.4°/o) 
after incubation in IL-2 containing medium (P< 0.01 for both groups). The 
levels of LAK activity induced in malignant and benign specimens were not 
significantly different and there was also no relation between levels of 
LAK activity and the extent of carcinoma spread. 
3.4 Generation of LAK cells using recombinant human IL-2. 
I 
To confirm that IL-2 was the factor, or at least one of the factors, 
responsible for the LAK activity induced by MLA 144 CM, 14 LPMC 
specimens were cultured in the same manner with human recombinant IL-2 
substituted for MLA 144 CM. The effect of IL-2 concentration in culture on 
the development of LAK activity is shown in Figure 3.3. The optimal IL-2 
concentration of 250 U/ml was used for the generation of LAK cells. 
Culture of LPMC in the presence of recombinant IL-2 alone produced high 
levels of LAK activity (mean activity 91.5°/o at an E:T ratio of 50:1 ). LAK 
activity increased gradually during culture with IL-2, with peak levels 
attained at six days (Fig 3.4). 
The dependence of LAK activity on the presence of IL-2 was studied 
by withdrawing IL-2 from cultures of LAK cells which had been initiated 
five days previously. Twenty-four hours after the removal of IL-2, the 
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Figure 3.3 The effect of IL-2 concentration on the generation of intestinal 
LAK activity. LPMC from a specimen resected for carcinoma were cultured 
with serial dilutions of human recombinant IL-2 in medium for a period of 
six days and were then assayed for LAK activity against K562 cells at an E:T 
ratio of 50: 1. The vertical bars represent the standard errors of the mean 
cytotoxicities. 
100 
,.... 
~ 80 
<( 
w 
....J 
w 
a: 
u 
-~ 60 u 
w 
a.. 
Cl) 
*' ...., 
~ 40 
u 
-X 
0 
t-
o 
t-b 20 
0 
2 4 6 8 10 
DAYS CULTURE IN IL -2 
Figure 3.4 The kinetics of intestinal LAK cell activation derived from serial 
assays of LAK activity during the culture of 14 LPMC populations with 
human recombinant IL-2. The vertical bars represent the standard errors of 
the mean cytotoxicities. 
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cytotoxicity of deprived populations had declined by an average of 40°/o 
compared to paired specimens which were maintained in culture with IL-2 
(Table 3.5). In four of the seven specimens, the decrease in activity 
exceeded 30°/o and the greatest decline noted was 57°/o. 
3.5 Changes in the morphology of LPMC populations after culture in 
MLA144 CM. 
The predominant cell type in freshly isolated LPMC was lymphocytic 
in appearance, comprising 70°/o of the total population, while macrophages 
(identified by NSE staining) represented 17°/o of the cells. Few 
lymphoblasts or large granular lymphocytes (LGL) were detected in freshly 
isolated cells (< 0.5°/o for both populations). There was no significant 
difference in the proportion of cell types between specimens resected for 
carcinoma or for nonmalignant conditions. In order to assess the 
efficiency of the Percell gradient system in enriching LGL and depleting 
macrophages, these cells were counted in the 1.063 g/ml cell fractions 
used in this study. Compared to unfractionated LPMC cells, macrophages 
were depleted from 17°/o to 8°/o, LGL's were minimally increased from O.So/o 
I 
to 1°/o and lymphoblasts were rarely seen(< 0.05°/o). After LPMC were 
cultured in MLA 144 CM, the proportion of blasts increased markedly to 
35°/o, whereas minimal expansion of the LGL population (2°/o) was observed 
(Fig 3.5). 
A 
Figure 3.5 (A) LPMC from the 1.063 g/ml Percell fraction used for assay of 
NK activity were mainly lymphocytes (L), with a small proportion (8°/o) of 
macrophages (arrow), 1 °/o LGL (not easily demonstrable at this 
magnification), and less than 0.5°/o blast cells (not shown). (8) Culture of 
LPMC from this fraction in MLA 144 CM generated a heterogenous cell 
population consisting predominantly of 35°/o blast cells (BL) , lymphocytes (L) 
and 2°/o LGL. (May Grunwald-Giemsa stain, magnification x 800 for A and B) 
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3.6 Effect of the anti-Tac antibody on the generation of intestinal LAK 
cells. 
To test whether the generation of LAK cells was IL-2 dependent, four 
LPMC specimens from colon carcinoma and PBMC from 1 normal control 
subject were cultured in MLA 144 CM supplemented with a 1 /200 dilution 
of anti-Tac antibody. Anti-Tac is a mouse monoclonal antibody directed 
specifically against the IL-2 receptor which blocks IL-2 induced 
proliferation of lymphocytes (409). 
Addition of the anti-Tac antibody to cultures of LPMC in MLA 144 CM 
reduced LAK activity against K562 cells in all five cases to levels of 
cytotoxicity comparable to those of LPMC cultured in medium alone (Table 
3.6). To control for a possible nonspecific effect of anti-Tac on MLA144 
CM-induced cytotoxicity, the four LPMC specimens were simultaneously 
cultured with MLA 144 CM and an irrelevant antibody of the same isotype 
(OKT4). The OKT4 antibody is nonmitogenic and defines T helper 
lymphocytes (410). In three specimens, LAK activity was unaffected, 
suggesting that anti-Tac specifically blocked the IL-2 receptor. In a 
further control experiment, the anti-Tac antibody was added to LAK cells 
immediately before assaying for cytotoxicity. No effect on cytotoxicity 
was observed, thereby excluding the possibility that cell-bound anti-Tac 
persisting after washing could inhibit LAK activity. 
I 
Table 3.6 The effect of the anti-Tac antibody on MLA 144 CM-induced LAK activity. 
culture conditions 
Intestinal disorder 
MLA144 CM MLA144 CM+ MLA144 CM+ 
control anti-Tac OKT4 
colon carcinoma 19.2°/o(a) 0.2°/o 26.5°/o 
colon carcinoma 24.4°/o 0.0°/o 11.5°/o 
colon carcinoma 24.5°/o 0.2°/o 29.9°/o 
colon carcinoma 41.1 °/o 0.3°/o 39.5°/o 
PBMC (control) 10.6°/o 0.2°/o _(b) 
(a) Percent specific release from K562 cells at an E:T ratio of 50:1. 
(b) Experiment not performed. 
Medium 
control 
0.2°/o 
1.0°/o 
0.2°/o 
3.6°/o 
0.6°/o 
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3.7 Phenotype of intestinal LAK cells. 
Eight LPMC populations (seven carcinoma, one nonmalignant) with 
MLA 144 CM-induced LAK activity against K562 cells were phenotyped by 
antibody and complement-mediated lysis. During culture in MLA 144 CM, 
multiple assays were performed on individual specimens to ensure that 
the results were reproducible and representative data from these assays 
are shown in Table 3.7. In all specimens, treatment with OKT11 and 
complement reduced LAK activity by at least 30°/o of control values 
(complement treatment alone), with average residual cytotoxicity being 
30°/o of control values for all 16 estimations. For the remainder of the 
monoclonal antibody panel, no consistent reduction in LAK activity was 
noted. All samples tested were unaffected by the Leu-7 and Leu-11 
antibodies which detect 80-85°/o and 100°/o of peripheral blood NK activity 
respectively (28). 
Freshly isolated PBMC from two normal controls were enriched for NK 
cells and were phenotyped in the same way. In contrast to intestinal LAK 
cells, the NK phenotypes in both cases were co2+3-15+Leu-7+, as reported 
by others (28,394,411). 
3.8 Intestinal LAK precursor cell phenotype. 
The surface phenotype of LPMC required as precursors for LAK cells 
Table 3.7 The phenotype of intestinal LAK cells induced by culture in MLA 144 CM. 
Monoclonal antibodies(a) 
Intestinal 
disorder (b) OKT4 OKT8 OKT11 OKM1 Leu-M2 Leu-7 C control OKT3 Leu-11 b 
carcinoma (1 )(c) 26.9(d) 25.0 _( e) 30.2 0.0 22.9 
carcinoma (5) 64.4 73.4 61.3 33.8 53.5 52.9 72.8 63."9 
carcinoma (3) 67.3 58.8 62.8 62.8 46.0 67.8 67.9 
carcinoma (1) 35.7 26.3 31.0 15.7 5.2 27.4 27.1 27.3 
carcinoma (2) 45.0 36.6 48.7 32.2 14.4 49.8 41.1 46.0 
carcinoma (2) 17.7 17.7 20.0 22.0 11.3 21.3 24.4 20.0 21.5 
carcinoma (1) 12.3 20.8 14.3 13.5 0.0 14.4 15.2 14.8 
diverticular 4.0 8.7 6.4 4.5 2.2 3.9 4.4 4.9 
disease (1) 
(a) Intestinal LAK cells were phenotyped by antibody and complement-mediated lysis using the 
panel of monoclonal antibodies shown plus complement. 
(b) Controls were LPMC treated only with complement before cytotoxicity testing. 
(c) The number of experiments performed for each specimen are shown in parentheses. When 
multiple estimations were done, the single result shown is representative. 
(d) Percent specific release from K562 cells. 
(e) Experiment not performed. 
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was determined by complement-mediated lysis and panning methods. 
Freshly isolated LPMC from three specimens were treated with one of the 
panel of monoclonal antibodies and complement, and the LAK activity 
developing in culture with MLA144 CM was then compared with specimens 
treated with complement alone. For all three specimens, only treatment 
with OKT11 and complement caused a consistent reduction in LAK activity 
from a mean control LAK activity of 48.9°/o to 14.3°/o. After treatment with 
any of the other antibodies and complement, no consistent or comparable 
reductions were noted. When OKTS was added to LPMC cultured in 
MLA144 CM or medium alone, a significant increase in cytotoxicity over 
expected values occurred. This OKTS-induced cytotoxicity may be 
attributable to the mitogenic properties of this reagent (412) or to the 
activation of LPMC capable of lectin-induced cellular cytotoxicity (368). 
The addition of complement alone or any antibody except OKT3 to LPMC 
before culture in MLA 144 CM did not affect the development of LAK 
activity. To confirm that precursor cells were co2+3-, four LPMC 
populations sorted into co2+ and co3+ cells were used to generate LAK 
activity. The mean LAK activity of co2+ cells (74.4°/o) was markedly 
higher than that of CO2- cells (46.0°/o) and the LAK activity of cos- cells 
(68.1 °/o) exceeded that of cos+ cells (7.8°/o) by a factor of nine. 
The results from the two previous sections indicate that intestinal 
LAK cells active against K562 cells are co2+3-16-Leu-7-. Precursor cells 
required for the generation of LAK activity by IL-2 bear an identical 
phenotype as established by two different methods. 
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IV. Discussion. 
Previous studies of nonspecific cytotoxic cells in the intestinal 
mucosa have dealt mainly with NK activity (350-353,355,360,361) which 
was usually found to be present at low levels or completely absent. In the 
present study, a novel type of nonspecific cytotoxic cell recently 
described as the lymphokine-activated killer (LAK) cell has been examined. 
Intestinal LAK cells with cytotoxicity comparable to, or exceeding 
peripheral blood NK activity, were produced by exposing LPMC to IL-2 in 
culture. It was confirmed that IL-2 was responsible for LAK activity by 
blocking generation of LAK cells with the anti-Tac antibody and also by 
the induction of LAK activity by using recombinant human IL-2. 
The ability of LAK cells to lyse both NK-resistant and sensitive 
tumour cell lines (403) in addition to freshly isolated tumour cells (11) 
suggests that they may be important in defence against neoplasia. 
However the levels of intestinal LAK activity generated by exogenous IL-2 
in vitro were comparable in colon carcinoma and nonmalignant disorders. 
Moreover, no relation was found between LAK activity in vitro and the 
extent of carcinoma spread. The existence of LAK activity in the 
intestinal mucosa in vivo may depend upon the availability of IL-2 within 
the intestinal mucosa. A possible deficit of mucosal LAK (or NK) cells 
predisposing to malignancy may therefore occur secondarily to defective 
local endogenous IL-2 production. Studies of IL-2 production by LPMC in 
vitro report conflicting results, but the bulk of evidence does not indicate 
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a gross underproduction of mucosa! IL-2 in the presence of colon 
carcinoma (413,414,Chapter 7). 
Intestinal LAK cells cytotoxic towards K562 cells were 
co2+3-16-Leu-7- and were generated from lamina propria precursor cells 
of identical phenotype. This phenotype differs from that reported for 
peripheral blood LAK cells which are derived from and bear the phenotype 
of NK or T cells (38,309). Recently a subpopulation of LPMC giving rise to 
intestinal LAK cells has been phenotyped by Shanahan et al (321) as 
co2+3-g+16-Leu-19+. In the present study, the expression of Leu-19 on 
LAK cell precursors was not examined but they were similar to the cells 
described by Shanahan et al except for lack of expression of CD8. The 
phenotypes of intestinal and peripheral blood LAK cells may differ for a 
number of reasons. First, mononuclear cells from these locations 
represent different populations as assessed by surface markers (415,416). 
Unlike PBMC, intestinal lymphoid cells are subjected to sustained 
antigenic challenge from the luminal surface of the intestinal mucosa. 
Evidence exists to suggest that this may alter their activation status 
(385). Comparison is also rendered difficult by the different target cells 
used as LAK-sensitive targets. Data from the present study are based on 
the lysis of K562 cells whereas freshly isolated human tumour cells or 
NK-resistant tumour cell lines were used in the peripheral blood studies 
(11,300,317). Although intestinal and peripheral blood LAK cell 
phenotypes differ, their activation kinetics are similar. As was reported 
for peripheral blood (11), intestinal LAK cell activity was detectable after 
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two days and increased to a maximum after six days in culture with IL-2. 
LPMC cultured in IL-2 were a heterogenous population which included a 
large proportion of lymphoblasts and small numbers of LGL. LAK activity 
is likely to be mediated by the blast cell population, which is the cell type 
implicated in peripheral blood LAK activity (300,403). The small numbers 
of LGL observed, together with the unique phenotype of the intestinal LAK 
cell , suggest that activation (68) or proliferation (77) of NK cells in 
IL-2-containing cultures does not account for the cytotoxicity attributed 
to LAK cells 
In contrast to LAK activity, spontaneous NK activity was either 
present at very much lower levels or totally absent in the intestinal 
lamina propria. Similar findings using the NK-sensitive K562 cell have 
been reported previously for LPMC and for lymphocytes infiltrating colon 
carcinomas (350-353,355). The low or absent NK activity of LPMC 
populations does not appear to be due to the isolation procedure, as 
results from the present study and from others (350,353) show that the 
NK activity of PBMC is unaffected by the enzymatic dissaggregation 
method. Moreover, incubation of LPMC for 24 h after their isolation did not 
lead to a consistent improvement in NK activity. It also does not appear 
that the NK activity of LPMC is suppressed by intestinal macrophages. 
Although monocytes suppress peripheral blood NK activity (417), it was 
found in the present study and previously (350) that the presence or 
absence of intestinal macrophages does not affect the minimal NK activity 
of LPMC. Indeed, monocytes have been reported to lyse K562 cells (418). 
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Because NK cells may temporarily adhere to plastic surfaces (21 ), density 
gradient centrifugation without prior adherence was used to prepare the 
LPMC populations examined in this chapter. This procedure resulted in 
significant depletion of macrophages to 8°/o of the cell populations used for 
testing NK activity. 
Studies of intestinal NK cells using alternative targets to the K562 
cell have also shown reduced or absent NK activity (352,360). In a study 
using MOL T-4 cells, peripheral blood NK activity far exceeded that of 
colonic mucosa! NK cells. Significant intestinal NK activity against 
autologous colonic epithelial cells has been reported using a single cell 
cytotoxicity assay (360) ,and a microcytotoxicity method (361 ), but these 
results are difficult to compare to standard chromium release data. 
Results from the present paper and from others (360) indicate only 
minimal augmentaton of mucosa! NK activity by IFN, thus suggesting that 
"pre-NK" cells are not present in significant numbers in the lamina propria. 
Morphological analysis of LPMC showed less than 0.5°/o LGL in freshly 
isolated suspensions and only 1 °/o LGL in fractions enriched for NK activity. 
This small proportion of LGL in LPMC is consistent with the low levels of 
NK activity found. These findings contrast with those using human 
peripheral blood, where LGL comprise 20°/o of lymphocytes (419) although 
only a proportion of these are active NK cells (16). Surveys of human LPMC 
suspensions (321,355) and mucosa! tissue sections (354,387) using the 
NK-associated markers Leu-7 and CD16 have also confirmed the paucity of 
these cells in the intestinal mucosa. 
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In conclusion, the results presented in this chapter indicate that 
significant LAK activity can be generated in vitro from precursor cells 
present within the human intestinal mucosa. By virtue of the broad range 
of susceptible target cells reported for peripheral blood LAK cells and 
their ready inducibility by IL-2, intestinal LAK cells may have important 
antineoplastic and immunoregulatory functions in the intestinal mucosa. 
Further support for the biological role(s) of intestinal LAK cells would be 
enhanced by experimental evidence for their cytotoxicity against freshly 
isolated cells from the colonic mucosa. These experiments are described 
in Chapter 4. 
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CHAPTER 4. 
Intestinal lymphokine-activated killer cells: modulation of their 
generation and cytotoxic action against colon carcinoma cells. 
I. Introduction. 
The role of cytotoxic lymphocytes in defence against tumours 
remains controversial. Both experimental and clinical studies suggest 
that peripheral blood natural killer (NK) cells may inhibit the development 
of primary and secondary malignancies (184,192,386). The trend in recent 
investigations of NK activity in patients with colon carcinoma has been to 
examine the intestine for evidence of local mucosa! NK cell activity 
(27,354,356). lmmunohistochemical surveys of tissue sections and lamina 
propria mononuclear cell (LPMC) populations isolated from the intestinal 
mucosa have revealed very low proportions of cells bearing surface 
markers that are expressed on NK cells (354,356). Furthermore, most 
studies of isolated LPMC report only minimal levels of NK activity, 
although this may be in part due to artefacts associated with the isolation 
procedure (27,354,356,358). The activity of such mucosa! cells against 
freshly isolated tumour cells has not been reported but studies of 
peripheral blood NK cells have shown fresh tumour cells to be generally 
resistant to lysis unless the cells are stimulated by interferon or 
interleukin 2 (IL-2) (11,68,88,303,317). Lymphokine-activated killer 
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(LAK) cells are a recently described cell population which can be generated 
from peripheral blood mononuclear cells (PBMC) by stimulation with IL-2 
in culture (11,317). Peripheral blood LAK cells exhibit potent 
non-MHC-restricted cytotoxicity against NK-resistant and susceptible 
tumour cell lines and freshly isolated tumour cells. Recent studies from 
our laboratory and from others have demonstrated that LAK cells can be 
generated from precursor cells contained within LPMC populations isolated 
from the intestinal mucosa (27,354). As yet, the activity of LAK cells 
against the most relevant tumour target, the colon cancer cell, has not 
been examined systematically. 
The intestinal LAK cell may require conditions for its generation 
and activation which are specific to the intestinal mucosa. The critical 
role of IL-2 in intestinal LAK cell generation has been proven by using the 
anti-Tac antibody which blocks the IL-2 receptor (27). However the 
immunomodulating effects of corticosteroids, cyclosporin and interferon 
on the biology of the intestinal LAK cell has not been reported. Analysis of 
the effects of these agents is not only of therapeutic interest but may 
also yield clues to the biological function of LAK cells. 
Thus the prime aim of this study was to investigate the possible 
role of intestinal LAK cells in colonic neoplasia by testing their cytotoxic 
activity against cells isolated from resected colorectal carcinoma and 
adenomas. In addition the mechanisms underlying intestinal LAK cell 
generation and activation were investigated by examining the in vitro 
effects of mitomycin C, hydrocortisone, cyclosporin and interferon. 
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II. Materials and Methods. 
4.1 Patients and specimens. 
Lamina propria mononuclear cells (LPMC) were isolated from 34 
samples of histologically normal colonic mucosa obtained from surgical 
resection specimens. Thirty-three specimens of colon and one of ileum 
were taken from intestines resected for colonic carcinoma (32 patients); 
diverticular disease (one patient) and adhesive small bowel obstruction 
(one patient). In cancer-bearing colons, mucosa! specimens were removed 
from an area at least 5cm distant from the tumour. 
4.2 Isolation and primary culture of colon carcinoma and adenoma cells. 
Samples of tissue from colon carcinoma or adenoma were washed in 
I 
phosphate buffered saline to remove bowel contents, trimmed with 
scissors to remove necrotic tissue, minced finely and then disaggregated 
by digesting in medium containing 1.2 U/ml Dispase (Boehringer Mannheim, 
Australia) and SOU/ml collagenase (CLSPA Worthington, USA) and 5°/o Nu 
serum (Collaborative Research Inc., Lexington, USA) for 2 hr at 37°C with 
agitation. The digest was passaged twice through a 20 gauge needle, 
washed and then dispensed into plastic tissue culture flasks in Dulbecco's 
Minimal Essential Medium (Flow Laboratories, Virginia, USA) supplemented 
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with 20°/o Nu serum; 2°/o Luria Broth (bactotryptone 1 Og, yeast extract 5g 
and NaCl 5g in 1 L distilled water adjusted to pH 7.0); 5 ng/ml pentagastrin 
(I.C.I. Australia); 20mM HEPES buffer; 4mM L-glutamine, 
penicillin (100 IU/ml) and gentamicin (25 µg/ml). After 1-2 day's 
incubation at 37°C in an atmosphere of 5°/o CO2 in air, viable 
plastic-adherent tumour cell monolayers were established and could be 
maintained for up to 30 days using changes of culture medium three times 
weekly. 
When required for use as target cells, adherent tumour cell 
monolayers were resuspended by exposure for 15 min at 37°C to calcium 
and magnesium-free Hank's balanced salt solution containing 0.5mM EDTA 
and 0.2°/o trypsin. The detached cells were washed twice and resuspended 
in medium supplemented 5°/o FBS for labelling with 51 Cr. The target cell 
suspensions contained greater than 80°/o viable tumour cells (as evidenced 
by their histological and growth characteristics) with additional small 
numbers of fibroblasts, lymphocytes and macrophages. If the viability of 
tumour cells was less than 80°/o, dead cells were removed before labelling 
by centrifugation over Ficoll-Hypaque. 
The spontaneous release of 51 Cr from each target cell expressed as 
a percentage of maximum release was 31 °/o for colon carcinoma cells, 20°/o 
for adenoma cells and 12°/o for K562 cells. A specific release value was 
considered to represent significant cytotoxicity when it exceeded a cut 
off level equal to the mean plus three times the standard deviation of 
spontaneous releases controls. The cut off levels for significant 
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cytotoxicity for the target cells were 7.1 °/o (colon carcinoma ), 4.6°/o 
(adenoma) and 3.0o/o (K562). 
4.3 Phenotypic analysis of intestinal LAK cells. 
Three intestinal LAK cell populations from specimens resected for 
colon carcinoma displaying cytotoxicity towards tumour cells from an 
adenomatous polyp with carcinoma in situ were phenotyped using antibody 
and complement-mediated lysis as described previously (27). The 
monoclonal antibodies used in the dilutions indicated were 1 /50 OKT3; 
1/50 OKT11 (Ortho Diagnostic Inc. Raritan, NJ) and 1/20 anti-Leu 11 b 
(Becton Dickinson, Mountain View, Ca). 
4.4 Cellular proliferation assay. 
Six hours before termination of cultures, 1 µCi of tritiated 
thymidine was added to each microculture well containing LPMC to be 
tested. LPMC were harvested on Titertek glass fibre filter paper using a 
Skatron cell harvester (Flow Laboratories, UK). Tritiated thymidine uptake 
was measured as counts per minute in a Tri Carb 460 liquid scintillation 
counter (Packard, Illinois, USA). 
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4.5 Treatment of LPMC with mitomycin C, hydrocortisone and cyclosporin. 
Prior to incubation with IL-2, 8 x 106 LPMC were treated for 45 min 
in 2 ml of medium with 50 µg/ml mitomycin C, (Sigma Chemical Co., St. 
Louis, Mo) and were then washed and resuspended in IL-2-containing 
medium and cultured in microculture wells. Control cultures of LPMC were 
not treated with mitomycin C but were otherwise processed in an 
identical manner. Mitomycin C-treated and control LPMC from triplicate 
wells were tested daily for cell proliferation and cytotoxicity against 
K562 targets during the seven days' culture period. 
Hydrocortisone (Sigma Chemical Co., St Louis, MO) was dissolved at 
2 x 1 o-1 M in absolute ethanol, diluted in medium to a stock solution of 
1 a-3M and titrated in concentrations from 1 o-4 to 1 o-1 OM into triplicate 
microculture wells containing LPMC at the commencement of culture with 
IL-2. Addition of equivalent concentrations of ethanol to cultures of LPMC 
with IL-2 had no effect on the generation of LAK activity (data not shown). 
Cyclosporin was a gift from Sandoz Ltd (Basel, Switzerland) and 
was prepared as a stock solution of 50 µg/ml in medium as described by 
Warren et al (428). Cyclosporin in concentrations of 0.1 µg/ml and 0.3 
µg/ml was added to LPMC at the beginning of cultures with IL-2. Both 
hydrocortisone and cyclosporin remained in the cultures until they were 
terminated for testing. Untreated LPMC in culture with IL-2 were included 
as controls for each agent tested. After six days' culture, treated and 
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control LPMC were washed twice in the microculture wells and then tested 
for cytotoxicity against K562 cells. 
The effects of hydrocortisone and cyclosporin were also tested on 
two freshly isolated and unfractionated LPMC populations cultured either 
with a mitogenic dose of phytohaemagglutinin (PHA) (Commonwealth 
Serum Laboratories, Melbourne, Australia) or in mixed lymphocyte culture 
(MLC). For mitogen stimulation, LPMC were cultured for four days at a 
concentration of 1 x 106 /ml in microculture wells in 0.1 ml of medium 
supplemented with 3°/o AB serum and 20 µg/ml PHA. Mixed lymphocyte 
cultures of ten days' duration were performed in microculture wells by 
mixing 5x1 o4 LPMC with an equal number of mitomycin C-treated PBMC 
from a combined pool of five normal donors in 0.2 ml of medium 
supplemented with 3°/o AB serum. Hydrocortisone and cyclosporin in the 
concentrations outlined above were present at commencement and 
throughout the period of culture. Upon completion, the proliferative 
activity of treated cultures was compared with untreated controls . 
4.6 Treatment of intestinal LAK cells with interferon. 
Intestinal LAK cells generated after five to eight days' culture of 
LPMC with IL-2 were tested for cytotoxic activity against K562 cells both 
before and after treatment with human leucocyte interferon (IFN) (Medical 
Research Council, UK Reference Standard 869/19). Triplicate samples of 
LAK cells were incubated with 125 U/ml and 250U/ml of IFN for 1 h prior 
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to and during the cytotoxicity assay against K562 cells at an E:T ratio of 
50:1. 
Details of LPMC and PBMC isolation, NK cell enrichment, the 
cytotoxicity assay and statistical analysis are given in Chapter 3. 
Lymphokine-activated killer cells were generated using 250 U/ml human 
recombinant IL-2 as described in Chapter 3. 
111. Resu Its 
4.1 Intestinal LAK cell activity against colon carcinoma cells. 
As previously shown (27), LAK cells generated by culture of LPMC 
with 250U/ml recombinant human IL-2 develop maximum cytotoxicity 
against K562 cells after six days. In the present study, intestinal LAK 
cells induced under identical conditions were tested for their ability to 
lyse freshly isolated colon carcinoma cells. Significant levels of LAK cell 
activity against colon carcinoma cells were demonstrated in seven of 
eight specimens tested (Table 4.1 ). In the single LAK cell population 
lacking significant activity, lysis of K562 cells was also low. Lysis was 
not restricted to autologous combinations of effector and target cells, as 
the colon carcinoma cells were lysed by LAK cells prepared from either 
the same or different specimens. Parallel cultures of LPMC in the absence 
of IL-2 failed to develop cytotoxicity against colon carcinoma or K562 
targets (data not shown). 
Table 4.1 Cytotoxicity of intestinal LAK cells against colon carcinoma
 cells 
Target cells 
Indication for intestinal resection 
colon carcinoma K562 
carcinoma 11.
9°/o(a) 42.4°/o 
carcinoma 19.7°/o 
41.7°/o 
carcinoma 48.4°/o 
76.4°/o 
carcinoma (autologous)(b) 0.2°/o 18.6°/o 
carcinoma (autologous) 35.7°/o 52.3°/o 
carcinoma (autologous) 12.4°/o 55.5°/o 
carcinoma (autologous) 27.3°/o 66 .6°/o 
carcinoma (c) 14.4°/o 82.0°/o 
carcinoma (c)(autologous) 25.4°/o 82.0°/o 
(a)percent specific release from target cells at an E:T ratio of 50:1. 
(b) LAK cells and colon carcinoma cells were from the same specimen. 
(c) LAK cells from the same specimen were tested against two different colon carcinom
a targets. 
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LPMC and normal donor PBMC were tested within one day of isolation 
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for cytotoxicity against colon carcinoma targets. All five LPMC 
populations tested either before (data not shown) or after enrichment for 
NK cells (Table 4.2) showed no significant activity against colon 
carcinoma cells. 
In agreement with previous findings (27), the LPMC displayed 
minimal levels of cytotoxicity against K562 cells even after enrichment 
for NK cells ( 3.9°/o specific lysis at an E:T ratio of 50:1 ). Five normal 
PBMC populations with moderately high levels of NK activity against K562 
cells (mean specific lysis of 38.7°/o, E:T ratio 50:1) displayed minimal 
cytotoxicity against colon carcinoma targets (mean activity 3.5°/o). Only 
one of the donors tested caused significant lysis (10.1 °/o) of colon 
carcinoma cells (Table 4.2). Peripheral blood LAK cells generated from 
two of these normal donors displayed levels of activity against colon 
carcinoma targets that were comparable to those of intestinal LAK cells. 
The cytotoxic activities of freshly isolated LPMC and donor PBMC and 
paired LAK cell populations against colon carcinoma and K562 targets are 
shown in Figure 4.1. 
4.2 The phenotype of intestinal LAK cells active against colon adenoma 
cells. 
Phenotypic analysis of intestinal LAK cells active against tumour 
cells from a colonic adenoma with carcinoma in situ showed that they 
Table 4.2. The cytotoxicity of freshly isolated LPMC and normal donor PBMC against colon 
carcinoma cells. 
Intestinal disorder Target cells 
colon carcinoma K562 
colon carcinoma (autologous)(a) 0.0°/o(b) 4.1 °/o 
colon carcinoma (autologous) 0.40/0 4.9°/o 
colon carcinoma (autologous) 0.3°/o 5.8°/o 
colon carcinoma 0.8°/o 0.2°/o 
diverticular disease 1.0°/o 4.4°/o 
Donor PBMC (initials) 
FG 0.2°/o 52.3°/o 
PH(c) 6.2°/o 33.9°/o 
PH 0.3°/o 33.9°/o 
cs 10.1°/o 34.9°/o 
WA O.Oo/o 45.4°/o 
JR(c) 1.2°/o 26.8°/o 
JR 0.0°/o 26.8°/o 
LPMC isolated from intestines resected for the conditions shown and PBMC from five normal 
donors were enriched for NK cells and then tested for cytotoxicity against colon carcinoma and 
K562 cells. 
(a) LPMC and colon carcinoma cells were from the same patient. 
(b) Percent specific release from target cells at an E:T ratio of 50:1. 
(c) The donor PBMC populations indicated were each tested against two different colon 
carcinoma targets. 
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Figure 4.1 The activity of intestinal LAK cells and LPMC against 
autologous colon carcinoma cells. The cytotoxic activity of intestinal LAK 
cells generated by culture of LPMC with IL-2 (•) is compared to that of 
freshly isolated LPMC (0) and also with freshly isolated PBMC (e) and 
peripheral blood LAK cells (~) from a normal donor. Cytotoxicity is 
expressed as percent specific release from colon carcinoma cells at E:T 
ratios from 12.5 to 100:1. 
100: 1 
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were co2+3-15- (Table 4.3). These findings agree with previous 
phenotypic studies of intestinal LAK cells using K562 targets (27). 
4.3 The effects of mitomycin C, hydrocortisone and cyclosporin on the 
generation and cytotoxic activity of intestinal LAK cells. 
The effect of an inhibitor of cell proliferation on LAK cell 
generation was tested by treating a single LPMC population with 
mitomycin C prior to culture in IL-2-containing medium. Daily 
measurements of cell proliferation and LAK activity against K562 cells 
were made in the test cultures and compared with concurrent control 
cultures of LPMC treated with IL-2 alone. Mitomycin C-treated LPMC 
exhibited minimal proliferative activity and cytotoxicity during culture 
(Fig 4.2). The control LPMC not exposed to mitomycin C developed parallel 
increases in cytotoxicity and cell proliferation, reaching maximum levels 
on the fifth and sixth days of culture respectively. The. presence of 
mitomycin-C in the concentrations used did not affect the viability of 
LPMC for up to 24 h after treatment or the activity of intestinal LAK cells 
already generated by culture with IL-2 (data not shown). 
When hydrocortisone was added to LPMC cultured with IL-2, 
inhibition of LAK cell generation occurred in all ten specimens treated. 
The inhibitory concentrations were equal to, or substantially less than, 
physiological serum levels of cortisone (1 o-6M) (420). The sensitivity of 
LPMC populations to hydrocortisone varied widely. For the three 
Table 4.3 The phenotype of intestinal LAK cells tested against adenoma cell targets. 
Indication for 
intestinal resection 
colon carcinoma 
colon carcinoma 
colon carcinoma 
C contro1(a) 
36.2°/o(b) 
15.8°/o 
22.0°/o 
OKT3 
32.4°/o 
16.8°/o 
18.9°/o 
OKT11 
16.5°/o 
3.0°/o 
10.0°/o 
Leu-11b 
30.4°/o 
13.4°/o 
17.5°/o 
(a) The cytotoxic activities of intestinal LAK cells treated with the indicated monoclonal 
antibodies and complement are compared with LAK cells treated wi th complement alone 
(C control) 
(b) Percent specific release from colon carcinoma cells at an E:T ratio of 50:1. 
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specimens with the minimum, median and maximum sensitivities to 
hydrocortisone, the concentrations causing 50°/o inhibition of LAK cell 
generation were 1 o-6 M, 1 o-8 Mand 5 x 1 o-9 M (Fig 4.3). The degree of 
inhibition caused by hydrocortisone was not related to the level of LAK 
activity that was achieved without treatment. In addition, the activities 
of two intestinal LAK cell populations against K562 cells were not 
affected by therapeutic concentrations of hydrocortisone (1 o-5 M) present 
for 1 h prior to and during cytotoxicity testing (data not shown). The 
preparation of hydrocortisone used for the LAK cell experiments was also 
tested in in mixed lymphocyte cultures and PHA-stimulated cultures of 
unfractionated LPMC. Significant inhibition of LPMC proliferation (greater 
than 30°/o) occurred only at concentrations of hydrocortisone equal to or 
greater than 1 o-5 M. 
Concentrations of cyclosporin approximating therapeutic blood 
levels of 100-400 ng/ml serum (421) had no effect on the generation of 
intestinal LAK cells (Table 4.4). Addition of the same concentrations to 
LAK cells immediately before the cytotoxicity assay had no effect upon 
their activity towards K562 cells (data not shown). Similar 
concentrations of cyclosporin blocked LPMC proliferation in response to 
. 
alloantigens or PHA by more than 75°/o. 
4.4 The effect of interferon on intestinal LAK cell activity. 
Four LPMC populations with culture-generated LAK cell activity 
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Figure 4.3 The effect of hydrocortisone on the generation of intestinal 
LAK cells. Hydrocortisone in the concentrations shown was added at the 
initiation of cultures of LPMC with IL-2. After six days' culture, the 
cytotoxicity of treated and control LPMC was tested against K562 cells. 
The effect of hydrocortisone was expressed as the percent inhibition of 
LAK cell activity after treatment compared with control cultures. Of the 
10 populations tested, those with the minimum(•), median (o) and 
maximum(£) sensitivity to inhibition by hydrocortisone are shown. 
Table 4.4 The effect of cyclosporin on the generation of intestinal LAK cells. 
Indication for intestinal 
resection 
Control (IL-2 alone) Cyclosporin + IL-2 
0.1 µg/ml 
colon carcinoma 15.8°/o(a) 20.3°/o 
colon carcinoma 61.9°/o 64.5°/o 
colon carcinoma 61.4°/o 62.8°/o 
colon carcinoma 35.5°/o - (b) 
colon carcinoma 26.9°/o 23.5°/o 
adhesive bowel obstuction 61.4°/o 57.5°/o 
(a) percent specific release from K562 cells at an E:T ratio of 50:1. 
(b) experiment not performed. 
0.3 µg/ml 
15.4°/o 
67.6°/o 
61.0°/o 
37.7°/o 
23.8°/o 
49.7°/o 
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were treated with I FN in concentrations of 125 U/ml and 250 U/ml. Doses 
of IFN which cause maximum stimulation of peripheral blood NK activity 
(87,88) produced only slight increases in LAK cell activity (Table 4.5). 
IV. Discussion 
This study shows that intestinal LAK cells lyse colon carcinoma 
cells that are resistant to lysis by freshly isolated LPMC. Similarly, 
peripheral blood LAK cells but not unstimulated PBMC can lyse colon 
tumour cells, a finding consistent with earlier observations in which colon 
cancer and other fresh tumour cells were used as targets (79). Earlier 
studies reported lysis of colon carcinoma cells by autologous lymphocytes 
from peripheral blood, mesenteric lymph nodes and the tumour itself and 
attributed this activity to cytotoxic T cells (206). In the present study, it 
is unlikely that the activity observed was due to specific cytotoxic T cells 
since the lysis was not MHC-restricted and the phenotype of intestinal 
LAK cells was not that of cytotoxic T cells or NK cells. Moreover, the LAK 
precursor cell populations were selected from the 1.063 g/ml Percell 
interface which is depleted of T cells (25). 
The ability of intestinal LAK cells to kill fresh colon cancer cells in 
vitro lends support to their proposed role as an antineoplastic cell in vivo. 
It could be argued that the lysis of colon carcinoma cells by LAK cells 
reflects a high level of nonspecific cytotoxicity which has little 
particular relevance to the pathogenesis of colon cancer. Indeed, the 
Table 4.5 The effect of interferon (IFN) on intestinal LAK cell activity. 
Indication for intestinal 
resection 
Control (no IFN) IFN added 
colon carcinoma 
colon carcinoma 
colon carcinoma 
colon carcinoma 
67.8°/o(a) 
61.0°/o 
36.0°/o 
12.2°/o 
125 U/ml 
78.9°/o 
60.8°/o 
34.5°/o 
13.2°/o 
(a) percent specific release from K562 targets at an E:T ratio of 50:1. 
250 U/ml 
75.3°/o 
64.0°/o 
39.6°/o 
14.8°/o 
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possibility that LAK cells lyse nonmalignant cells supports this argument, 
although there is disagreement about the extent to which this occurs 
(288,289). However, the recent observation that intestinal LAK cells do 
not lyse normal colonic epithelial cells suggests that these cells display 
selective reactivity against malignant epithelial cells (422). 
The phenotypic differences between co2+3-16- intestinal LAK cells 
cytotoxic towards K562 (27) or colon carcinoma targets and peripheral 
blood LAK cells are probably accounted for by the limited range of LAK 
precursor cell types available in the intestinal mucosa. The major 
peripheral blood LAK effector cells are NK cell-derived 
(Co2+3-16+Leu-19+) or T cell-derived (Co2+3+16- ) but a small population 
with a phenotype similar to the intestinal LAK cell (Co2+3-16-Leu-19+) 
has been reported (38,39). The lack of NK or T cell-associated markers on 
intestinal LAK cells implies therefore, that the intestinal LAK precursor 
cell differs from its counterparts in the peripheral blood. There is also 
phenotypic evidence from this laboratory (27) and from others (321) 
reporting the existence of a co2+ intestinal LAK precursor cell which 
lacks markers found on NK cells (CD16) or T cells (CD3). 
Evidence that LAK cells may exist and function in vivo comes from 
adoptive transfer studies in both man and experimental animals where 
culture-generated LAK cells have significant anti-tumour effects 
(111,423). Moreover, lymphocytes with cytotoxic properties similar to 
those of LAK cells have been isolated from the antigen-stimulated murine 
intestinal epithelium (343); after IL-2 administration to mice (346) and in 
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man from the joint fluid in active rheumatoid arthritis (347) and in the 
blood following bone marrow transplantation (65). Although no direct 
evidence of LAK cells has been found in freshly isolated LPMC or 
tumour-infiltrating lymphocyte populations, the potentially suppressive 
effect of the isolation procedure may mask their presence (27,352 
354,356,358). The lack of IL-2 in the medium during the long period of 
isolation is also potentially suppressive as the activity of LAK cells 
declines rapidly in the absence of IL-2 (Chapter 3). The apparent lack of 
LAK cells in the intestine is unlikely to be a consequence of low IL-2 
levels in the mucosa, as biologically significant amounts of this 
lymphokine are released by mitogen-stimulated LPMC irrespective of the 
underlying intestinal disorder (412,413,424 and Chapter 7). 
Kinetic analysis of LAK activity and cell proliferation in the 
Mitomycin C experiments confirms previous findings that proliferation of 
cells is integral to the generation of LAK activity (354). The suppression 
of intestinal LAK cell generation by hydrocortisone is similar to that 
reported for peripheral blood LAK cells (295,425) and the concentrations 
inhibitory for LAK cell generation (1 o-6 M or lower) contrast with the 
substantially larger concentrations (1 o-5 M or higher) needed to inhibit 
IL-2 production and resulting T cell activation in alloantigen or 
mitogen-stimulated cultures (295,426,427). In the presence of 1 o-5 M 
hydrocortisone however, the response of previously activated T cells to 
exogenous IL-2 is unaffected (427). Thus, the inhibition of LAK cell 
generation by lower concentrations of hydrocortisone suggests that there 
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may be differences between the mechanisms of activation of LAK 
precursor cells and T cells by IL-2. On the other hand, the resistance of 
LAK cell generation to cyclosporin suggests that this process has features 
in common with the IL-2-induced proliferation of T cell blasts (427) and 
activation of NK cells (428), both of which are also unaffected by similar 
concentrations of cyclosporin. 
The reason for the minimal effect of IFN on LAK activity may be that 
the cells are already maximally activated by IL-2 alone, or in combination 
with other factors produced during culture. A recent study supports this 
view by showing that LAK cell generation is dependent not only on 
exogenous IL-2 but also upon endogenous· production of IFN in culture (69). 
In accordance with studies on peripheral blood LAK cells (295), the 
cytotoxicity of intestinal LAK effector cells was unaffected by mitomycin 
C and therapeutic concentrations of hydrocortisone and cyclosporin. 
In conclusion, this study has demonstrated that NK cell-resistant 
colon carcinoma cells are lysed by intestinal LAK cells. The generation of 
intestinal LAK cells appears to be controlled by mechanisms similar to 
those operating for peripheral blood LAK cells, as shown by the inhibitory 
effect of mitomycin C and hydrocortisone but not cyclosporin in induction 
cultures. The ability of intestinal LAK cells to lyse colon carcinoma cells 
supports their postulated role as an important component of mucosa! 
defence against the development of colon carcinoma. 
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CHAPTER 5. 
Intestinal lymphokine-activated killer cells in inflammatory bowel 
disease. 
I. Introduction 
Efforts to identify an underlying immunological mechanism for 
Inflammatory Bowel Disease (IBD) have focused recently on the 
immunoregulatory and cytotoxic functions of intestinal lymphocytes. 
Substantial evidence indicates that abnormalities in immunoregulation by 
T cells from the intestinal mucosa may be important in predisposing 
towards IBD (365,430,431). By comparison, little is known about the 
involvement of cytotoxic lymphocytes in the pathogenesis of IBD (336, 
350,353,356). Early reports showing that peripheral blood mononuclear 
cells (PBMC) from patients with 180 lysed colonic epithelial cells 
stimulated interest in natural killer (NK) cells as a potential cause of 
mucosa! damage in IBD (432,433). However the importance of NK cells is 
now in doubt, as most studies of intestinal lymphocytes from IBD mucosa 
report minimal levels of NK activity (336,350,353). Moreover, even in 
studies where significant mucosa! NK activity was reported in IBD, the 
levels were comparable to those assayed in histologically normal mucosa 
(356). Interpretation of these data is also limited by the use of K562 
target cells, which may not detect the presence of cytotoxicity directed 
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against epithelial cells and other cell types present in the intestinal 
mucosa. 
Previous studies of intestinal mucosa! lymphocytes have reported 
the generation of lymphokine-activated killer (LAK) cells which are 
potentially important nonspecific cytotoxic cells in the intestinal mucosa 
(27,197,321,354). Intestinal LAK cells were generated by culture of LPMC 
with interleukin 2 (IL-2) and displayed levels of cytotoxicity markedly 
higher than the minimal spontaneous NK activity of freshly isolated LPMC. 
Intestinal LAK cells lysed not only NK-sensitive and resistant tumour cell 
lines (27,354) but also freshly isolated colon carcinoma cells which were 
NK cell-resistant (197). 
In the present study the role of intestinal LAK cells in the 
pathogenesis of IBD was investigated. The aims of this study were to 
determine whether intestinal lymphocytes isolated from mucosae affected 
by IBD possessed IL-2-inducible LAK activity and to test this LAK activity 
in IBD against target cells isolated from the intestinal mucosa. The LAK 
cell populations generated in IBD were examined for cytotoxic activity 
against epithelial tumour cells and fibroblasts freshly isolated from the 
intestinal mucosa and were compared to LAK cells from histologically 
normal mucosae. The ability of intestinal lymphocytes from IBD to display 
LAK activity against target cells of intestinal origin suggests that these 
cells may contribute to mucosa! injury in IBD. 
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II. Materials and Methods 
5.1 Patients and specimens. 
Eighteen specimens of mucosa were taken from surgically 
resected intestine from patients with IBD. There were 11 specimens of 
ileum and three of colon obtained from 13 patients with Crohn's disease 
and four specimens (three colon and one ileum) from three patients with 
ulcerative colitis. At the time of resection, all patients with Crohn's 
disease and one with ulcerative colitis were receiving corticosteroids; 
additional therapy with azathioprine was being administered in four cases 
of Crohn's disease and pne of ulcerative colitis. Histological examination 
I 
of the 18 mucosal specimens with IBD demonstrated active inflammation 
in all cases. The diagnoses of Crohn's disease and ulcerative colitis were 
based on standard clinical, radiological and histological criteria. 
Specimens of histologically normal intestinal mucosa were also 
obtained from patients undergoing surgical resection for colon carcinoma 
(12 cases), diverticular disease (seven cases) and sigmoid volvulus (one 
case). Tissue from which tumour cells and fibroblasts were isolated was 
obtained from three colon carcinomas, one colonic adenoma and the normal 
intestinal mucosa of four patients undergoing surgical resection for colon 
i 
carcinoma. 
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5.2 Preparation of fibroblast target cells from intestinal mucosa. 
Intestinal fibroblasts were obtained by disaggregation of 
histologically normal mucosa resected for carcinoma or nonmalignant 
conditions. The mucosa was scraped from the muscularis, minced finely 
and digested as described for colon carcinoma tissue. The digest was 
centrifuged at 50g for 3 min and the supernatant was then washed and 
cultured as described for colon carcinoma cells. Fibroblasts formed an 
adherent continuous monolayer by four weeks in culture. There was no 
contamination of cultures by mononuclear or intestinal epithelial cells as 
determined by morphological and surface marker studies (data not shown). 
When required for use as target cells, adherent fibroblast 
monolayers were resuspended by exposure for 15 min at 37°C to calcium 
and magnesium-free Hank's balanced salt solution containing 0.5mM EDTA 
and 0.2°/o trypsin. The detached cells were washed twice and resuspended 
in medium supplemented 5°/o FBS for labelling with 51 Cr. 
The mean spontaneous release expressed as a percentage of 
maximum release was 16°/o for fibroblasts. Specific release was 
considered to represent significant cytotoxic activity when it exceeded a 
cut off value equal to the mean plus three standard deviations of the 
spontaneous release controls. This cut off value for significant 
cytotoxicity for fibroblast target cells was 5.4°/o. 
Details of LPMC and PBMC isolation, NK cell enrichment, the 
cytotoxicity assay and statistical analysis are given in Chapter 3. 
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Lymphokine-activated killer cells were generated using 250 U/ml human 
recombinant IL-2 as described in Chapter 3. 
Ill. Results 
5.1 Spontaneous cytotoxicity of LPMC tested against K562 cells. 
Eighteen LPMC populations isolated from IBD mucosae and twenty 
populations from uninflamed mucosa were enriched for NK cells and tested 
for spontaneous cytotoxicity against K562 cells. The LPMC populations 
from 180 displayed very low or insignificant levels of NK activity (Fig 5.1 ). 
This contrasted with the much higher levels of NK activity exhibited by 
enriched PBMC from normal donors tested in the same assay (p < 0.01 ). As 
previously reported (11 ), the spontaneous NK activity of LPMC populations 
from histologically normal mucosa was also very low (mean specific 
releases of 1.1 °/o and 0.6°/o for co lo rectal carcinoma and non-malignant 
conditions respectively). These values were not significantly different 
from the IBD specimens. 
5.2 LAK activity of LPMC tested against K562 cells. 
Intestinal LAK activity was generated by culture of LPMC in 
IL-2-containing medium and was assayed against K562 targets. The 
marked difference between the spontaneous NK activity and 
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Figure 5.1 The spontaneous NK activity of LPMC isolated from patients 
with Crohn's disease (•) and chronic ulcerative colitis (o). Shown for 
comparison are the NK activities of PBMC (0) from six normal subjects 
assayed under identical conditions. NK activity is expressed as 0/o specific 
release from K562 cells at an E:T ratio of 50:1 and mean NK activities for 
the two groups are indicated by horizontal bars. The mean NK activity of 
PBMC was significantly greater than that of LPMC (p< 0.01 ). 
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culture-generated LAK activity of 11 LPMC populations from 180 is 
illlustrated in Figure 5.2. The mean LAK activity of LPMC from 180 was 
28.3°/o (E:T ratio 50:1) which was significantly higher than their NK 
activity prior to culture (0.6°/o; p < 0.01 ). Cultures of LPMC in medium 
without IL-2 did not acquire significant cytotoxicity (mean activity 0.2°/o). 
In accordance with previous studies of LPMC from histologically normal 
mucosa (27), LAK activity of LPMC from 180 increased progressively during 
culture reaching peak levels after six days (data not shown). While nine of 
eleven LPMC populations developed LAK activity, two specimens (one 
ulcerative colitis and one Crohn's disease) failed to gain significant 
cytotoxicity. These two cases did not differ from the remaining 
specimens in clinical disease activity or in the dosage or type of 
medication administered. The LAK activity of enriched LPMC from 
mucosae affected by 180 was not significantly different from that of LPMC 
populations from colon carcinoma or nonmalignant disorders (mean LAK 
activities 34.8°/o and 30.3°/o respectively). 
5.3 The NK and LAK activity of LPMC tested against tumour cells and 
fibroblasts from the intestine. 
In view of the high levels of LAK activity against K562 cells, LPMC 
from five cases of Crohn's disease were also tested for cytotoxic activity 
against target cells of intestinal origin. Freshly isolated LPMC and the 
corresponding LAK cell populations were assayed for NK and LAK activity 
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Figure 5.2 The lymphokine-activated killer (LAK) cell activity of LPMC 
isolated from intestines resected for Crohn's disease (•) and ulcerative 
colitis (o) after culture in medium supplemented with IL-2. For each 
specimen the maximum LAK activity developed against K562 cells is 
., 
compared with the spontaneous NK activity present before culture. 
Cytotoxic activity is expressed as 0/o specific release at an E:T ratio of 50 :1 
and the mean activities before and after culture with IL-2 are indicated by 
horizontal bars. The mean LAK activity for the 11 specimens was 
significantly greater than their spontaneous NK activity (p< 0.01 ). 
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against both colon tumour cells and fibroblasts (Table 5.1 ). Before culture 
with IL-2, none of the five LPMC populations displayed significant 
spontaneous cytotoxic activity against either tumour or fibroblast targets 
(mean activities for each target were 0.7°/o and 1.0°/o respectively). In four 
of the five Crohn's disease LPMC preparations, LAK cells with high levels 
of activity against K562 targets also mediated significant cytotoxicity 
towards target cells disaggregated from colon carcinomas and an 
adenomatous polyp (mean specific release 19.9°/o ). Intestinal mucosa! 
fibroblasts were also susceptible to lysis by LAK cell populations from all 
four Crohn's disease specimens tested (mean specific lysis 29.6°/o). 
Further studies using PBMC from five normal control donors showed that 
colon carcinoma, adenqma and fibroblast targets were resistant to lysis 
I 
by NK cell populations which caused an average of 37.8°/o specific lysis of 
K562 targets (Table 5.1 ). 
Lymphokine-activated killer cells from histologically normal 
specimens of mucosa resected for colon carcinoma served as disease 
controls. These intestinal LAK cell populations also lysed colon carcinoma 
and fibroblast targets. As presented fully in chapter 4, colon carcinoma 
cells were lysed by LAK cells from eight mucosa! specimens resected for 
colon carcinoma (mean specific lysis 22.7°/o). Three of these populations 
lysed intestinal fibroblasts with a mean specific lysis of 40.4°/o (Table 
i 
5.1 ). These results indicate that LAK cells from IBD specimens lysed 
NK-resistant intestinal tumour cells and fibroblasts. This finding 
however, was not confined to IBD, as LAK cells from uninflamed mucosa 
Table 5.1 The NK and LAK activity of LPMC assayed against tumour cells and fibroblasts from the 
intestinal mucosa and K562 cells. 
Intestinal disorder 
Crohn's disease(b) 
Crohn's Disease 
Crohn's Disease 
Crohn's Disease 
Crohn's Disease 
colon carcinoma 
colon carcinoma 
colon carcinoma 
Donor PBMC (initials) 
PH 
PG 
JR 
DS 
WA 
colon carcinoma/adenoma 
NK (a) 
0.2 
1.2 
2.9 
0.0 
0.9 
0.3 
NK 
0.0 
0.7 
NK 
6.5 
0.7 
1.2 
10.0 
0.0 
LAK (a) 
52.8(c) 
22.0 
7.0 
10.1(e) 
15.1(e) 
12.1 
LAK 
12.3 
48.4 
35.6 -
Target cells 
NK 
0.4 
_(d) 
1.3 
0.4 
2.2 
0.9 
NK 
4.4 
2.0 
0.7 
NK 
5.2 
4.2 
2.3 
fibroblast 
LAK 
41.1 
30.3 
19.8 
27.0 
LAK 
33.6 
58.9 
28.8 
K562 
NK 
0.2 
0.0 
0.7 
0.8 
1.2 
0.8 
NK 
4.4 
6.3 
NK 
30.2 
52.4 
26.9 
34.8 
44.9 
LAK 
70.2 
70.2 
62.9 
36.4 
43.3 
19.8 
LAK 
41.9 
75.8 
51.8 
(a) For each LPMC specimen both the NK and LAK activities against each target are listed. 
Only the NK activity of PBMC was studied. 
(b) LPMC from this specimen was assayed against two different colon carcinoma targets. 
(c) Cytotoxic activity is expressed as 0/o specific release from target cells at an E:T·ratio of 50:1. 
(d) Experiment not performed 
(e) Adenoma cell targets. 
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resected for colon carcinoma also lysed the same targets. 
IV. Discussion 
The present investigation of intestinal NK and LAK cells addresses 
recent controversy concerning the role of nonspecific cytotoxic cells in 
neoplastic and inflammatory diseases of the human intestine (400,434). 
In agreement with previous reports using comparable assay conditions, the 
spontaneous NK activity of LPMC from 180 was found to be minimal and did 
not differ from the similarly low cytotoxic activity found in histologically 
normal intestinal mucosa (350,353,336). Moreover, normal and neoplastic 
target cells from the intestine are insensitive to lysis by freshly isolated 
LPMC. These findings suggest that NK cell-mediated cytotoxicity may not 
be important in the pathogenesis of mucosa! injury in IBD. 
On the other hand, both the present and previous studies have 
demonstrated the presence of IL-2-inducible LAK cell precursors in the 
histologically normal or inflamed intestinal mucosa (27,321,354). The 
chronic inflammatory lesion of 180 is characterized by infiltration of the 
mucosa with T cells which may release cytokines such as IL-2 into the 
mucosal microenviroment as part of local immune events. Thus, 
appropriate and sustained growth factor production may be present for the 
generation of LAK cells in the inflamed intestinal mucosa in vivo. Indeed, 
intestinal lymphocytes with cytotoxic properties similar to LAK cells 
have been isolated from immunized animals following oral challenge with 
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large doses of antigen (346). Furthermore, LAK cells are present in 
synovial fluid extracted from inflamed joints of patients with active 
rheumatoid arthritis (347). 
To date, few of the reported studies investigating the role of 
intestinal LAK cells has used target cells that are relevant to 
inflammation of the intestinal mucosa (197,336,350,354). In order to 
establish the pathogenetic significance of intestinal LAK cells in IBD, it is 
essential to demonstrate that these effector cells are cytolytic towards 
other cells derived from the intestinal mucosa. The study reported here 
demonstrates that neoplastic epithelial cells and normal fibroblasts 
freshly obtained from intestinal mucosa are sensitive to the cytotoxic 
action of LAK cells from IBD mucosae. Such activity is not exclusive to 
IBD as LAK cells from histologically normal mucosa also displayed 
comparable levels of cytotoxicity against intestinal target cells. 
Nevertheless, the presence of mucosa! LAK cell precursors in IBD and the 
ability of intestinal LAK cells generated in vitro to lyse biologically 
relevant intestinal target cells suggest a role for LAK cells in producing 
mucosa! injury in the inflamed intestinal mucosa. 
At present there is no direct evidence for the existence of 
intestinal LAK cells in vivo in IBD. No specific phenotypic markers able to 
I 
detect LAK cells have been reported, although intestinal LAK cells were 
shown to be co2+3-16-Leu-7-(27). As reported in this and other studies, 
freshly isolated LPMC show little evidence of spontaneous LAK activity 
(27,354). This observation may not be unexpected however, as both 
137 
suppressive and cytotoxic factors are released during isolation of LPMC 
from the intestine (358). Another contributing factor may be the lack of 
I 
detectable IL-2 in the digest during the period of isolation, as intestinal 
LAK cell activity declines rapidly in the absence of IL-2 (Chapter 3). A 
complementary approach to examining the question of LAK cell generation 
in vivo is to examine the capacity of LPMC to produce IL-2 in vitro. 
Populations of LPMC from patients with 180 are capable of releasing IL-2 
when stimulated by phytohaemagglutinin (414,435) although reduced 
synthesis was noted when the stimulating factor was phorbyl-myristic 
acetate (414). 
In conclusion, LAK cells generated from LPMC from intestinal 
mucosae affected by 180 are capable of lysing normal and neoplastic 
target cells freshly isolated from the intestinal mucosa. The presence of 
precursors of LAK cells in the intestinal lamina propria and their ability 
to lyse biologically relevant intestinal cells in vitro combined with the 
likely production of IL-2 in the microenviroment of the inflamed mucosa 
suggest that LAK cells may contribute to intestinal damage in 180. 
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CHAPTER 6. 
Antibody-dependent cellular cytotoxicity of lamina propria 
mononuclear cells from the human intestinal mucosa: the effect of 
interleukin 2 and characterization of the effector cells. 
I. Introduction 
Although the cytotoxicity of intestinal lymphocytes has been 
studied extensively, little is known about their role in mucosa! defence 
mechanisms or in the pathogenesis of intestinal diseases (400,434). 
Recent studies of nonspecific cytotoxicity in the intestinal mucosa have 
concentrated on natural killer (NK) cell activity (27,354,356,321), 
antibody-dependent cellular cytotoxicity (ADCC)(350,352,363,364) and 
lymphokine-activated killer (LAK) cell activity (27,1 97,321,354). 
Lymphocytes mediating ADCC are classified separately from NK cells as 
killer (K) cells (53), although recent evidence indicates that the majority 
of K cells in the peripheral blood may be identical to, or overlap 
substantially with, the lymphocyte population displaying NK activity 
(50,53). In contrast to the nonspecific cytotoxicity of NK and LAK cells, 
ADCC is directed specifically against targets by the interaction of Fe 
receptors on K cells with antibody directed against a target cell surface 
antigen (53). Through this mechanism, K cells may participate not only in 
the protection of the normal intestinal mucosa but also in the 
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pathogenesis of intestinal diseases. The reported ADCC of intestinal 
lymphocytes against enteric bacterial and protozoan pathogens suggests 
that K cells may protect the intestine against microbial invasion 
(47,48,213). Furthermore, the antineoplastic properties of K cells (53) 
may be important in preventing the development of neoplasia in the 
intestinal mucosa. 
Despite the potential importance of mucosa! K cells, several 
studies have shown that human intestinal lymphocytes display minimal 
levels of spontaneous ADCC against nucleated cell line targets 
(350,352,363,364). Similar results reported for intestinal NK cell 
activity suggest that cells of the NK/K type are infrequent in the human 
intestinal mucosa (27,354). Previous studies of human lamina propria 
mononuclear cells (LPMC) reported that low levels of spontaneous 
cytotoxicity against K562 cells could be enhanced markedly by culture of 
intestinal lymphocytes in medium containing interleukin 2 (IL-2) 
(27,321,354). The cytotoxic cells induced by IL-2 were characterized as 
intestinal LAK cells (27) because of their ability to lyse NK-resistant 
tumour cell targets and also by their lack of expression of the NK/K 
cell-associated surface markers Leu-7 (394) and CD16 (436). Peripheral 
blood-derived LAK cells differ from intestinal LAK cells in that the 
majority arise from NK cells and express the CD16 surface antigen (284). 
The objectives of this study were to investigate the effect of IL-2 
on the ADCC of lamina propria mononuclear cells (LPMC) isolated from 
histologically normal human intestinal mucosa and to identify the 
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intestinal cells responsible for APCC. The ADCC of paired LPMC 
populations was therefore measured and compared immediately upon 
isolation and after culture in IL-2-containing medium. It was found that 
freshly isolated LPMC had minimal spontaneous ADCC, but IL-2-stimulated 
LPMC mediated substantial levels of ADCC. Phenotypic analysis showed 
that the IL-2-induced ADCC of LPMC was mediated by both CD16- and 
CD16+ LAK effector cell populations. These results suggest that 
intestinal LAK cells generated from IL-2-stimulated LPMC mediate high · 
levels of ADCC which have potentially important functions in the normal 
and diseased intestinal mucosa. 
II. Materials and Methods 
6.1 Mucosa! specimens. 
Lamina propria mononuclear cells (LPMC) were isolated from 
samples of histologically normal colonic mucosa resected for colonic 
carcinoma '(eight patients); diverticular disease (two patients); sigmoid 
volvulus (one patient) and ileocaecal lipoma (one patient). 
6.2 Preparation of target cells. 
Target cells for the cytotoxicity assay were from the K562, P815 
and HL60 cell lines. One million cells from each cell line were incubated 
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for 1 h in medium containing 50 µCi of sodium 51 chromate and 10°/o FBS. 
The target cells were then washed 4 times prior to cytotoxicity testing. 
Targets for measurement of ADCC were P815 cells labelled with 
anti-P815 antibody (P815-lgG targets). Anti-P815 antibody was prepared 
by immunization of rabbits with P815 cells in complete Freund's adjuvant. 
Multiple serum specimens were collected and the lgG fraction prepared by 
ammonium sulphate precipitation. The specificity of the antibody 
preparation was confirmed by demonstration of antibody and 
complement-mediated cytotoxicity of P815 cells but none of the other 
tumour cell lines used in this study. To prepare P815-lgG targets, 5 x 1 o5 
51 Cr-labelled P815 cells were incubated with an optimal dilution of 
anti-P815 antibody in medium (1/20) for 20 min at room temperature and 
were then washed three times before cytotoxicity testing. 
The spontaneous release of 51 Cr from each target cell expressed 
as a percentage of maximum release was as follows : P815 (14°/o); 
P815-lgG (13°/o) and HL60 (13°/o). Specific release was considered to 
represent significant cytotoxic activity when it exceeded a cut off value 
equal to the mean plus three times the standard deviation of spontaneous 
release controls. Mean cut off values for the target cells were 4.4°/o 
(P815); 4.2°/o (P815-lgG) and 3.0°/o (HL60). 
6.3 Cold target inhibition experiments. 
Two LPMC populat}ons with IL-2-induced LAK activity were tested 
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against 51 Cr-labelled P815-lgG target cells in the presence of unlabelled 
(cold) P815, P815-lgG, K562 or HL60 targets. Varying numbers of cold 
targets of each type were combined with 5 x 1 o3 51 Cr-labelled P815-lgG 
cells and 1.25 x 1 o5 LPMC in 0.2 ml of medium in triplicate microculture 
wells to produce competitor to labelled target ratios from 0.5:1 to 20:1. 
The cytotoxic activity of LAK cells towards 51 Cr-labelled P815, 
P815-lgG, HL60 and K562 cells in the absence of cold target cells served 
as controls. After incubation for 4 h at 37°C in an atmosphere of 5°/o CO2 
in air, the cytotoxic activity of test and control wells was calculated as 
described in Chapter 3. The effect of cold target cells at each competitor 
to target cell ratio was expressed as the percent inhibition of the lysis of 
51 Cr-labelled P815-lgG targets by LPMC in control wells. 
6.4 Phenotyping of LPMC by antibody and complement-mediated lysis. 
The surface phenotype of LPMC populations displaying 
IL-2-induced LAK activity towards P815-lgG and K562 targets was 
determined using antibody and complement-mediated lysis. The 
monoclonal antibodies used were OKT3 and OKT11 (Ortho Diagnostic Inc., 
Raritan, NJ) and anti-Leu 11 b (Becton Dickinson, Mountain View, Ca). Ten 
µL of each antibody diluted 1 in 5 in medium was added to 2.5 x 1 o5 LPMC 
in 30µL of medium with 1 °/o FBS in triplicate round bottom microculture 
wells. After incubation at room temperature for 7 min, 1 OµL of 
complement (Rabbit MA, Cedar Lane Laboratories Ltd., Ontario, Canada) was 
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added to each well and incubated at 37°C for 60 min in an atmosphere of 
5°/o CO2 in air. In control wells, LPMC were treated with antibody, medium 
or complement alone. The treated LPMC were then washed three times in 
the microculture plates and resuspended in individual wells in 0.1 ml of 
medium with 5°/o FBS for cytotoxicity testing. The final 1 in 20 dilutions 
of OKT3 and OKT11 used were shown by fluorescent antibody analysis to 
produce maximum complement-mediated lysis of the relevant LPMC 
subpopulation. A 1 in 20 dilution of anti-Leu 11 b resulted in 90°/o or 
greater reduction in the NK activity and ADCC of normal control PBMC 
(data not shown). 
Details of LPMC and PBMC isolation, NK cell enrichment, the 
cytotoxicity assay and statistical analysis are given in Chapter 3. 
Lymphokine-activated killer cells were generated using 250 U/ml human 
recombinant IL-2 as described in Chapter 3. 
Ill. Results 
6.1 The ADCC of freshly isolated lamina propria and peripheral blood 
mononuclear cells. 
The mean spontaneous ADCC of seven freshly isolated LPMC 
populations (four with colon carcinoma and three with nonmalignant 
conditions) was 2.0°/o when tested at an E:T ratio of 50:1 (Fig. 6.1 ). 
Simultaneous assay for NK activity against K562 targets showed a 
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Figure 6.1 The antibody-dependent cellular cytotoxicity (ADCC) of freshly 
isolated LPMC (•); PBMC from normal donors (O); and LPMC after culture in 
IL-2-containing medium (o). The horizontal bars shown indicate the mean 
level of ADCC for each group. ADCC was assayed against P815-lgG targets 
at an E:T ratio of 50:1 and is expressed as 0/o specific release. The ADCC of 
freshly isolated LPMC was significantly less than that of PBMC (P< 0.01) 
and intestinal LAK cells (P< 0.01 ). 
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similarly low mean cytotoxicity of 1.1 °/o (data not shown). The 
spontaneous ADCC of LPMC was markedly less than the ADCC of PBMC 
isolated from seven normal donors (mean activity 52.3°/o; p< 0.01 ). 
Incubation of LPMC for 24 h in medium supplemented with 3°/o AB serum 
before cytotoxicity testing did not alter their ADCC significantly (mean 
activity 2.5°/o). The low ADCC of LPMC was not a consequence of the 
isolation procedure, as identical treatment of two PBMC populations did 
not affect their ADCC (data not shown). These findings indicate that LPMC 
from histologically normal intestinal mucosa possess minimal 
spontaneous ADCC compared to normal donor PBMC. 
6.2 The effect of interleukin 2 on the ADCC of LPMC. 
As the spontaneous NK activity of LPMC is boosted by incubation 
with IL-2 (27,321,354), LPMC were cultured with IL-2 to determine if 
ADCC could be increased. Twelve LPMC populations (including the seven 
studied in the previous section) were tested for ADCC after culture for up 
to eight days in the presence of IL-2 (Fig. 6.1 ). The cultured LPMC 
populations displayed high levels of activity (mean ADCC 49.2°/o) which 
were comparable to normal peripheral blood ADCC and significantly 
greater than the spontaneous ADCC of LPMC (p< 0.01 ). The ADCC of LPMC 
increased during culture to a maximum at six days which is similar to the 
kinetics described in Chapter 3 for intestinal LAK cells. Assay of LPMC 
cultured for similar periods in medium without IL-2 showed no 
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spontaneous increase in ADCC (mean activity 1.2°/o). In agreement with 
previous results (27,354), the 12 LPMC specimens cultured with IL-2 also 
developed high levels of cytotoxic activity against K562 targets. 
The spontaneous and IL-2-induced ADCC of a representative LPMC 
population measured over a range of E:T ratios is shown in Figure 6.2. At 
all E:T ratios up to and including 200:1, the spontaneous ADCC of the LPMC 
specimen was substantially less than that induced by culture of the same 
population with IL-2. Untreated PBMC from a normal control subject 
showed greater spontaneous ADCC than cultured LPMC at lower E:T ratios 
but similar levels of activity at higher ratios. 
6.3 Cold target inhibition of the ADCC mediated by intestinal LAK cells. 
Because control experiments showed that LPMC cultured with IL-2 
lysed P815 cells not labelled with antibody (mean cytotoxicity was 58.4o/o 
for eight specimens), cold target inhibition studies were performed to 
confirm that the lysis of P815-lgG targets by LPMC was due to ADCC 
rather than nonspecific cytotoxicity directed against nonimmunoglobulin 
I 
receptors on P815 cells. Two LPMC specimens with IL-2-induced LAK 
activity against P815-lgG cells were studied with identical results (Fig. 
6.3). Addition of cold P815 cells did not interfere with the lysis of 
P815-lgG targets, indicating that the lysis of P815-lgG and P815 target 
cells were mediated by different cytotoxic mechanisms. There was a 
similar lack of competition between P815-lgG and HL60 target cells which 
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Figure 6.3 Cold target inhibition studies of the ADCC mediated by 
intestinal LAK cells. Cold P815, K562, HL60 or P815-lgG cells were added 
to microculture wells containing LAK cells and cr51 _labelled P815-lgG 
cells. The degree of inhibition of ADCC was measured at competitor to 
target ratios from 0.5:1 to 20:1. The cytotoxicity of the LAK cell 
population against the target cell panel was as follows: P815-lgG (67.3o/o); 
P815 (49.8°/o); K562 (44.2°/o) and HL60 (55.4°/o). The addition of cold K562 or 
P815-lgG cells resulted in inhibition of lysis of P815-lgG targets by LAK 
cells, whereas added P815 and HL60 cells had no effect. The result_s. 
shown are representative of experiments performed on two LPMC 
populations. 
20:1 
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were also sensitive to lysis by LAK cells. Maximum inhibition of 
cytotoxicity against P815-lgG targets occurred after the addition of 
identical cold P815-lgG targets. With both LPMC specimens, comparable 
levels of inhibition of ADCC were also produced by the addition of cold 
K562 cells (Fig. 6.3). The lack of competition between P815-lgG and P815 
cells in these cold target inhibition assays confirms that intestinal LAK 
cells lyse P815-lgG targets by ADCC. 
6.4 Phenotypic analysis of intestinal LAK cells mediating ADCC. 
The effector cells in eight LPMC populations mediating 
IL-2-induced ADCC and cytotoxicity against K562 cells were phenotyped 
by antibody and complement-mediated lysis (Table 6.1 ). Treatment with 
Leu-11 b and complement resulted in variable reductions in ADCC which 
exceeded 30°/o of control levels in three of eight LPMC populations. 
I 
Parallel studies of PBMC from five normal donors using Leu-11 b showed 
greater than 90°/o loss of ADCC in all cases (two representative results are 
shown in Table 6.1 ). The ADCC of all four LPMC populations tested was 
reduced by more than 50°/o after incubation with OKT11 but was unaffected 
in all cases after using OKT3. Analysis of the same LPMC populations 
using K562 cells as targets showed consistent decreases in cytotoxicity 
only after treatment with the OKT11 antibody. After incubation with 
Leu-11 b, two LPMC populations out of the eight tested showed minor 
losses of activity against K562 targets (both less than 25°/o). These 
Table 6.1 The phenotype of intestinal LAK cells mediating ADCC. 
Intestinal 
disorder 
P815-lgG target K562 target 
C control(a) OKT3 OKT11 Leu-11 b C control OKT3 OKT11 Leu-11 b 
Carcinoma 
Carcinoma 
Carcinoma 
Diverticular 
disease 
Carcinoma 
Carcinoma 
Carcinoma 
Carcinoma 
PBMC (PH) 
PBMC (JS) 
37.8%(b) 34.1°/o 13.3% 31 .1% 
23.9% 27.8% 4.2% 10.0% 
24.8% 27.4% 0.0% 26.4% 
56.8% 66.4°/o 27.7% 37.2% 
44.6% 32.2% 
35.8% 37.3% 
75.8% 76.0% 
26.8% 18.4% 
33.2% 32.1% 18.9% 3.0% 
72.8% 75.8% 43.9% 3.9% 
35.5% 31.9% 14.2% 30.0°/o 
16.4°/o _(c) 0.0% 12.2% 
40.0°/o 43.1 °/o 20.3% 41.4% 
25.5°/o 22.7% 12.8% 18.8% 
34.4°/o 35.5°/o 
72.8% 68.8% 
44.4% 34.9% 
Intestinal LAK cells cytotoxic towards the target cells P815-lgG and K562 were phenotyped by ant ibody 
and complement-mediated lysis using the pane l of monoclonal antibodies shown. Two representative 
results from similar studies'of PBMC from five normal donors are shown for the P815-lgG target. 
(a) Control values were from ce lls treated with complement alone before cytotoxicity testing. 
(b) Cytotoxic ity is expressed as 0/o specific release from target cells at an E:T ratio of 50:1. 
(c) Experiment not performed. 
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experiments demonstrate that IL-2-induced ADCC is mediated by LPMC 
which are predominantly co2+3-16-. In three out of eight specimens, 
CD15+ cells mediated a significant but minor proportion of the ADCC. The 
co2+3-15- LPMC cytotoxic towards K562 cells have been characterized 
previously as intestinal LAK cells (Chapter 3). 
IV. Discussion 
This investigation of ADCC in the human intestinal mucosa 
confirms the findings of previous studies showing that freshly isolated 
) 
LPMC failed to mediate significant levels of ADCC (350,352,363,364). 
After exposure to IL-2 in culture however, LPMC acquired high levels of 
ADCC against P815-lgG targets comparable to those found in the 
peripheral blood of normal donors. This finding is similar to the 
IL-2-induced generation of intestinal LAK cells from cultures of LPMC 
(27,321,354) and therefore raises the possibility that LAK cells mediate 
the ADCC described in the present study. The majority of LPMC mediating 
IL-2-induced ADCC were co2+3-15- which is the same phenotype reported 
in Chapter 3 for intestinal LAK cells cytotoxic towards K562 cells. This 
profile of surface markers distinguishes the LPMC effector cell from the 
co2+3-15+ NK cell and the co2+3+15+ Ty cell which are regarded as the 
only lymphocyte types capable of mediating spontaneous ADCC in the 
peripheral blood (15, 17). It is probable therefore, that the effector cell 
mediating IL-2-induced ADCC is the intestinal LAK cell. Whether both 
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forms of cytotoxicity are mediated by the same cell or by different 
subpopulations of LAK cells was not addressed in this study. 
Although it is generally accepted that only lymphocytes with 
CD1 s+ Fe receptors mediate ADCC, the findings of the present study and of 
others (292,437) suggest that activated killer cells which lack the CD16 
determinant may also be capable of ADCC. An explanation for the ADCC of 
intestinal LAK cells may be that they express functional Fe receptors 
which are antigenically different from those on NK cells. This hypothesis 
is supported by the variation in antigen expression on the Fe receptors of 
lymphocytes, granulocytes and monocytes (436). 
The lack of competition between P815 and P815-lgG cells in the 
cold target inhibition studies suggests that intestinal LAK cells lyse 
P815-lgG targets by ADCC. The reason for the inhibition of P815-lgG 
target lysis by K562 cells is unclear. The K562 cell expresses Fe 
receptors which may block the ADCC of P815-lgG targets by binding to the 
rabbit lgG fixed to the targets (438-440). However, there was no evidence 
of inhibition by the P815 and HL60 cell lines which express apparently 
similar Fe receptors (440,441). The blocking properties of the K562 cell 
lines may be explained by a higher Fe receptor density or affinity for 
rabbit lgG compared to P815 and HL60 cells. Alternatively, if the same 
LAK cell can mediate both LAK activity and ADCC, K562 competitors may 
be the most effective at blocking ADCC by steric hindrance. Complete 
explanation of the observations reported here will require investigation of 
the lgG binding properties of the K562, P815 and HL60 cell lines and the 
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use of competing target cells which do not express Fe receptors. 
In three out of eight LPMC specimens treated with IL-2, minority 
populations of CD1 s+ lymphocytes mediated a variable but significant 
proportion of the ADCC. This population may originate from cells 
belonging to the NK/K lineage which mediates ADCC through CD1 s+ Fe 
receptors. Although immunohistochemical studies suggest that CD1 s+ 
cells are infrequent in the intestine (321,356), small numbers of cells 
present in some specimens may proliferate in response to IL-2, resulting 
in an expanded population of CD1 s+ LAK cells (78). The cytotoxic 
properties of these cells was not examined in detail, but previous studies 
suggest that CD1 s+ NK. cells exposed to IL-2 in culture acquire the 
unrestricted cytotoxic properties characteristic of LAK cells (309). Thus 
the CD1 s+ cells described in this study may be NK cell-derived LAK cells 
which are known to be capable of mediating ADCC (292). Despite the 
presence of CD1 s+ cells mediating ADCC against P815-lgG cells in three 
LPMC populations, phenotypic studies of the same specimens did not detect 
significant numbers of CD1 s+ cells when tested against K562 target cells. 
This finding may be explained by differences in the susceptibility of 
target cells to lysis by cytotoxic cells and suggests that P815-lgG cells 
are more sensitive than K562 cells as targets for the detection of CD1 s+ 
' LAK cytotoxic cells. Previous studies of intestinal lymphocytes have also 
found that the results of cytotoxicity testing can be influenced by the 
nature of the cells used as targets (360). Contrary to the findings of most 
studies, Targan et al reported significant levels of spontaneous 
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cytotoxicity in the intestinal mucosa against intestinal epithelial cells 
but not NK cell-susceptible cell line targets. The implication of these 
results is that the characterization of cytotoxic cells in the intestinal 
mucosa may be affected by the choice of target cell. 
The potential for LPMC to mediate AOCC in vivo would depend 
partly upon the availability of IL-2 within the microenviroment of the 
intestinal mucosa. In response to mitogen stimulation in vitro, LPMC from 
histologically normal or inflamed intestinal mucosa release biologically 
significant amounts of IL-2 (413,414,435). Therefore under conditions 
favouring the local production of IL-2, LPMC in the guise of LAK cells may 
protect against microbial invasion or neoplastic transformation of the 
normal intestinal mucosa. Through their ability to mediate AOCC, 
intestinal LAK cells may also have adverse effects in diseases such as 180. 
High levels of circulating antibody against intestinal epithelial cells and 
other components of the bowel have been documented in patients with 180 
I 
(442). It is possible that by interacting with these antibodies, LAK 
activity may be directed against cellular constituents of the intestine, 
thus contributing to mucosa! injury and ongoing inflammation in 180. 
The data presented in this study show that LPMC isolated from the 
intestinal mucosa mediate significant levels of ADCC only after 
IL-2-induced transformation into LAK cells. The cell population mediating 
ADCC consisted predominantly of C016- LAK cells with a minor 
contribution by CD1 s+ cells. The ability of intestinal LAK cells to 
mediate AOCC complements their nonspecific cytotoxic properties by 
1 51 
providing high levels of antibody-directed specific cytotoxicity against 
cellular or microbial targets. 
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CHAPTER 7. 
Interleukin 2 production by lamina propria mononuclear cells in colon 
carcinoma and nonmalignant intestinal disorders. 
7 .1 Introduction 
Interleukin 2 (IL-2) is a 15 kD molecular weight glycoprotein which 
plays a pivotal role in the regulation of key elements of the cellular 
immune system (443). In response to antigenic or mitogen stimulation, T 
cells from both the helper and cytotoxic/suppressor subgroups secrete 
IL-2 (444,445). The prime function of IL-2 is as a growth and 
differentiation factor for T cells (446-448) but it has been recognised 
that activated B cells also proliferate and differentiate in response to 
IL-2 (449-450). In addition to its effects on T and B cells, IL-2 is also the 
major stimulus for the proliferation of natural killer (NK) and 
lymphokine-activated killer (LAK) cells (27,451) which possess 
antineoplastic, antimicrobial and regulatory properties (27,197,452). 
Recent evidence also svggests that IL-2 may play a part in the activation 
I 
of macrophages (453). Under the influence of IL-2, subpopulations of 
peripheral blood mononuclear cells (PBMC) secrete immunoregulatory 
lymphokines, including gamma interferon (255,454) and tumor necrosis 
factor and lymphotoxin (455). 
Following characterization of IL-2 and its effects in the normal 
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immune system, there has been mounting speculation concerning the role 
of IL-2 in the pathogenesis of a wide range of human diseases. Defective 
production of IL-2 by PBMC has been reported in association with primary 
immunodeficiency states (456), autoimmune diseases (457,458) and 
malignancy (459). Recent studies have focused on diseases of unknown 
aetiology such as inflammatory bowel disease, where reduced production 
of IL-2 by intestinal lymphocytes is one of several documented 
immunoregulatory abnormalities (369,414,460). 
Because PBMC populations are most accessible for investigation, 
relatively little is known about IL-2 production by lymphoid cells 
underlying mucosa! surfaces. Preliminary studies report that lamina 
propria mononuclear cells (LPMC) isolated from the human intestinal 
mucosa are capable of producing significant amounts of IL-2 after 
mitogenic stimulus (413,414,435). However little is known about the 
effects of neoplastic or inflammatory disease on the production of IL-2 by 
intestinal mucosa! lymphocytes. The mucosa! production of IL-2 may be 
important in limiting the development of colorectal carcinoma as 
intestinal NK and LAK cells with antineoplastic properties are 
IL-2-dependent (27,71,451 ). 
The purpose of the present study was to determine whether LPMC 
from the human intestine were capable of producing IL-2 in biologically 
significant amounts. Populations of LPMC from resected intestinal mucosa 
were stimulated with mitogens and the culture supernatants were assayed 
for IL-2 activity. A secondary objective was to explore the possible 
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relationship between intestinal IL~2 production and both the presence and 
extent of colorectal carcinoma. The levels of IL-2 production by LPMC 
were therefore compared in histologically normal specimens of intestinal 
mucosa resected for nonmalignant conditions or for colorectal carcinomas 
which were categorized according to their degree of spread. 
II. Materials and Methods. 
7 .1 Patient details. 
Samples of colonic mucosa were obtained from 26 patients at the 
time of surgery for colorectal carcinoma or for nonmalignant conditions 
excluding inflammatory bowel disease. The extent of tumour spread in the 
I 
18 subjects with carcinoma was staged according to the Duke's 
classification (461) as follows : Duke's A (three patients); Duke's B (five 
patients); Duke's C (eight patients) and Duke's D (two patients). The 
nonmalignant conditions resected included diverticular disease (three 
patients); angiodysplasia of the caecum (one patient); villous adenoma (one 
patient); polyposis coli (one patient); rectal prolapse (one patient) and 
ileocaecal lipoma (one patient). All samples of colonic mucosa were 
histologically normal and were obtained from areas at least five cm away 
from tumours or polyps. 
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7.2 Induction of cytokine productron from mononuclear cells. 
Mononuclear cells were stimulated to produce cytokines by 
incubation at a concentration of 5 x 106 cells/ml in RPMI 1640 medium 
(Flow laboratories, Virginia, USA) supplemented with 5 or 20 µg/ml of 
phytohaemagglutinin-P (PHA) (Commonwealth Serum Laboratories, 
Melbourne, Australia) without added serum. After incubation for 1 h at 
37°c in an atmosphere of 5°/o CO2 in air, mononuclear cells were washed 3 
times and cultured in medium alone at a concentration of 2 x 106 cells/ml 
in 24 well flat bottom culture plates (Linbro, Flow laboratories, Virginia, 
USA). Following incubation for 24 h, supernatants were aspirated from 
wells and stored at -20°c until assayed. Five specimens treated by 
mitogen stimulation were also tested in parallel for spontaneous cytokine 
production by incubation in medium without PHA. 
7.3 Assay for interleukin 2 activity. 
The concentration of IL-2 in culture supernatants was measured in a 
proliferation assay using a cloned IL-2-dependent mouse cytotoxic T cell 
line (CTLL-2) (462). Serial dilutions of culture supernatant were 
combined with 1 o4 CTLL-2 cells in triplicate in 96 well flat bottom 
microculture plates (Nunc lntermed, Denmark) in a final volume of 0.1 ml 
of medium supplemented with 10°/o foetal bovine serum (FBS) and 1 o-5M 
6-mercaptoethanol. After incubation for 18 h, the cultures were pulsed 
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with 1 µCi of tritiated thymidine for 6 h, harvested on glass fibre paper 
using a cell harvester (Skatron, Flow laboratories, UK) and measured for 
tritiated thymidine uptake in counts per minute (cpm) using a scintillation 
counter (Tri Carb, Packard, Illinois, USA). In each assay, control wells 
measured the background proliferation of CTLL-2 in medium alone and also 
the response of CTLL-2 to PHA and the preparation of human recombinant 
IL-2 used to generate LAK cells in Chapters 3,4,5 and 6. The amount of 
IL-2 in culture supernatants was expressed as end point units (U) which 
were defined as the reciprocal of the sample dilution producing a level of 
CTLL-2 proliferation equal to the mean plus three standard deviations of 
the background proliferation for each assay. Minimum inter-assay 
variation in the estimation of IL-2 activity was achieved in the following 
ways (i) CTLL-2 cells from a stock population frozen at -7o0c were 
expanded under identical culture conditions for each assay in medium 
containing an optimum concentration of MLA 144 CM (408) and (ii) each 
assay included titrations of known concentrations of human recombinant 
IL-2. 
Details of LPMC and PBMC isolation and statistical analysis are 
given in Chapter 3. 
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111. Results 
7.1 The production of interleukin 2 by LPMC. 
All 26 LPMC populations studied produced detectable levels of IL-2 
after mitogenic stimulus with 5 µg/ml PHA (Fig 7.1 ). For analysis of the 
IL-2 levels, LPMC populations were divided into nonmalignant and 
carcinoma groups and then specimens with carcinoma were further 
subdivided according to the degree of tumour spread. Specimens with the 
tumour confined to the bowel wall or mesentery were staged as Duke's 
grades A or B while further spread to mesenteric lymph nodes or distant 
organs was signified by Duke's grades C or D respectively. The IL-2 
activity in culture supernatants from nonmalignant LPMC (mean activity 
149 U) was significantly higher than the IL-2 levels produced by all 
specimens with carcinoma (mean activity 49 U; P< 0.05). When the 
carcinoma group was subdivided according to the extent of tumour spread 
nonmalignant IL-2 production was significantly higher compared to the 
Duke's A and B tumours (p< 0.05) but not to the Duke's C and D tumours (P> 
0.05). Despite the significant difference demonstrated between 
nonmalignant and carcinoma specimens, there was substantial overlap 
between the amounts of IL-2 produced by individual LPMC populations from 
either group (Fig 7.1 ). Eleven LPMC populations treated with 20 µg/ml PHA 
produced two to three times the amounts of IL-2 resulting from exposure 
of LPMC to 5 µg/ml. The IL-2 activity of the nonmalignant LPMC (mean 
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Figure 7.1 The IL-2 activity of culture supernatants from LPMC 
populations stimulated with 5 µg/ml PHA. The 26 populations are grouped 
into one nonmalignant and two carcinoma groups according to the extent of 
tumour spread as defined by the Duke's classification (see text). The 
activity of IL-2 is expressed as end point units (U) and the mean activity 
for each group is indicated by the horizontal bars. Significant differences 
were found between the nonmalignant group and all carcinoma specimens 
(P< 0.05) and the Duke's A and B subgroup (P< 0.05). 
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activity 326 U; four specimens) w~s again noted to be higher than that of 
the carcinoma group (mean activity 143 U; seven specimens). Significant 
levels of spontaneous IL-2 production (mean activity 30U) were detected 
in all five LPMC specimens (three nonmalignant and two with carcinoma) 
which were cultured without prior PHA treatment. 
Representative titration curves of the IL-2 activity of nonmalignant 
and carcinoma specimens treated with 5 or 20 µg/ml of PHA are shown in 
Figure 7.2. Included for comparison are titrations of the spontaneous IL-2 
activity of a LPMC population and also the activity of the recombinant 
human IL-2 preparation used to generate intestinal LAK cells (Chapters 
3,4,5 and 6). 
Control experiments performed as part of each assay of IL-2 
activity showed that concentrations of PHA from 0.1 to 100 µg/ml did not 
affect the thymidine uptake of CTLL-2 (data not shown). Finally, to 
exclude an effect of the enzymatic isolation procedure on the production 
of IL-2 by LPMC, PBMC from two normal donors were exposed to the same 
treatment before induction of IL-2 production. In both cases there was no 
significant difference between the levels of IL-2 produced by 
PHA-stimulated PBMC either before or after enzyme treatment (data not 
shown). 
These results indicate that LPMC produce significant levels of IL-2 
spontaneously in small amounts and in greater quantities after 
stimulation with the mitogen PHA. Although there was considerable 
overlap between the levels of IL-2 from different groups, LPMC isolated 
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Figure 7.2 Titration curves of IL-2 activity in culture supernatants of 
LPMC stimulated with 5 or 20 µg/ml PHA. The proliferation assay 
measured the uptake of tritiated thymidine in cpm (vertical axis) by the 
10 
CTTL-2 cell line. Serial dilutions (Log2) of the sample are shown on the 
horizontal axis. The titrations shown are representative results obtained 
with LPMC from a carcinoma specimen ( 0 5µg/ml PHA ; • 20 µg/ml PHA) 
and a nonmalignant specimen (diverticular disease) (-'. 5µg/ml PHA; 11 20 
µg/ml PHA). Also shown are results from the assay of a human 
recombinant IL-2 preparation (•) and the culture supernatant of a LPMC 
population (from the specimen with colon carcinoma shown) incubated in 
medium without prior PHA stimulation (O). 
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from nonmalignant specimens produced significantly higher mean levels of 
IL-2 when compared with specimens resected for colorectal carcinoma. 
IV. Discussion. 
Analysis of the phenotypic and functional characteristics of 
intestinal mucosa! lymphocytes has proven to be an effective approach 
towards the investigation of immunoregulation at mucosa! surfaces (400). 
Although numerous studies have shown that intestinal lymphocytes 
influence cellular proliferation and antibody production (460,463), very 
little is known about their ability to produce lymphokines (413,414,435). 
In the present study, another facet of the immunoregulatory potential of 
intestinal lymphocytes was investigated by testing their capacity to 
produce IL-2. The important initial observation of this study was that 
LPMC produce significant levels of IL-2, both spontaneously and after 
mitogen stimulation. The spontaneous production of IL-2 is consistent 
with the activated state of LPMC (385,389,414) and contrasts with PBMC 
which produce IL-2 only after stimulation with antigens or mitogens 
(445). The LPMC population producing IL-2 is therefore potentially capable 
of influencing the differentiation and function of IL-2-responsive T cells, · 
B cells and nonspecific cytotoxic cells in the intestinal mucosa. The LPMC 
population responsible for IL-2 production was not characterised in this or 
previous studies, but inyestigations using PBMC suggest that T cells of 
either helper or suppressor phenotype (444,445) or cells related to the NK 
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lineage (464) may be responsible.-
A further aim of this study was to investigate the role of mucosal 
IL-2 production in the pathogenesis of colorectal carcinoma. The presence 
of significant levels of IL-2 in the intestinal mucosa may protect against 
malignancy, as colon carcinoma cells are lysed in vitro by LAK cells (197) 
and possibly cytotoxic T cells (206), both of which are IL-2-dependent. 
The present finding of reduced IL-2 production in relation to colon 
carcinoma has been reported previously (413), but other studies have 
failed to confirm such an association (414,435). This disparity in findings 
may be partly attributable to differences in the cellular content of LPMC 
populations and the type of mitogen used to stimulate IL-2 production 
(414). The significantly lower levels of IL-2 production found in 
specimens resected for carcinoma could be due to reduced IL-2 production 
on a per cell basis and/or to smaller numbers of IL-2 producing cells. This 
finding may indicate the existence of a primary defect in mucosal IL-2 
production which could predispose towards the development of malignancy. 
Alternatively, the lower levels of mucosal IL-2 observed in colorectal 
carcinoma may be an immunosuppressive effect secondary to the presence 
of malignancy. A range of tumours including colorectal carcinoma are 
reported to release poorly characterized high molecular weight factors 
which inhibit lymphocyte proliferation (465-467) and IL-2 production 
(466,468). In addition, colorectal carcinomas contain detectable amounts 
of prostaglandin E which also ·impairs IL-2 production by PBMC (469,470). 
As a consequence of this acquired defect in IL-2 production, localised and 
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potentially curable colorectal carcinomas may undergo accelerated 
progression to more extensive or disseminated tumours. 
The production of IL-2 locally in the intestinal mucosa may be of 
importance in the pathogenesis of inflammatory bowel disease (IBD), 
where abnormalities in the immunoregulatory properties of both 
peripheral blood and intestinal lymphocytes are prominent findings 
(431,460). However, the existence of a defect in IL-2 production by LPMC 
in IBD is so far unproven, as insufficient numbers of IBD specimens have 
been examined and compared with histologically normal mucosal 
specimens from intestinal disorders other than IBD. Independent studies 
of IBD have reported normal levels of IL-2 production by PHA-stimulated 
LPMC (414,435), but when phorbyl-myristic acetate was used as the 
stimulus, IL-2 production was found to be depressed (414). The question 
of IL-2 availability in the IBD mucosa requires further investigation, as 
regulatory T cell dysfunction secondary to reduced levels of this 
lymphokine may perpetuate the chronic inflammation typical of this 
disorder (414). 
Interleukin 2 was the only known T cell growth factor until the 
recent description of interleukin 4 (IL-4), which is also known as B cell 
stimulatory factor-1 (471). Although its major effect is on B cells, this 
20 kD molecule is capable of stimulating T cell proliferation 
independently of IL-2 through interaction with a specific receptor. The 
effect of IL-4 on the system used to assay IL-2 in this chapter is unknown, 
but CTLL lines are reported to be responsive to IL-4, although to a lesser 
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extent than IL-2 (471 ). At the time_ the experiments reported here were 
performed, pure preparations of IL-4 were unavailable. Future studies of 
IL-2 production by LPMC will have to assess the effect of IL-4 on the IL-2 
assay and attempt to detect the presence of IL-4 in LPMC supernatants by 
the use of ion exchange chromatography and specific inhibitory antisera. 
The induction of IL-2 production by mitogenic stimulation in vitro 
may not reflect the in vivo production of IL-2 by LPMC in the intestinal 
mucosa. A critical factor influencing the amount of IL-2 induced in 
culture is the proportion of macrophages present. In cultures of PBMC, 
excess numbers of monocytes inhibit IL-2 production by the prostaglandin 
E2-induced activation of suppressor T lymphocytes (472), but on the other 
hand, optimum IL-2 production requires a minimum presence of monocytes 
(1-5°/o) to provide a source of interleukin 1 for T cell activation (472). The 
possible effect of intestinal macrophages on IL-2 production by LPMC has 
not been systematically studied, although Fiocchi et al (414) found that 
the removal of macrophages from LPMC populations made no difference to 
IL-2 production. In the present study, the relatively constant proportion 
of intestinal macrophages (17°/o) present in the LPMC populations (Chapter 
3) may have influenced the total amounts of IL-2 produced, but not the 
differences observed between nonmalignant and carcinoma specimens. 
Although control experiments showed no effect of the isolation procedure 
on IL-2 production by PBMC, the large amounts of prostaglandin liberated 
during isolation of LPMC (358) may also affect their ability to produce 
optimum levels of IL-2. Other variables affecting IL-2 production include 
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the amount and type of mitogenic ·stimulus and the concentrations of 
serum used in culture (473). The amount of IL-2 measured in culture 
supernatants is also determined by the balance between lymphokine 
production and consumption by activated lymphocytes (474). This 
observation is pertinent to the study of LPMC populations which contain 
activated T cells (389,414). All these variables must be considered in the 
interpretation and comparison of IL-2 production by mononuclear cell 
populations. 
The findings of the present study confirm that LPMC produce 
biologically significant levels of IL-2 and suggest that cells with this 
property have a potentially important immunoregulatory function in the 
intestinal lamina propria. A deficit of mucosa! IL-2 production 
associated with colon carcinoma may have important implications because 
of deleterious effects on local cell-mediated immune mechanisms within 
the intestinal mucosa. Further investigation of IL-2 production by LPMC 
may yield important insights into the pathogenesis of colorectal 
carcinoma and IBD. 
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CHAPTER 8. 
Partial characterization of the colony stimulating factor activity 
produced by lamina propria mononuclear cells. 
I. Introduction 
The colony stimulating factors (CSF's) are a family of glycoproteins 
which were first recognized as essential growth factors for granulocyte 
and macrophage colonies derived from bone marrow precursor cells 
cultured in semi-solid agar (475). In the human, purification and 
molecular cloning techniques (476-479) have so far lead to the 
identification of 4 separate molecules with CSF activity, specific either 
for granulocytes (G-CSF), macrophages (M-CSF) or for both cell lineages 
(GM-CSF and IL-3). As well as supporting the growth and differentiation 
of granulocytes and macrophages, the CS F's are also responsible for 
modulating numerous functions of the mature cells (480,481). 
Antibody-dependent killing of tumour cells and helminth parasites by 
neutrophils and eosinophils is markedly enhanced by the CSF's (482-484) . 
Increased phagocytosis of yeast particles, augmented superoxide 
production and the upregulation of type 3 complement receptors (CR3) on 
granulocytes are also attributable to the CSF's (484-486). Many cellular 
and humeral components of the inflammatory response may be modified by 
CSF's which are produced in high concentrations at the site of 
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experimentally-induced inflammati9n (487). The chemotaxis of 
neutrophils and their immobilization and survival at inflammatory foci are 
CSF-dependent (484,485). Moreover, CSF's are able to stimulate the 
secretion of potent inflammatory mediators including leukotriene c4 
(483), tumour necrosis factor (488), interferon (489), interleukin 1 (490) 
and plasminogen activator (491 ). 
Although CSF production has been detected in a range of organs in 
the mouse (492), little is known about the endogenous production of CSF's 
within the human intestinal mucosa. By activating the cytocidal 
properties of granulocytes and macrophages, mucosa! CSF production may 
be important in maintaining defence mechanisms against infection or the 
development of neoplasia. Furthermore, CSF's may be an important 
regulator of disease activity in IBD, which is characterized by mucosa! 
infiltrates of granulocytes and macrophages (493). Because of the 
potential importance of CSF production in the normal or diseased bowel, 
I 
the present study tested the ability of LPMC to produce CSF activity. 
Histologically normal specimens of intestinal mucosa resected either for 
colorectal carcinoma or benign disorders were tested for CSF production 
by LPMC and the levels were correlated with the presence or absence of 
malignancy. The type of CSF produced was also investigated by using 
hydrophobic interaction chromatography which is able to differentiate 
between the activities of GM-CSF and G-CSF (494). The results of this 
investigation demonstrate that LPMC from the human intestinal mucosa 
produce significant levels of CSF activity which are not affected by the 
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presence of an underlying malignancy. 
II. Materials and Methods. 
The details of the patients studied and methods of mononuclear cell 
isolation, induction of lymphokine production and statistical analysis are 
outlined in Chapter 7. 
8.1 Assay of colony stimulating factor activity. 
Supernatants from cultures of mitogen-stimulated LPMC were 
tested for colony stimulating factor (CSF) activity in a proliferation assay 
using human bone marrow-derived stem cells (Hapel et al, unpublished 
data). Previous experiments using recombinant preparations of G-CSF and 
GM-CSF have shown that the bone marrow cells used in the assay are 
reponsive to at least both of these factors. Human bone marrow cells 
were obtained from operative specimens of medullary bone removed from 
patients undergoing joint replacement or corrective procedures for 
scoliosis. The marrow space was repeatedly flushed and aspirated with 
phosphate buffered saline (PBS) and the resulting cell suspension 
centrifuged over Ficoll-Hypaque gradients (Pharmacia, Uppsala, Sweden) at 
500g for 30 min at room temperature. Interface cells were harvested, 
washed three times and then cultured in flat bottom, six well culture 
plates (Costar, Mass, USA) at a concentration of 5 x 106 cells/ml in 
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lscove's minimal essential medium (IMEM) (Flow Laboratories, Virginia, 
USA) supplemented with 20°10 foetal bovine serum (FBS) and 1 o-5M 
hydrocortisone (Sigma Chemical Co., St. Louis, MO). After two to three 
weeks' culture (with changes of medium every 3 days), the semiadherent 
cells were removed by repeated gentle flushing and aspiration and 
fractionated by discontinous gradient centrifugation over three densities 
of Percell (Pharmacia, Uppsala, Sweden) as follows : 30°10 (3ml); 40°10 (3ml) 
and 50°10 (3 ml). After centrifugation at 500g at room temperature for 30 
min, the cell interface above the 50°10 Percell was harvested, washed and 
resuspended in IMEM medium supplemented with 20°10 FBS and 10-5M 
hydrocortisone. 
The assay for CSF activity was performed in 96 well, flat bottom 
microculture plates (Nunc lntermed, Denmark) by combining 104 bone 
marrow cells from the 50°10 Percell fraction in supplemented IMEM medium 
with serial dilutions of LPMC culture supernatants in a final volume of 0.1 
ml. After culture for 48 h at 37°C in an atmosphere of 5°10 CO2 in air, the 
cells were pulsed with 11 µCi of tritiated thymidine for 18 h, harvested 
and counted as described in Chapter 7. Background proliferation of bone 
marrow cells was determined in the presence of medium alone. Control 
wells in each assay contained serial dilutions of conditioned medium from 
the GCT and 5637 cell lines which are known sources of GM-CSF and G-CSF 
(495,496). In accompanying experiments, bone marrow stem cells were 
shown to be unresponsive to concentrations of PHA from 0.1 to 100 µg/ml 
(data not shown). The CSF activity of culture supernatants was expressed 
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as end point units (U) as described in Chapter 7. Reproducibility of results 
between assays using different preparations of bone marrow cells was 
ensured by the inclusion of standard preparations of conditioned medium 
from the GCT and 5637 cell lines in each assay. 
8.2 Ion exchange chromatography. 
Culture supernatants from two specimens (one carcinoma, one 
diverticular disease) were fractionated by ion exchange chromatography 
using diethylaminoethyl (DEAE)-sephacel (Pharmacia ,Uppsala, Sweden). 
Ten ml of DEAE-Sephacel was equilibrated in a 1.5 cm diameter column 
with starting buffer (0.05M Tris-HCI, pH 7.8) at a flow rate of 10 ml/h at 
room temperature. A 5 ml sample of culture supernatant was dialysed 
overnight at room temperature in 500 ml of starting buffer and was then 
applied to the column at a rate of 1 O ml/h. The sample was followed by 30 
ml of starting buffer and then 60 ml of an increasing linear salt gradient 
prepared from equal volumes of starting and finishing buffer (0.3M NaCl in 
0.05M Tris-HCI, pH 7.8) and finally 40 ml of finishing buffer. The column 
i 
was extensively re-equilibrated with starting buffer before the second 
lymphokine preparation _was fractionated. The eluate was collected in 5 
ml fractions and measured for conductivity, absorbance at 280 nm and CSF 
activity after passage through 0.45 µm filters (Millipore Corp., Bedford, 
Mass). 
169 
8.3 Hydrophobic interaction chromatography. 
Fractions with high CSF activity obtained by ion exchange 
chromatography were pooled and concentrated in dialysis tubing in an air 
stream and were then dialysed overnight at room temperature against 100 
volumes of starting buffer consisting of 1 M ammonium sulphate; 0.1 M 
sodium phosphate; 0.02°/o Tween 20 (Sigma Chemical Co., St Louis, Mo) and 
0.02°/o sodium azide in distilled water. Eight ml of phenylsepharose 
(Pharmacia, Uppsala, Sweden) was equilibrated in a 1.5 cm diameter 
column with starting buffer at a flow rate of 10 ml/h at room 
temperature. The dialysed culture supernatant was applied to the column 
at 1 O ml/h followed by 20 ml of starting buffer and a 60 ml decreasing 
linear gradient prepared from equal volumes of the starting buffer and the 
second buffer (0.02°/o Tween 20 and 0.02°/o sodium azide in distilled water). 
This was followed in turn by 20 ml of the second buffer; 60 ml of an 
increasing linear gradient prepared from equal volumes of second buffer 
and finishing buffer (70°/o ethylene glycol with 0.02°/o Tween 20 and 0.02°/o 
sodium azide in distilled water) and finally 40 ml of finishing buffer. Five 
ml fractions were measured for conductivity and absorbance and then 
dialysed against two changes of PBS before filtration and assay for CSF 
activity. 
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Ill. Results 
8.1 The production of colony stimulating factor activity by LPMC. 
Lamina propria mononuclear cells (LPMC) from all mucosa! 
specimens tested produced detectable levels of CSF activity after 
stimulation with PHA. Twenty-one LPMC specimens treated with 5µg/ml 
PHA produced a mean CSF activity of 347 U (Fig 8.1). There was no 
significant difference between the levels of CSF produced by LPMC 
populations from specimens resected for nonmalignant conditions or for 
carcinoma (mean activities were 476 and 268 U respectively). Further 
subdivision of carcinoma specimens according to Duke's classification 
(461) before statistical analysis did not alter this result. Little overall 
increase in CSF production was achieved by treating LPMC with 20µg/ml 
f 
PHA, which resulted in a mean CSF activity of 337 U for six specimens 
(four malignant, two benign). Comparatively large amounts of CSF were 
produced spontaneously by five LPMC populations which were cultured in 
medium alone (mean activity 109 U for two malignant and three benign 
specimens). 
The titration curves of the CSF activity produced by representative 
LPMC populations from a nonmalignant and a carcinoma specimen are 
illustrated in Figure 8.2. In similar experiments to those outlined for IL-2 
production by LPMC, the enzymatic isolation procedure had no effect on the 
PHA-stimulated production of CSF by PBMC populations from two normal 
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Figure 8.1 The CSF activities of culture supernatants from LPMC 
stimulated with 5 µg/ml PHA. The indications for colon resection are 
shown for each group of specimens. The activity of CSF is expressed as 
end point units (U) and the mean activities of each group are indicated by 
the horizontal bars. There was no significant difference between CSF 
titres for any of the groups shown. 
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Figure 8.2 Titration curves of CSF activity in the culture supernatant of 
LPMC stimulated with 5 or 20 µg/ml PHA. The proliferation assay 
measured the uptake of tritiated thymidine in cpm (vertical axis) by 
cultured bone marrow cells. Sample dilutions (Log2) are shown on the 
horizontal axis. The titrations shown are representative results obtained 
with LPMC from a carcinoma specimen ( • Sµg/ml PHA ; 0 20 µg/ml PHA) 
and a nonmalignant specimen (diverticular disease) (i1 Sµg/ml PHA; £ 20 
µg/ml PHA). Also shown are results from the assay of conditioned medium 
from the 5637 cell line (•) and the culture supernatant of a LPMC 
population (from the specimen with colon carcinoma shown) incubated in 
medium alone without prior PHA stimulation (0 ). 
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control subjects (data not shown). -The implication of these results is that 
LPMC are capable of producing other lymphokines in addition to IL-2. 
Although CSF was produced in greater amounts after PHA stimulation, 
LPMC also demonstrated significant spontaneous production of CSF. In 
addition, no correlation was found between the levels of CSF production 
and the presence or absence of malignancy. Experiments designed to 
identify the molecule(s) responsible for the CSF activity produced by LPMC 
are outlined in the following section. 
8.2 Ion exchange and hydrophobic interaction chromatography of culture 
supernatants from PHA-stimulated LPMC. 
Culture supernatants of PHA-stimulated LPMC were subjected to ion 
exchange chromatography by passage over a DEAE-Sephacel column in order 
to isolate the fractions containing CSF activity for further analysis. A 
single peak of CSF activity was detected in the eluate of culture 
supernatants from both nonmalignant and colon carcinoma specimens 
(Fig 8.3). In both specimens, the CSF activity bound to the column and was 
eluted in the linear salt gradient. 
Hydrophobic interaction chromatography was then used to 
determine the nature of the CSF activity isolated by ion exchange 
chromatography. Previous studies have shown that the CSF activity in 
human placental conditioned medium could be separated by hydrophobic 
interaction chromatography into separate peaks of CSF activity originally 
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Figure 8.3 Ion exchange chromatography of culture supernatants from 
PHA-treated LPMC populations from a carcinoma and a nonmalignant 
specimen fractionated on a column of DEAE-Sephacel. A peak of CSF 
activity was detected in fractions eluted during application of the 
increasing linear salt gradient. CSF activity is expressed as counts per 
minute (cpm) of tritiated thymidine uptake by human bone marrow cells in 
the proliferation assay. A count of greater than 3,200 cpm indicates -
significant activity. 
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designated as CSF- a and CSF-B (494). Subsequently, CSF- a and CSF-B 
were identified as GM-CSF and G-CSF respectively (495,496). As shown in 
Figure 8.4, no CSF activity was detected in any of the eluted fractions for 
either the nonmalignant or malignant specimens. The low amounts of total 
CSF activity applied to the columns may account for the absence of 
activity. To confirm that CSF activity could be separated into separate 
peaks using this method, conditioned medium from the 5637 cell line was 
fractionated over DEAE-Sephacel and the CSF peak applied to the 
phenylsepharose column. Two discrete peaks of CSF activity which 
correspond to the unbound GM-CSF peak in the decreasing salt gradient and 
the bound G-CSF peak in the ethylene glycol gradient (494) were eluted 
(data not shown). 
IV. Discussion. 
The data presented in this study represent the first reported 
demonstration that factors with CSF activity are produced by mononuclear 
cells from the human intestinal mucosa. The identity of the CSF activity 
was unclear as hydrophobic chromatography of supernatants from cultured 
LPMC failed to detect the peaks characteristic of either GM-CSF or G-CSF. 
Other factors possibly accounting for this intestinal CSF activity include 
the recently cloned human IL-3 which combines the properties of both 
GM-CSF and G-CSF (479), or a novel undescribed CSF. The presence of 
factors such as IL-4, which can potentiate the effects of the CS F's on 
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Figure 8.4 Hydrophobic interaction chromatography of CSF-containing 
fractions of LPMC supernatants from a carcinoma and a nonmalignant 
specimen on a phenylsepharose column. No detectable peaks of CSF 
activity were eluted during the decreasing linear salt gradient or the 
increasing ethylene glycol gradient. CSF activity is expressed as cpm of 
tritiated thymidine uptake by bone marrow cells. A value of greater than 
2,800 cpm indicates significant CSF activity. 
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haemopoietic precursor cells is also possible (497). The identity of the 
cells responsible for intestinal CSF activity remains speculative, but 
likely producer cells include macrophages or T lymphocytes which are 
known to synthesize G-CSF and GM-CSF respect ively (481 ). Other cells 
found in the intestinal mucosa but not isolated in LPMC preparations 
(Chapter 3) which may produce CSF in vivo include endothelial cells and 
fibroblasts (481 ). The augmentation of spontaneous CSF production by 
LPMC after mitogen stimulation is consistent with reports that low levels 
of constitutive CSF production by mononuclear cells can be rapidly 
increased after acute infection (481 ), treatment with endotoxin (492) or 
specific antigen exposure (498). 
The production of CSF activity by mononuclear cells from the 
intestinal mucosa may serve several important functions. It is known that 
the significant levels of CSF activity detected in the serum originates 
from local organ producton (491,499). Intestinal CSF production may 
contribute therefore, to a circulating pool of factor which supports the 
growth, differentiation and function of any cell in the body expressing CSF 
receptors (480,481). Homeostatic mechanisms which regulate the 
intestinal response to microbes or antigenic stimulation may be dependent 
on local CSF production. Antimicrobial properties of granulocytes and 
macrophages enhanced by CSPs include chemotax is, phagocytosis, 
superoxide production, complement receptor expression and 
antibody-dependent cellular cytotoxicity against helminths (482-486). 
The influence of CSF's on the phagocytic and receptor-mediated functions 
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of macrophages suggest that these factors may be important in antigen 
processing and presentation. Little is known about antigen presentation in 
the intestinal mucosa but CSF-responsive cells such as the intestinal 
macrophage may be involved. 
The production of CSF activity by LPMC may protect against the 
development of neoplasia in the intestinal mucosa. Macrophages, 
eosinophils and polymorphonuclear leucocytes frequently infiltrate 
colorectal carcinomas, but is not known if these cell types can lyse colon 
carcinoma cells (500,501). Although CS F's augment the ADCC of tumour 
cells by granulocytes and macrophages, there is no evidence to suggest 
that this mechanism is operative in defence against colon carcinoma. In 
the present study, the lack of association between the levels of CSF 
production and the presence of carcinoma argues against the importance of 
CSF-supported effector cell mechanisms against colon carcinoma. Similar 
conclusions have recently been reported by Pullman et al (435). 
The potent proinflammatory properties of CSF's may be important 
in the pathogenesis of inflammatory bowel disease (IBD). The ability of 
CSF's to first attract and then immobilize (484,485) neutrophils at sites 
of inflammation may contribute to the accumulatio n of granulocytes seen 
in the intestinal mucosa in active IBD. Once neutrophils are attracted to 
the intestinal mucosa, local CSF production may then lead to their 
activation and prolongation of life span (482-485). A recent study has 
documented significant CSF production by LPMC in IBD, but the levels of 
mitogen-stimulated CSF activity on a per cell basis were no different 
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from those produced by non IBD specimens (435). However, because of the 
increase in mucosal lymphoid cells in IBD, the overall amount of CSF 
activity in the intestinal mucosa may be increased (395). Thus, the 
augmented chemotaxis and phagocytosis of peripheral blood monocytes 
from patients with active IBD (389) may result from an enhanced 
intestinal production of CSPs and an increased release of CSF's into the 
circulation secondary to the effects of inflammation on the intestinal 
vasculature. 
In summary, this study has demonstrated that LPMC from 
histologically normal intestinal mucosa produce one or more factors with 
CSF activity. The levels of CSF produced were not influenced by the 
presence of colorectal carcinoma, suggesting that variations in local CSF 
production by LPMC may not predispose towards the development of 
malignancy. The intestinal production of CSF activity deserves further 
investigation as it may have an important role in homeostasis of the 
normal intestine as well as in the pathogenesis of IBD. 
176 
CHAPTER 9. 
Summation. 
9.1 Aims and experimental approach. 
The main aim of this thesis was to investigate the occurrence of 
nonspecific cytotoxic cells and cytokine production within the intestinal 
mucosa and then to relate possible abnormalities of these systems to the 
pathogenesis of colon carcinoma and inflammatory bowel disease (IBD). 
Intestinal natural killer (NK) and lymphokine-activated killer (LAK) cells 
were the focus of investigation because these cells have antineoplastic, 
antimicrobial and immunoregulatory functions which may be advantageous 
to the intestinal mucosa. 
As malignant transformation of the human colonic epithelium is a 
common event, the possible role of nonspecific cytotoxic cells in 
eradicating early foci of tumour cells is an important issue. Furthermore, 
the strong implication from a large number of experimental and clinical 
studies is that NK and LAK cells are most effective against localised 
tumours in their early stages. Although these cells have a measurable 
influence on large tumour burdens in vivo, this effect is unlikely to be of 
major significance. The place of NK cells among the host's early defences 
against microbial pathogens is now well established. The ability of NK and 
LAK cells to destroy parasites, bacteria and viruses in both intracellular 
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and extracellular locations would be an obvious asset to the mucosal 
defence system. Finally, through their cytotoxic and secretory activities, 
NK cells may influence other classes of cells within microenviroments of 
the intestinal mucosa. It is proposed that an efficient suppressor cell 
system prevents excessive mucosal lymphoid proliferation in response to 
the sustained and variable antigenic challenge from the intestinal 
contents. The predominately suppressive role of NK cells in the 
immunoregulation of antibody and cell-mediated immune responses in the 
blood and primary lymphoid organs suggests that NK cells may perform 
similar functions in the intestine. Little is known however, about the 
mechanisms controlling intestinal epithelial or connective tissue cell 
growth, but cytotoxicity mediated by NK or LAK cells against these rapidly 
proliferating populations is one possible form of control. The capacity of 
peripheral blood NK cells to secrete multiple cytokines raises the 
possibility that similar or related cells may be responsible for the 
production of IL-2 or CSFs by intestinal lymphocytes. 
A discussion of the possible functions of NK and LAK cells in the 
normal intestine leads to the hypothesis that abnormalities in the number 
or function of these cells may be of aetiological importance in diseases 
affecting the intestine. Critical to this experimental approach was the 
ability to isolate and ass.ay populations of intestinal mucosal lymphocytes 
from a large number of cases of colon carcinoma, IBD and other 
nonmalignant conditions. The relevance of the mucosal nonspecific 
cytotoxic activity detected was reinforced by using epithelial cells and 
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fibroblasts derived from the intestinal mucosa as targets, in addition to 
standard tumour cell lines. In order to emphasize the advantages of using 
mucosa! lymphoid tissue in the study of intestinal diseases, comparisons 
between mucosa! and peripheral blood mononuclear cell populations were 
made when possible. In addition to functional assays of NK and LAK cell 
activity, the issue of mucosa! nonspecific cytotoxicity was approached by 
the localizaton of intestinal NK cells by immunohistochemistry. 
In order to postulate that NK and LAK cells exist in the intestine in 
vivo, it was also necessary to show that the intestinal mucosa is capable 
of sustaining these cells by the local production of cytokines. Therefore, 
lamina propria mononuclear cell populations (LPMC) were investigated for 
their ability to produce IL-2 and colony stimulating factor (CSF) activity 
in vitro. The investigation of mucosa! CSF production may have little 
relevance to the function of NK and LAK cells, but it forms the basis for 
future studies of the role of the various CSF's in colon carcinoma and 180. 
9.2 Natural killer cells in the intestinal mucosa. 
Assay of LPMC against K562 cells and epithelial tumour cells from 
the intestinal mucosa did not show substantial spontaneous or interferon 
(IFN)-augmented NK activity. When significant amounts of cytotoxic 
activity were detected in LPMC populations, the average levels of 
cytotoxicity were still markedly lower than those of peripheral blood 
mononuclear cells (PBMC). This paucity of NK activity is a strong 
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argument against a significant role.for NK cell-mediated cytotoxicity in 
either the normal or diseased intestinal mucosa. The resistance of freshly 
isolated colon carcinoma cells to NK activity and the lack of an 
association between mucosa! NK activity and the presence of colon cancer 
together imply that mucosa! NK cells do not have an important 
antineoplastic function. 
For similar reasons, the infrequency of NK cells in the mucosa of 
intestines affected by IBD suggests that NK cell activity is not involved in 
the tissue injury and inflammation which accompany this disorder. 
Antibody-dependent cellular cytotoxicity (ADCC) is another effector 
mechanism which was investigated in the intestinal mucosa. In the 
presence of antibodies directed against tumour cells or components of the 
normal intestine, NK cells or Ty cells may participate in the pathogenesis 
of colon carcinoma or IBD. However, the very low levels of ADCC found in 
LPMC populations compared to the peripheral blood imply that NK cells and 
other cell types capable of ADCC are infrequent in the intestine and are 
therefore unlikely to mediate biologically significant ADCC even if the 
appropriate antibodies are present. 
It could be argued that a small population of functionally important 
NK cells exist in the intestinal mucosa, but are obscured by the vast 
majority of LPMC which lack cytotoxic activity. Indeed, the function of 
this minority population may have been further adversely affected by 
suppressive factors, such as prostaglandins, released during their 
isolation. The studies presented in this thesis do not suggest that 
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suppressive factors or cells are a m,ajor factor responsible for the low 
levels of LPMC NK activity. However the data indicate that there is a 
minimal presence of NK cells in many resected intestinal specimens. The 
immunohistochemical survey using the Leu-7 antibody detected very 
occasional positive cells in the lamina propria which may have been NK 
cells, although it is known that T cells lacking NK activity may express 
this antigen. The finding of low level, but significant activity against 
K562 targets in a substantial proportion of specimens and the ability to 
boost this activity slightly using NK enrichment procedures and IFN 
treatment supports the existence of a minor, but variable intestinal NK 
cell presence. Whether these cells are represented in sufficient numbers 
to exert biologically relevant cytotoxic or immunoregulatory influences 
similar to those of peripheral blood NK cells is doubtful. At present, there 
is no immunohistological evidence to suggest that intestinal NK cells 
exert their effects by clustering in strategic microenviroments such as 
the subepithelial lamina propria or in and around colon carcinomas. 
9.3 Lymphokine-activated killer cells in the intestinal mucosa. 
The most important conclusion from the present studies was that 
the intestinal mucosa contains LAK precursor cells which can mature in 
vitro in response to IL-2. By inference, precursor cells may give rise to 
LAK effector cells within the intestinal mucosa. The identity of intestinal 
LAK cells was confirmed by their ability to lyse NK cell-resistant tumour 
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cell lines and freshly isolated colon _carcinoma cells. Intestinal LAK cells 
could mediate ADCC, although they lacked the CD1 s+ Fe receptors usually 
expressed by peripheral blood NK or LAK cells. Unlike NK cell or T 
cell-derived peripheral blood LAK cells, intestinal LAK cells reactive 
against K562 and colon cancer cells expressed a co2+3-a-1 s-Leu-7-
phenotype. Analysis of intestinal LAK precursor cells showed a similar 
surface antigen profile. Recent studies of intestinal LAK precursor cells 
by other authors (321) provide partial confirmation of this phenotype 
except that the cells were coa+ and Leu-19+. As yet, there have been no 
other phenotypic studies on intestinal LAK effector cells apart from those 
presented in this thesis. While the majority of peripheral blood LAK cells 
express the phenotype of their NK or T cell precursors, a minority 
population bears the co2+3-1 s- Leu-19+ phenotype which is similar to 
that of the intestinal LAK cell described here. The intestinal LAK 
precursor and effector cells characterized in this thesis were not 
examined for the Leu-19 antigen as the anti-Leu-19 monoclonal antibody 
was unavailable at the time of completion of these studies. Phenotypic 
studies of intestinal LAK cells mediating ADCC revealed that a small 
minority in some specimens were CD1 s+ and therefore probably originated 
from infrequent NK cells within the LPMC populations. Thus, while the 
majority of intestinal LAK cells express a phenotype unrelated to any 
known cell lineage, a small proportion appear to resemble the most 
common type of peripheral blood LAK cell which is derived from 
IL-2-activated NK cells. 
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Conditions needed for the gsneration of intestinal LAK activity from 
precursor cells included an absolute requirement for IL-2 in 
concentrations sufficient to induce cellular proliferation. Inhibition of 
this process at the level of the IL-2 receptor using a monoclonal antibody 
directed against the receptor (Tac) or at the subsequent stage of cellular 
proliferation by mitomycin-C, blocked the induction of LAK activity. 
These data however, do not prove that IL-2 directly stimulates LAK cell 
precursors and they also do not exclude the possibility that additional cell 
types or cytokines such as IL-4 (297) may be involved in the generation of 
some forms of LAK cell. The induction of intestinal LAK activity was 
inhibited by physiological serum concentrations of hydrocortisone, unlike 
the proliferative response of activated T cells to exogenous IL-2 which 
was sensitive only to much higher hydrocortisone levels. This observation 
may indicate an intrinsic difference bet\veen the IL-2 receptor-mediated 
activation of T cells and LAK precursor cells. 
Because studies of LAK cells describe a largely in vitro phenomenon, 
any extrapolations concerning their role in vivo must be speculative. The 
dependence of LAK activity on IL-2 suggests that LAK cells are most likely 
to exist in vivo as part of the amplification mechanisms arising from a 
specific immunological response. LAK cells are reactive against a much 
wider spectrum of tumour cells than NK cells and so may be an important 
part of the host's innate defences against malignant transformation . . ~ike 
NK cells, LAK cells have a largely unexplored potential for cytotoxicity 
against microbial pathogens. Nothing is known about the 
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immunoregulatory properties of LAK cells, but they may exert control over 
immunological reactions by direct cytotoxicity and cytokine secretion. 
Therefore, the presence of LAK cells within the intestinal mucosa may 
confer protection against the development of malignancy, infection by 
microrganisms and excessive lymphoid proliferation in response to the 
antigen load of the intestinal contents. 
Apart from the known potential of LAK activity against tumour cells 
in vitro, definitive evidence supporting an antineoplastic role for LAK 
cells in vivo is lacking. In the studies described in this thesis, the levels 
of LAK activity against K562 cells generated from histologically normal 
intestinal mucosa resected for benign or malignant conditions were 
comparable, suggesting that there was no in vivo abnormality of LAK 
precursor cell number or function associated with colon carcinoma. 
Moreover, comparable levels of LAK activity against colon carcinoma 
targets were generated from intestinal mucosae affected by cancer or by 
IBD and from the peripheral blood of normal subjects. This observation 
raises the possibility that the lysis of colon cancer cells by intestinal LAK 
cells reflects the broad, nonspecific cytotoxicity of the LAK cell 
phenomenon rather than a finding directly linking LAK cells to the 
pathogenesis of colon cancer. 
The same arguments outlined for colon carcinoma apply when 
considering the role of intestinal LAK cells in IBD. Because of their 
ability to lyse fibroblasts and epithelial tumour cells from the intestine, 
LAK cells must be considered as possible mediators of mucosa! injury and 
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inflammation in IBD. However the~e is, as yet, no evidence to indicate that 
intestinal LAK activity is abnormal in IBD. Moreover, the ability of 
intestinal LAK cells to lyse intestinal fibroblasts and epithelial cells is 
not restricted to IBD specimens and thus the relevance of this cytotoxic 
activity to the causation of IBD is questionable. 
The place of LAK activity in the pathogenesis of colon carcinoma and 
IBD will not be settled until it is demonstrated that intestinal LAK 
effector cells can develop from their precursors in vivo in the intestinal 
mucosa. Mononuclear cells from the intestinal lamina propria have the 
capacity to produce IL-2 both spontaneously and after mitogen stimulation 
and the concentrations of IL-2 produced by mitogen-stimulated LPMC are 
of the same order of magnitude as the levels of recombinant IL-2 used to 
generate LAK cells in vitro. Therefore, conditions appear suitable for the 
activation of LAK precursor cells in the intestinal mucosa, but how these 
observations relate to the availability of IL-2 for LAK cell generation in 
the normal or diseased intestinal mucosa in vivo cannot be determined. 
Furthermore, although only IL-2 is apparently required for LAK cell 
generation in vitro, optimum requirements for the activation of LAK 
precursor cells in the intestinal mucosa may be more complex. The lower 
levels of IL-2 secreted spontaneously by LPMC indicates that under normal 
circumstances, LAK effector cells may not exist in large numbers in the 
intestinal mucosa. However, under conditions of immune stimulation 
which generate larger amounts of IL-2, LAK cells may represent an 
important multifunctional amplification mechanism which could have both 
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protective and deleterious effects. _ 
LAK cells are able to function in vivo, as adoptive transfer studies 
in animals and man have established that culture-generated peripheral 
blood LAK cells have a clinically measurable antitumour effect in organs 
affected by malignancy. However, the studies reported in this thesis 
failed to find any indication of spontaneous LAK activity in freshly 
isolated LPMC populations. This finding may be artefactual as intestinal 
LAK cell activity may decline in the absence of IL-2 during the prolonged 
isolation procedure. In experimental animals, intestinal LAK cells have 
been reported following oral challenge with large doses of alloantigen. 
Moreover, in humans, peripheral blood lymphocytes with the cytotoxic 
properties of LAK cells have been reported in abnormal situations such as 
bone marrow transplantation, infectious mononucleosis and Ty 
lymphoproliferative disease. Thus at present, the evidence supporting the 
existence of LAK cells in the peripheral blood of normal subjects or 
indeed, in the intestinal mucosa of patients with colon cancer or IBD is 
largely indirect. 
9.4 Cytokine production by LPMC populations. 
The ability of LPMC to produce cytotokines is an important 
consideration in the investigation of intestinal NK and LAK cell activity 
because without the local production of IL-2, it is unlikely that cells of 
this type exist or function in the intestinal mucosa. Therefore, the 
186 
production of significant amounts of IL-2 by mitogen-stimulated LPMC 
suggests that a favorable enviroment for NK and LAK cells may exist 
within the intestinal mucosa. Although there was a wide variation in the 
amounts of IL-2 produced by individual specimens, there was a 
statistically significant trend towards reduced levels of IL-2 production 
in association with colon carcinoma. This finding is consistent with 
reports of suppressive factors produced by colon cancers and raises the 
possibility that in vivo, mucosa! defences such as NK or LAK cells are 
inhibited in the presence of carcinoma due to reduced availability of IL-2. 
The cytokine(s) responsible for the CSF activity produced by LPMC 
were not identified in this thesis due to technical difficulties. Because 
the CSF activity measured may comprise several factors from different 
cell sources, the observation that total CSF activity was unaffected by the 
presence of cancer is of questionable significance. Nevertheless, the 
demonstration of endogenous CSF production in the intestinal mucosa is 
highly relevant to the function of resident intestinal macrophages and to 
granulocytes which migrate into the mucosa in response to inflammatory 
stimuli. 
The production of IL-2 and CSF activity by LPMC indicates that one 
or more cell types with important immunoregulatory potential exist in the 
intestinal lamina propria. The identity of the producer cells was not 
established, but it is possible that the cytokine activity assayed may have 
been derived from several different cell types. Although NK cells or 
related large granular lymphocytes secrete IL-2 and CSF's, these cells 
187 
were not present in the intestinal m_ucosa in sufficient numbers to account 
for the amounts of cytokine assayed. 
9.5 Directions for future research. 
Consideration of the data presented and discussed here suggests 
further areas of investigation which address questions left unanswered by 
this thesis. One of the main issues raised in this thesis is whether a 
small minority of cells possessing NK or LAK activity exists in the human 
intestinal mucosa. Evidence presented here and elsewhere supports the 
existence of small numbers of mucosa! NK cells, but methods used to 
detect and characterize them have so far been too imprecise. The 
isolation of homogenous minority cell populations from the intestinal 
mucosa would best be achieved by fluorescent-activated cell sorting or 
cell panning using selected monoclonal antibodies. The surface antigens of 
most interest would be those found on peripheral blood NK and LAK cells 
(CD7, CD16, Leu-19 and LAK-1 ). Populations of LPMC selected on the 
basis of expression of a particular surface antigen could then be tested for 
spontaneous cytotoxicity against a panel of targets sensitive to NK and 
LAK cells. The targets used should include freshly isolated colon 
carcinoma cells and intestinal epithelial cells, in addition to established 
tumour cell lines of known susceptibility. Further studies which could be 
carried out include assay of spontaneous cytotoxicity after short term (up 
to 18 h) incubation with IL-2 and I FN, in order to detect the full potential 
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of any cytotoxic cells present. The lPMC populations can also be assessed 
for their potential as LAK precursor cells by culture with IL-2 and IL-4 for 
longer periods (2-6 days). Characterization of the surface antigen profile 
expressed on generated LAK cells can then be performed. 
The isolation of purified LPMC expressing uncommon surface 
antigens requires a large starting population of LPMC (approximately 1 o9 
cells). This number of cells is obtainable with the isolation techniques 
used in this thesis. Parallel experiments using peripheral blood NK and 
LAK cells would be needed to control for the possible inhibitory or 
stimulatory effects of the monoclonal antibodies on LPMC cytotoxicity. 
Another issue needing investigation is the identification of surface 
epitopes unique to peripheral blood or intestinal LAK cells. The 
preparation of monoclonal antibodies specific for these antigens would 
allow the detection of LAK cells in normal and pathological situations and 
facilitate their isolation for further characterization. This strategy 
would be the most effective way of determining whether LAK effector 
cells exist in vivo. In order to raise monoclonal antibodies against LAK 
cells, purified or preferably cloned intestinal LAK cell populations could 
be used as the immunogen in standard monoclonal antibody preparation 
protocols. Such an approach has been used recently to prepare the LAK-1 
monoclonal antibody which is reactive with both peripheral blood LAK 
precursor and effector cells (316). 
The field of cytokine production by intestinal lymphocytes is of 
potentially great importance in elucidating the pathogenesis of malignant 
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and chronic inflammatory diseases-of the human intestine. The cytokines 
described in this thesis require further characterization and identification 
of the cell(s) of origin. The T cell growth factor produced by LPMC is 
likely to consist mainly of IL-2, but a contribution from IL-4 is possible. 
The effect of recombinant IL-4 on the IL-2 assay used in this thesis is the 
first lin~ of investigation to pursue. If the CTTL line used is responsive to 
IL-4, then the supernatants of mitogen-stimulated LPMC can be probed for 
IL-4 by using ion exchange chromatography and specific inhibitory 
antisera. The use of hydrophobic interaction chromatography and specific 
inhibitory antisera will also determine whether the CSF activity produced 
by LPMC is due to the presence of G-CSF, GM-CSF, IL-3 or other CSF's. 
Investigating the amount and types of cytokine produced by purified or 
cloned LPMC subpopulations will assist in identifying the cells responsible 
for cytokine production in the intestinal mucosa. 
The intestinal mucosa provides an ideal enviroment in which to 
study the biology of cytokines associated with antigen presentation and 
antibody class switching. The production of Interleukin 1 in the intestinal 
mucosa has not been studied and the question as to whether antigen 
presenting cells such as intestinal macrophages, epithelial cells or 
dendritic cells produce this cytokine is also unanswered (502). Little is 
known about the production and properties of immunoglobulin class switch 
factors in the human intestine. Recent evidence indicates that the 
switching of lgM+ B cells to lgG1 + or lgE+ cells requires the participation 
of IL-4 (471 ). IL-4 may also enhance antigen presentation by activating 
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macrophages and increasing their expression of la molecules (503). 
Mucosa! IL-4 production may thus be critical to the functioning of the 
secretory immune system and it follows that cells capable of secreting 
this cytokine and switch factors for lgA are likely to exist in the 
intestinal mucosa. LPMC populations isolated from the small and large 
bowel would therfore be a logical population to probe for the production of 
these cytokines. 
9.6 Conclusion 
The main conclusions of this thesis form the basis for further 
investigations into the pathogenesis of the important human diseases 
colon carcinoma and 180. On numerical and functional grounds, NK cells 
probably exist in the intestine in small numbers, but their cytotoxic 
activity is unlikely to be an important factor in the biology of these 
diseases. However, plentiful numbers of LAK precursor cells with the 
potential to give rise to highly cytotoxic LAK effector cells are found 
within the intestinal mucosa in both colon carcinoma and IBD. The ability 
of LPMC to produce concentrations of IL-2 appropriate for the generation 
of intestinal LAK cells suggest that these cells exist within the intestinal 
mucosa. Further investigation is needed to determine the extent and 
relevance of the LAK cell phenomenon in vivo. 
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